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TRPML1 is an inwardly-rectifying Ca
2+
-permeable channel in late endosomes and lysosomes (LELs). 
Loss-of-function mutations on the human TRPML1 gene cause a devastating pediatric 
neurodegenerative disease called type IV Mucolipidosis (ML4). Although it is well established that 
TRPML1 is involved in multiple late endocytic membrane trafficking processes, the regulatory 
mechanism for TRPML1 remains elusive. By directly patch-clamping endolysosomal membranes, 
we found that PI(3,5)P2, a low abundance endolysosome-specific phosphoinositide, potently and 
specifically activates TRPML1 in both heterologous and endogenous systems (Chapter 2). Lipid-
protein binding assays showed that PI(3,5)P2 binds directly to the poly-basic region of the N 
terminus of TRPML1. Overexpression of TRPML1 rescued the enlarged vacuole phenotype in 
PI(3,5)P2-deficient cells, suggesting that TRPML1 is a downstream effector of PI(3,5)P2. 
Notably, this PI(3,5)P2-dependent regulation of TRPML1 is evolutionarily conserved. In budding 
yeast, the activity of a yeast functional TRPML homologue is also PI(3,5)P2-dependent. These 
results indicate that lysosomal PI(3,5)P2 is a physiological regulator of TRPML1, providing a 
previously unknown link between these two important regulators of intracellular membrane trafficking. 
        In Chapter 3, a membrane-permeable small-molecule synthetic agonist for TRPMLs, Mucolipin-
Synthetic Agonist 1 (ML-SA1), was identified. Electrophysiological results showed that ML-SA1 
potently and specifically activates recombinant TRPMLs, as well as endogenous TRPML-like currents 
in many cell types. In addition, ML-SA1 evoked TRPML1-dependent Ca
2+
 release from 
endolysosomes in intact cells. ML-SA1 can therefore serve as a valuable tool for studying intracellular 
functions of TRPMLs.  
xiii 
        By taking advantage of ML-SA1, the activity of TRPML1 was examined under a pathological 
context (Chapter 4). We found that TRPML1-mediated lysosomal Ca
2+
 release, measured using a 
genetically-encoded Ca
2+
 indicator (GCaMP3) attached directly to TRPML1, was dramatically 
reduced in Niemann-Pick (NP) disease cells. Patch-clamp analyses revealed that TRPML1 
channel activity was inhibited by sphingomyelin, but potentiated by spingomyelinase. Importantly, 
increasing the expression/activity of TRPML1 was able to alleviate the lipid accumulation and 
trafficking defects in NPC cells. Our findings suggest that compromised channel activity of TRPML1 
is the pathogenic cause for secondary lysosomal storage seen in many lysosomal storage disorders 
(LSDs). Thus manipulating TRPML1 channel activity by chemical agonists may provide therapeutic 











1. Overview of the lysosomal membrane dynamics 
1.1. Lysosomes and their diverse functions 
Efficient waste disposal is an essential and basic process in cells - the tiny, autonomous, functional 
units of our body. In eukaryotic cells, the major degradation centers are lysosomes discovered by 
Christian de Duve more than 50 years ago using a cell fractionation technique (de Duve 2005). 
Lysosomes are membrane-enclosed organelles of ~0.5 µm diameter and often have electron-dense 
cores (Luzio, Pryor et al. 2007). They are heterogeneous in morphology and comprise up to 5% of 
the intracellular volume (Luzio, Pryor et al. 2007; Saftig and Klumperman 2009). A hallmark 
feature of lysosomes is their acidic luminal environment that is enriched with more than 50 kinds of 
acid hydrolases, such as proteases, glycosidases, and phosphatases. Each of these hydrolases has its 
specific substrate, and collectively, they degrade the majority of cellular waste (Luzio, Pryor et al. 
2007; Saftig and Klumperman 2009).  
      In addition to their degradation function, lysosomes are also involved in various 
physiological processes (Luzio, Pryor et al. 2007). They have been shown to mediate plasma 
membrane repair, antigen presentation, and neurite outgrowth via the exocytosis of lysosomal 
contents, i.e. lysosomal exocytosis (Rao, Huynh et al. 2004; Andrade and Andrews 2005; McNeil 
and Kirchhausen 2005). The release of lysosomal cathepsins is also implicated in the lysosome 
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mediated cell death pathway through direct activation of caspase 8, though the detailed mechanism 
is still unknown (Guicciardi, Leist et al. 2004; Conus, Pop et al. 2012). In addition, lysosomes are 
also involved in lipid metabolism. For example, cellular cholesterol homeostasis is largely 
regulated by lysosomal cholesterol efflux through lysosomal membrane proteins (Maxfield and 
Wustner 2002; Mesmin and Maxfield 2009). These multifaceted functions highlight the 
significance of the lysosome as a central and dynamic organelle for various cellular activities, as 
opposed to simply the “garbage-disposal unit” in the cell. 
 
1.2.  Major membrane trafficking routes to and from lysosomes 
Lysosomes receive their substrates through fusion with endocytic, phagocytic, and autophagic 
vesicles (see Fig 1.1). During endocytosis, membrane proteins are internalized into primary 
endocytic vesicles. These vesicles undergo maturation and become early endosomes and later 
develop into late endosomes, on the time scale of minutes to tens of minutes (Luzio, Pryor et al. 
2007; Cheng 2010). Both early and late endosomes can bud inwardly from their limiting 
membranes to form luminal vesicles referred to as multi-vesicular bodies (MVBs) (Gruenberg and 
Stenmark 2004; Slagsvold, Pattni et al. 2006; Malerod and Stenmark 2009; Raiborg and Stenmark 
2009). During this inward budding process, ubiquitinated membrane proteins are sorted into MVBs 
and eventually delivered into lysosomes for degradation after late endosomes fuse with lysosomes 
(Hurley and Emr 2006; Saftig and Klumperman 2009). Lysosomes also receive substrates through 
fusion with phagosomes. This fusion process underlies the maturation of phagosomes to 
phagolysosomes in phagocytosis, and is essential for the cellular defense against pathogens 
(Desjardins 1995; Harrison, Bucci et al. 2003; Czibener, Sherer et al. 2006; Huynh, Eskelinen et al. 
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2007). The third pathway, autophagy, brings to lysosomes the obsolete intracellular 
components/organelles that have been sequestered in the autophagosome. This pathway is usually 
used for the turnover of cytoplasmic components in response to stress conditions, such as nutrition 
starvation in yeast cells (Levine and Klionsky 2004; Yang and Klionsky 2010). 
      The fusion of a lysosome with a late endosome, phagosome or autophagosome, produces an 
intermediate fusion-hybrid organelle, inside which the degradation of macromolecules takes place 
(Mullock, Bright et al. 1998; Saftig and Klumperman 2009). These fusion processes occur 
constantly and would eventually consume all the lysosomes if it were not for a process known as 
lysosome biogenesis (Fig 1.1) (Pryor, Mullock et al. 2000; Bright, Gratian et al. 2005; Luzio, Pryor 
et al. 2007). Lysosome biogenesis is the regeneration of lysosomes from the fusion-hybrid 
organelles. It involves two coupled but separate processes: firstly the formation of spherical or 
tubular structures oriented toward the surrounding cytosol and secondly the membrane scission 
(Eskelinen, Illert et al. 2002; Treusch, Knuth et al. 2004; Saftig and Klumperman 2009; Yu, 
McPhee et al. 2010). The first step requires multiple events of content condensation so that 
lysosomal specific membrane proteins and hydrolyses are again enriched. The second step is a 
membrane fission event that gives rise to new lysosomes (Eskelinen, Illert et al. 2002; Saftig and 
Klumperman 2009).  
      There are two major outgoing routes of membrane traffic from lysosomes, namely, 
lysosomal exocytosis and retrograde trafficking from lysosome to Golgi (Fig 1.1). Lysosomal 
exocytosis is essentially a fusion event between the limited lysosomal membrane and plasma 
membrane. This process is Ca
2+
- and synaptotagmin VII- dependent, and delivers the membranes 
needed for plasma membrane repair or phagocytosis of large pathogen particles from extracellular 
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environment (Rao, Huynh et al. 2004; Andrade and Andrews 2005; McNeil and Kirchhausen 2005). 
Along with the exocytosis release the contents of the lysosomes, which are involved in cytokine 
secretion, antigen presentation and neurite outgrowth (Blott and Griffiths 2002; Chow, Toomre et al. 
2002; Saftig and Klumperman 2009). The other outgoing route is the retrograde transportation to 
trans-Golgi network (TGN) of vesicles that bud off from late endosomes/lysosomes (LELs). In this 
way the degraded and recycled materials from lysosomes can be reused for synthesis of new 
proteins or lipids. In return, vesicles from the Golgi convey newly synthesized integral membrane 
proteins, hydrolyses, and lipids to endosome and lysosome membrane systems (endolysosomes, 
collectively) (Janvier and Bonifacino 2005; Luzio, Pryor et al. 2007). 
 
1.3.  Putative fusion/fission machinery in the endolysosome system 
The various trafficking routes enable lysosomes to orchestrate their myriad cellular functions by 
specifically exchanging their contents and membranes with other organelles or plasma membrane. 
These trafficking routes must be tightly regulated to ensure their specificity and direction. Yet due 
to the inherent difficulties of studying intracellular organelles, the trafficking machineries and their 
regulators are still far from being fully characterized for endolysosomes. Here I will mainly discuss 
about the machinery for the fusion process, since membrane fission events are much less well 
understood - they are generally viewed as the reverse of membrane fusion events and therefore may 
share some common mechanisms with fusion processes. (Chernomordik and Kozlov 2003; Dong, 
Wang et al. 2010).  
      Extensive studies of exocytosis, particularly neurotransmission, have elucidated many of 
the essential components of membrane fusion events that take place during exocytosis (Suudhof 
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2008).  For example, soluble NSF attachment protein receptors (SNAREs) have been identified as 
the basic structural components needed for membrane fusion events (Suudhof 2008; Wickner 2010).  
For the regulation of pre-fusion steps (i.e., priming, tethering, and docking), Rab small GTPases, 
Rab effectors, tethering factors, and phosphoinositides have been found to be important factors 
(Martens and McMahon 2008; Suudhof 2008; Stenmark 2009; Wickner 2010; Yu and Hughson 
2010).    
      Recent in vitro and in vivo studies have provided tantalizing glimpses of the similar 
regulatory mechanisms shared by the exocytosis and the endolysosomal fusion processes (Hay 
2007; Martens and McMahon 2008; Suudhof 2008).  These studies suggest that endolysosomal 
fusions also involve sequential stages of tethering, docking and finally bilayer fusion (Luzio, Pryor 
et al. 2007). Tethering, the initial interaction between membranes, requires the Rab GTPases, which 
are compartmentalized in specific organelle membranes. For example, Rab5 is localized in the 
early endosomes, while Rab7 is localized to late endosomes and lysosomes (Stenmark 2009; 
Hutagalung and Novick 2011). Rab GTPases recruit their effectors to further determine the 
organelle identity and transport specificity. These effectors include tethering factors such as early 
endosome antigen 1 (EEA1) or homotypic fusion and protein sorting (HOPS) proteins which 
bridge two endolysosomal membranes, lipid kinases/phosphotases that change the lipid 
composition and thus the fusogenic potential of the opposing microdomains, as well as sorting 
adaptors that redistribute membrane proteins (Grosshans, Ortiz et al. 2006; Stenmark 2009). 
Tethered membranes are then brought into proximity by the formation of trans-SNARE complexes, 
a highly stable, four-helix bundle comprised of three Q-SNAREs on one membrane, and one 
R-SNARE on the opposing membrane (Martens and McMahon 2008).  In lysosomes, Vamp7 has 
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been identified as an R-SNARE, and Syntaxins -7 and -8 are Q-SNAREs (Luzio, Pryor et al. 2007). 
After the formation of the trans-SNARE complex, a bilayer mixing reaction is initiated. 
 
 
1.4. Calcium release from endolysosomes regulates membrane trafficking 
Ca
2+
 is hypothesized to be another important regulator of endolysosomal membrane trafficking 
(Peters and Mayer 1998; Burgoyne and Clague 2003; Hay 2007). Similar to the well-established 
role of Ca
2+
 as a key regulator of synaptic vesicle fusion during neurotransmitter release (Suudhof 
2008), the transient rise of the Ca
2+
 concentration near the endolysosomal fusion site is considered 
as the final trigger of intracellular membrane fusion (Cheng, Shen et al. 2010; Shen, Wang et al. 
2011). In vitro membrane fusion assays using cell extracts from yeast or mammalian cells have 
shown that both homotypic and heterotypic fusion events between LELs are inhibited by BAPTA, 
but not by EGTA (Peters and Mayer 1998; Pryor, Mullock et al. 2000). Although both BAPTA and 
EGTA are Ca
2+
 chelators, the former binds to Ca
2+
 10–100 times faster than the latter. The most 
plausible explanation for this distinct difference in sensitivity to BAPTA versus EGTA is that the 
putative fusion site is in close proximity to the Ca
2+
-release site (Pryor, Mullock et al. 2000; Chen, 
Ahluwalia et al. 2002; Hay 2007). By using membrane permeable forms of Ca
2+ 
chelators, i.e. 
BAPTA and EGTA fused with acetoxymethyl ester (AM), additional studies of intact cells have 
further demonstrated that distinct BAPTA/ EGTA sensitivities are also associated with multiple 
steps during endolysosomal transport, including endolysosomal fusion and retrograde trafficking 
from endolysosomes to the TGN (Ahluwalia, Topp et al. 2001; Burgoyne and Clague 2003; Hay 
2007). Thus, both in vitro and in vivo evidence suggests that Ca
2+ 
release from endolysosomes 
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participates in most, if not all, fusion and fission events along the endolysosomal pathway. 
      Based on the ionic composition and electrical properties of endolysosomes, the capacity for 
endolysosomes to release Ca
2+ 
during membrane trafficking has been considered (Dong, Wang et al. 
2010). The luminal Ca
2+ 
concentration of lysosomes is estimated to be 0.5 mM (Christensen, Myers 
et al. 2002; Lloyd-Evans, Morgan et al. 2008), while Ca
2+ 
concentrations associated with 
endosomes have been shown to vary from 0.003 to 2 mM (Gerasimenko, Tepikin et al. 1998). Thus, 
both endosomes and lysosomes may represent sources of Ca
2+ 
release along the endolysosome 
trafficking pathway. Dysregulation of luminal Ca
2+ 
concentration is known to cause a block of 
phagosome maturation in macrophages (Shaughnessy, Hoppe et al. 2006), and trafficking defects in 
neurons and subsequent neurodegenerative diseases (Lloyd-Evans, Morgan et al. 2008; 
Lloyd-Evans, Waller-Evans et al. 2010) 
      Several putative endolysosome Ca
2+ 
-release channels have been identified using Ca
2+ 
imaging and a lysosomal patch-clamp technique (see Fig 1.2b). TRPMLs are the principle Ca
2+
 
release channels on endolysosomes (Cheng, Shen et al. 2010). Two-pore channels (TPC1 and TPC2) 
are another type of Ca
2+ 
channels that are ubiquitously expressed and are associated with 
endolysosomes. Recent studies have shown that TPCs may mediate nicotinic acid adenine 
dinucleotide phosphate (NAADP)-activated Ca
2+ 
release from endolysosomes (Zhu, Ma et al. 2010), 
while overexpression of TPCs has been shown to cause defective membrane trafficking in 
endolysosomes (Galione, Morgan et al. 2010). Finally, TRPV2 and TRPM2 were detected as cell 
specific Ca
2+ 
permeable channels present in endolysosomes (Saito, Hanson et al. 2007; Lange, 
Yamamoto et al. 2009). However, characterization of these channels in the membrane trafficking of 
endolysosomes is ongoing. 
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      Currently, one of the most challenging questions in the field of endolysosomal trafficking is 
how Ca
2+
 release is tightly regulated in vivo. Emerging evidence suggests that while many 
components of the trafficking machinary, such as Rabs, SNAREs and phosphoinositides, have their 
own specific major functions (Martens and McMahon 2008; Wickner 2010), they may coordinate 
with each other and play additional roles as regulators of the Ca
2+
 signaling during fusion/fission 
process. For example, recent evidence suggests that in addition to their role as structural 
determinants of fusion, SNAREs can also regulate Rab effectors (Stenmark 2009) and plasma 
membrane Ca
2+ 
channels (Dong, Wang et al. 2010). In yeast, trans-SNARE complex formation 
may directly induce Ca
2+
 release from the lumen of the vacuole (Merz and Wickner 2004).  
Similarly, phosphoinositides have been shown to be important not only for the recruitment of Rabs 




 sensors (Bai, Tucker et 
al. 2004).   
      This thesis will focuses on TRPMLs - the principle Ca
2+ 
release channels on endolysosomes, 
and lipids on lysosomal membrane such as phosphoinosites, sphingolipid and cholesterol, and 
discuss how they interact with each other to regulate the Ca
2+ 
signaling that fine-tune the 
endolysosomal dynamics. An overview of TRPMLs and lysosomal lipids will be presented in the 
next two sections. 
 
2. TRPML channels: the principle Ca2+ release channels on endolysosomes 
Transient receptor potential (TRP) channels are a large family of cation channels with diverse 
physiological functions particularly in sensory signaling (Clapham 2003; Wu, Sweet et al. 2010). 
TRPML channels are the mucolipin family of the TRP superfamily (Puertollano and Kiselyov 2009; 
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Cheng 2010). They are six transmembrane (TM) - spanning proteins with the amino-- and carboxy- 
terminal tails facing the cytosol. In mammals, there are three TRPML proteins (TRPML1-3). They 
share high amino acid similarity (~75%), especially in the putative pore region (>90%) between 
TM 5 and 6 (Puertollano and Kiselyov 2009). A long luminal loop spans across TM1 and TM2, and 
contains several N-glycosylation sites that may regulate TRPMLs activity. Another structural 
similarity shared by TRPMLs is the clusters of positively charged amino-acid residues on both 
amino-- and carboxy- terminus. These residues are important for the channels to interact with 
acidic lipids such as phosphoinositides (Dong, Shen et al. 2010). 
 
2.1.  Intracellular localization and tissue distribution of TRPMLs 
At the subcellular level, TRPMLs primarily localize to the endolysosomal system. Overexpression 
studies using different epitope-tagged versions of TRPML1have revealed that TRPML1 primarily 
resides on LEL compartments, based on it co-localization with the lysosome-associated membrane 
protein 1 (Lamp-1) - a LEL specific marker (Dong, Wang et al. 2009; Puertollano and Kiselyov 
2009; Cheng 2010). Immunostaining and gradient fractionation methods further confirmed that the 
endogenous TRPML1 proteins are also localized at LELs. Two acidic di-leucine motifs on both 
ends of the channel are proposed to be the important regulators for the delivery of TRPML1 to 
LELs (Pryor, Reimann et al. 2006; Vergarajauregui and Puertollano 2006). The di-leucine motif at 
N-termini mediates the direct trafficking pathway in which newly synthesized protein are 
transported from Golgi to LELs, while the di-leucine motif at C-termini mediates the indirect 
pathway where TRPML1 is first transported to the plasma membrane and then internalized and 
delivered to LELs. Mutations on both di-leucine motifs largely block the transport of TRPML1 
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from Golgi to LELs and trap the channel on the plasma membrane (Vergarajauregui and 
Puertollano 2006). 
      Similar overexpression essays with tagged channel proteins revealed that TRPML2 and 
TRPML3 are also localized in LEL compartments and co-localized with Lamp-1 (Cuajungco and 
Samie 2008; Puertollano and Kiselyov 2009; Zeevi, Frumkin et al. 2009). Immunolocalization 
studies have also shown that TRPML2 localizes to the vesicles along the long, tubular structures 
within cells in addition to the LELs (Karacsonyi, Miguel et al. 2007). These long, tubular structures 
correspond to the recycling endosomes of the GTPase ADP-ribosylation factor-6 (Arf-6) associated 
pathway. By using cellular fractionation and primary antibodies raised against TRPML3, Kim et al. 
provided evidence that TRPML3 localizes to LELs, early endosomes (EEs), and the plasma 
membrane (Kim, Soyombo et al. 2009). The plasma membrane localization of TRPML3 is 
consistent with the substantial whole-cell currents that can be recorded from TRPML3-expressing 
HEK293 cells. 
      In the tissue level, TRPML1 has been shown to be ubiquitously expressed, with the highest 
levels of expression located in the brain, kidney, spleen, liver, and heart (Cheng 2010). In contrast, 
TRPML2 and TRPML3 are associated with a more restricted expression profile: Real-time PCR 
analysis reveals that TRPML2 is mainly expressed in the thymus, kidney, and spleen; TRPML3 is 
expressed in the cochlea, thymus, lung, kidney, spleen, eye and skin (Puertollano and Kiselyov 
2009; Cheng 2010). 
 
2.2.  Channel properties of TRPMLs 
TRPML3 was the first TRPML channel to be electrophysiologically characterized (Kim, Li et al. 
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2007; Xu, Delling et al. 2007; Kim, Li et al. 2008). As mentioned earlier, wild-type TRPML3 is 
present at the plasma membrane when it is overexpressed, and thus can be characterized using the 
conventional whole-cell patch clamp technique. These studies have shown that TRPML3 is an 
inwardly rectifying, Ca
2+
-permeable cation channel. TRPML3-mediated current (ITRPML3) is 
inhibited by an acidic extracellular (analogous to the luminal side) pH with H
+
 presumably binding 
to multiple histidine residues within the TM1–TM2 loop (Kim, Li et al. 2007; Kim, Li et al. 2008). 
Interestingly, ITRPML3 is potentiated by the removal and subsequent re-addition of extracellular Na
+
. 
The physiological implications of these two observations remain to be established. A amino acid 
mutation of mouse TRPML3 (A419P) causes the varitint-waddler (Va) phenotype, which is 
characterized by deafness, circling behavior, and pigmentation defects (Cuajungco and Samie 2008; 





compared to WT TRPML3 under basal/non-stimulated conditions, consistent with the high open 
probability of ITRPML3-Va (Xu, Delling et al. 2007). ITRPML3-Va resembles ITRPML3 in the basic channel 
pore properties including current - voltage (I - V), single channel conductance, and ion selectivity. 
However, since ITRPML3-Va cannot be further activated by Na
+
 manipulation, the Va mutation is 
likely to disrupt channel gating by locking the channel into an open state. 
      The channel properties of TRPML1 and TRPML2 are more difficult to be characterized due 
to their intracellular localization. Initial studies on the wild-type TRPML1 were carried out by 
using the standard whole cell patch clamp method (LaPlante, Falardeau et al. 2002; LaPlante, Ye et 
al. 2004; Soyombo, Tjon-Kon-Sang et al. 2006). But without an effective method of bringing 
TRPML1 to the plasma membrane and/or specific agonist for TRPML1, these observations are at 
best questionable. In fact, they give rise to contradicting results. For example, one group reported 
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TRPML1 as a monovalent cation channel permeable to and regulated by Ca
2+
, and with linear 
conductance (LaPlante, Falardeau et al. 2002), while another group reported that TRPML1 is an 
outwardly rectifying monovalent cation channel that was blocked by Ca
2+ 
(Soyombo, 
Tjon-Kon-Sang et al. 2006). There were also controversies over the H
+
 permeability of TRPML1, 
which points to the debate whether TRPML1 regulates lysosomal pH (Raychowdhury, 
Gonzalez-Perrett et al. 2004; Soyombo, Tjon-Kon-Sang et al. 2006). 
      The application of Va activation-mutation approach facilitated the characterization of the 
pore properties of TRPML1-2 (Grimm, Cuajungco et al. 2007; Kim, Li et al. 2007; Xu, Delling et 
al. 2007). By introducing Va-like mutations to TRPML1 (V432P) and TRPML2 (A396P), a large 
proportion of the channels are mislocalized to the plasma membrane, and thus become accessible to 
whole cell patch clamp. Similar to TRPML3, TRPML1
Va
 is identified as an inwardly rectifying 
channel that is permeable to Ca
2+
- but not H
+
. Interestingly, unlike ITRPML3, ITRPML1-Va is potentiated 
by low pH (Xu, Delling et al. 2007).  
      Yet, since the Va mutation locks the channel into a constitutively open state, a concern 
remains that the mutation might change the pore properties of TRPML1 and TRPML2. A technique 
called lysosomal patch clamp was developed by directly record from isolated endo-lysosomes 
which were pharmacologically enlarged (from 0.5 to 2 - 3 µm) using the small molecule compound 
vacuolin-1 (Cerny, Feng et al. 2004; Dong, Cheng et al. 2008). This technique paved the way to 
study endolysosomal channels in their native membrane (LELs). It was found that lysosomal 
ITRPML1 and ITRPML2 exhibited almost identical pore properties as their Va-mutant counterparts 
(Dong, Cheng et al. 2008; Dong, Shen et al. 2010). Despite many previous controversial results, 









 permeable but proton-impermeable cation channels (Cheng 2010). 
 
2.3. TRPMLs in membrane trafficking 
Mutations of human TRPML1 causes type IV mucolipidosis (ML4) disease, a childhood 
neurodegenerative disease characterized by severe mental retardation, psychomotor defect and 
retinal degeneration. Human ML4 mutations cause the abnormal accumulation of sphingolipids, 
phospholipids, acidic mucopholysaccharides, and cholesterol in swollen/enlarged LEL-like 
vacuoles in all cell types (Bargal and Bach 1988; Chen, Bach et al. 1998). Consistent with this 
observation, abnormal lipid accumulation and enlarged LELs are also seen in cells from TRPML1 
knockout mice, TRPML
-/-
 (cup-5) C. elegans, and TRPML
-/-
 Drosophila (Treusch, Knuth et al. 
2004; Venugopal, Browning et al. 2007; Venkatachalam, Long et al. 2008). Electron microscopy 
(EM) studies suggest that enlarged LELs in TRPML
-/-
 cells are likely to be the late endosome - 
lysosome hybrid organelles from which lysosomes are reformed under normal conditions (Piper 
and Luzio 2004). Since the hydrolase activity that is involved in lipid processing is relatively 
normal, the defect observed in TRPML
-/-
 cells is most likely related to the sorting and trafficking 
processes of the endocytic pathway (Chen, Bach et al. 1998). Analyses of trafficking kinetics 
suggest that the defect is in the late endocytic pathways only. Specifically, the exit of lipids from 
the LELs to the TGN is defective in ML4 cells (Chen, Bach et al. 1998; Pryor, Reimann et al. 
2006). In support of these observations, shRNA-mediated knockdown of TRPML1 expression in 
mouse macrophages results in a similar defect in retrograde lipid transport (Thompson, Schaheen et 
al. 2007). Taken together, TRPML1 is likely to be required for the formation of transport vesicles 
from the LEL compartments to the TGN and for the reformation of lysosomes from the late 
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endosome - lysosome hybrid organelles (Piper and Luzio 2004; Treusch, Knuth et al. 2004). This 
hypothesis is supported by the observation that TRPML1 expression is dramatically increased 
following induction of lysosome biogenesis (Sardiello, Palmieri et al. 2009). Since membrane 
fission and/or stabilization of transport vesicles is known to be dependent on luminal Ca
2+
 release 
(Pryor, Mullock et al. 2000; Luzio, Bright et al. 2007), it is likely that the Ca
2+
 permeability of 
TRPML1 is required for the membrane fission from LEL compartments or late endosome - 
lysosome hybrids and the biogenesis of both retrograde transport vesicles and lysosomes (Fig. 1.1). 
TRPML1 may also be required for the reformation of lysosomes from autolysosomes 
(Venkatachalam, Long et al. 2008; Vergarajauregui, Connelly et al. 2008).   
      Other trafficking defects are also observed in TRPML
-/-
 cells. ML4 fibroblasts have been 
reported to exhibit a delay in the delivery of platelet-derived growth factor receptor (PDGFR) to 
lysosomes (Vergarajauregui, Connelly et al. 2008). In mouse macrophages where TRPML1 protein 
level has been reduced by shRNA, the transport of endocytosed molecules to lysosomes is delayed 
(Thompson, Schaheen et al. 2007). Autophagosomes have also been shown to accumulate in ML4 
cells. This could be due to either increased autophagosome formation or delayed fusion of 
autophagosomes with lysosomes to form autolysosomes (AL) (Fig. 1.1) (Vergarajauregui, Connelly 
et al. 2008). ML4 fibroblasts also show a defect in ionomycin-induced lysosomal exocytosis 
(LaPlante, Sun et al. 2006). However, this effect could be a secondary observation, since 
ionomycin (a Ca
2+
 ionophore) presumably acts directly on the Ca
2+
 sensor synaptotagmin VII  
thereby bypassing upstream TRPML activation. Nevertheless, experiments showing that HEK293 
cells transfected with a gain-of-function mutant of TRPML1 exhibit enhanced lysosomal 
exocytosis provide additional evidence that TRPML1 plays a role in this process (Dong, Wang et al. 
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2009). The gain-of-function mutation is likely to have mimicked an unidentified cellular 
stimulation to induce intralysosomal Ca
2+
 release since these experiments were performed using a 
Ca
2+
-free extracellular solution to exclude the involvement of the gain-of-function TRPML1 
channels at the plasma membrane. Taken together, TRPML1 plays a role in multiple membrane 
fusion processes related to late endosomes and lysosomes. TRPML1 may be tightly regulated to 
release Ca
2+
 as a mechanism of modulating the endocytic process in a correct spatiotemporal way. 
      In comparison to TRPML1, the role of TRPML2 and TRPML3 in regulating membrane 
trafficking is less understood. TRPML2 and TRPML3 may function indirectly through the 
formation of heteromultimers with TRPML1, since both heterologously-expressed (Venkatachalam, 
Hofmann et al. 2006) and endogenous (Zeevi, Frumkin et al. 2009) TRPMLs can physically 
associate with each other. However, the extent of co-localization appears to be limited (Zeevi, 
Frumkin et al. 2009). Therefore, it is more likely that TRPML2 and TRPML3 functions are 
primarily cell type specific. In LELs, it is reasonable to hypothesize that TRPML2/3 play a similar 
role in membrane trafficking as TRPML1. TRPML2 has been reported to traffic via the 
Arf6-associated recycling pathway in Hela cells (Karacsonyi, Miguel et al. 2007). While 
overexpression of TRPML2 promotes efficient activation of Arf6, inactivation of TRPML2 by a 
dominant-negative approach decreases recycling of CD59 proteins to the plasma membrane 
(Karacsonyi, Miguel et al. 2007). Thus, TRPML2 may interact and cross-talk with other trafficking 
regulators to control cargo sorting. The localization of TRPML3 is more dynamic with expression 
in multiple intracellular compartments. The diverse expression of TRPML3 may correlate with its 
role in membrane trafficking (Kim, Soyombo et al. 2009; Martina, Lelouvier et al. 2009). 
Overexpression of TRPML3 causes enlarged early-endosome-like structures and defective delivery 
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and degradation of EGF and EGFR that is consistent with its expression in EEs (Kim, Soyombo et 
al. 2009; Martina, Lelouvier et al. 2009). Since heterologously-expressed TRPMLs display basal 
activity in the LELs, it is possible that overexpression of TRPML3 promotes endosomal membrane 
fusion. Interestingly, knockdown of TRPML3 appears to enhance endocytosis and degradation 
(Zeevi, Frumkin et al. 2009), a result that is inconsistent with the role of TRPML1 in degradation 
and trafficking in the late endocytic pathways (LaPlante, Falardeau et al. 2002; Pryor, Reimann et 
al. 2006). It is possible that this observed effect is due to a function of TRPML3 in early endocytic 
pathways. The exact step where TRPML3 functions in the early endocytic pathway is still not clear. 
While Kim et al. showed that TRPML3 overexpression decreases constitutive and regulated 
endocytosis in HEK and HeLa cells (Kim, Soyombo et al. 2009), Martina et al. found that 
internalization of EGFR is not affected but that its delivery from the plasma membrane to the 
lysosome is impaired in human epithelial cells (Martina, Lelouvier et al. 2009). It is possible that 
these observed differences are due to the use of different cell types. Finally, TRPML3 may also be 
involved in the regulation of autophagy since both overexpression and knockdown of TRPML3 
affect autophagy (Kim, Soyombo et al. 2009; Martina, Lelouvier et al. 2009).  
      It is yet unclear how TRPMLs coordinate with the other key regulators of vesicle trafficking 
such as GTPases (Rab and Arf) and phosphoinositides to control endolysosomal dynamics; 
however, we do know that dysfunctions of these regulators all cause similar cellular defects. 
Constitutive activation of Rab5 causes enlarged early endosomes by stimulating homotypic fusion 
(Stenmark 2009). This is reminiscent of the enlarged endosomes seen in cells with TRPML3 
overexpression. It is possible that Rab5 may recruit effectors to activate TRPMLs. Alternatively, 
the activity of TRPMLs may regulate the activity of Rabs, as shown in the case of TRPML2 and 
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Arf6 GTPase (Karacsonyi, Miguel et al. 2007). Similarly, alterations of the levels of endolysosomal 
phosphoinositides (PI(3)P and PI(3,5)P2) also results in enlarged endolysosomes and defective 
endosome-to-TGN retrograde trafficking (Roth 2004), a situation that is similar to the enlarged 
LELs and abnormal late endocytic trafficking phenotype seen in ML4 cells. It is possible that 
TRPMLs are regulated directly by phosphoinositides as shown for many other plasma membrane 
TRPs (Rohacs and Nilius 2007). Alternatively, TRPMLs may regulate key enzymes involved in the 
production or hydrolysis of phosphoinositides. Chapter 2 will discuss one of these possibilities. 
 
3. Lipids on the lysosome membrane 
Like all membranes, the limiting lysosomal membranes have a remarkably complex composition 
and organization of lipids, the function of which are only starting to be unraveled. The major types 
of lipids on the limiting lysosomal membrane include phophatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), sphingolipids, 
cholesterol, as well as their various metabolic derivatives (Kolter and Sandhoff 2005; van Meer, 
Voelker et al. 2008; Lippincott-Schwartz and Phair 2010; Blom, Somerharju et al. 2011; 
Sztolsztener, Dobrzyn et al. 2012). These lipids on lysosomal membranes can affect the vast 
numbers of cellular processes that lysosomes are associated with in at least three principle ways. 
First, they serve as structural components of the lysosomal membrane and define its physical 
properties (Hannun and Obeid 2008; Graham and Kozlov 2010; Lingwood and Simons 2010; 
Lippincott-Schwartz and Phair 2010). The structural features of lipids can influence the flexibility, 
thickness and fusogenic potentials of membranes. For example, glycerophospholipids (GPLs, 
including PC, PE, PS and PI) mostly have unsaturated fatty acyl chains; thus the membrane 
18 
 
enriched with GPLs are highly flexible (Lippincott-Schwartz and Phair 2010). On the other hand, 
sphingolipids and cholesterol usually form more ordered and stiff membrane (Graham and Kozlov 
2010; Lippincott-Schwartz and Phair 2010; Blom, Somerharju et al. 2011). In lysosomes, the 
concentrations of sphingolipids and cholesterol are lower than those in PM, thus providing a 
relatively flexible lipid environment suitable for dynamic fusion/fission process (van Meer, Voelker 
et al. 2008). Second, a variety of signaling factors and lipid enzymes can be recruited to and 
interact with specific lysosomal lipids (van Meer, Voelker et al. 2008; Breslow and Weissman 
2010), generating a complicated regulatory network that modulate the trafficking and activity of 
lysosomes. Such regulatory network helps change the local shape of membranes, sort proteins into 
differentiated subdomains within membranes, and modulate the activity of integral membrane 
proteins. Third, some lysosomal lipids and their metabolic derivatives play critical roles as 
signaling molecules that regulate the activity of lysosomal enzymes and integrity of lysosmal 
membrane (Heinrich, Wickel et al. 2000; Breslow and Weissman 2010; Kirkegaard, Roth et al. 
2010). For example, ceramide, a kind of sphingolipids, can function as an intracellular second 
messenger that binds to and activates a hydrolytic enzyme called cathepsin D in the lysosome 
(Heinrich, Wickel et al. 2000). A recent report provides another striking example that 
bis(monoacylglycero)phosphate (BMP), a membrane-bound, anionic phospholipid predominantly 
localized to the inner lysosomal membrane, can interact with heat-shock protein 70 (Hsp70) and 
help preserve the integrity of membranes under stress conditions (Kirkegaard, Roth et al. 2010). 
      In addition to the lipids on the limiting lysosomal membrane, a considerable number of 
membranes and lipids are passively delivered into lysosomes for degradation during the 
endocytosis, phagocytosis and autophagy processes (Saftig and Klumperman 2009; Kolter and 
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Sandhoff 2010). These membrane lipids reside on the internal vesicles in lysosomal lumen, where 
some of them are broken down into their “building blocks” such as fatty acid, or sphingoid base 
(Kolter and Sandhoff 2005; Kolter and Sandhoff 2010), while others like cholesterol are freed from 
the “lipid raft” (Gallala, Breiden et al. 2011; Gallala and Sandhoff 2011). This recycling and 
turnover process of membrane lipids in lysosomes is essential for overall cellular lipid metabolism, 
the failure of which leads to severe fatal neurodegenerative diseases (Nixon, Yang et al. 2008; 
Bellettato and Scarpa 2010; Kolter and Sandhoff 2010). Although these luminal lipids cannot 
directly affect integral lysosomal membrane proteins (LMPs), under pathological condition their 
storages at the lysosomal lumen may indirectly change the lipid composition of the limiting 
lysosomal membrane, and therefore modulate LMPs (Fraldi, Annunziata et al. 2010).  
     Whether any of these lipids in lysosomes can modulate TRPML1 is a question nobody had 
the answer three years ago when I began to work on the thesis; in fact, this question was barely 
explored at that time due to the inaccessibility of TRPML1 and these lipids. One clue to this 
question is that under pathological conditions, the dysregulation of the metabolism of several lipids 
in lysosomes causes the same late endocytic trafficking defects as those observed in TRPML1
-/-
 
cells (Chen, Patterson et al. 1999; Puri, Watanabe et al. 1999), suggesting that these lipids may 
function in the same signaling pathway as TRPML1, or may even directly regulate TRPML1. 
Among these lipids are PI(3,5)P2, sphingomyelin and cholesterol, all of which could be potential 
regulators of TRPML1 and become the focuses of my thesis. In the following sessions, overviews 





3.1.  PI(3,5)P2 on the lysosome membrane 
Phosphoinositides are a group of negatively charged phospholipids derived from 
phosphatidylinositol, which play key roles in cell signaling and membrane trafficking (Roth 2004; 
McCrea and De Camilli 2009; Poccia and Larijani 2009). Seven phosphoinositide isoforms have 
been identified: PI(3)P, PI(4)P, PI(5)P,  PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3. They are 
concentrated on different parts of cellular membranes, with PI(4,5)P2 mainly on plasma membranes, 
PI(4)P on Golgi, PI(3)P on the cytoplasmic side of endosomes, and PI(3,5)P2 found on late 
endosome and lysosomes (see Fig 1.2). The best characterized phosphoinositides is PI(4,5)P2, 
which modulates a number of plasma membrane channels (Suh and Hille 2008). My major focus 
here will be PI(3,5)P2, a LEL specific phosphoinositide that has recently drawn the attention of 
many investigators.  
3.1.1. PI(3,5)P2 in late endosomes and lysosomes  
PI(3,5)P2 only represents ~0.05% of the total cellular phosphoinositides present in non-stimulated 
cells under basal conditions (Dove, Dong et al. 2009; Ikonomov, Sbrissa et al. 2011). This is ~10-fold 
less than the levels of PI(3)P that are normally maintained in cells (Zhang, Zolov et al. 2007).  Due 
to its low abundance and lack of a specific detection probe (Kutateladze 2010), the majority of 
PI(3,5)P2 studies have focused on PI(3,5)P2-metabolizing enzymes, including PIKfyve/Fab1 and its 
regulators (Shisheva, Rusin et al. 2001; Chow, Zhang et al. 2007; Zhang, Zolov et al. 2007; Jin, Chow 
et al. 2008).  PI(3,5)P2 is generated from PI(3)P via PIKfyve/Fab1 (see Fig 1.2a), a PI 5-kinase that 
localizes to endolysosomes in both yeast and mammalian cells (Duex, Nau et al. 2006; Duex, Tang et 
al. 2006; Botelho, Efe et al. 2008; Dove, Dong et al. 2009; Poccia and Larijani 2009; Ikonomov, 
Sbrissa et al. 2011).  Therefore, PI(3,5)P2 is hypothesized to predominantly localize to the LELs 
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(Bonangelino, Nau et al. 2002; Chow, Zhang et al. 2007; Zhang, Zolov et al. 2007; Dove, Dong et al. 
2009). The activity of PIKfyve/Fab1 has been shown to be positively regulated by several associated 
proteins such as Fig4 and Vac14 (Chow, Zhang et al. 2007; Zhang, Zolov et al. 2007; Jin, Chow et al. 
2008; Dove, Dong et al. 2009).  On the other hand, PI(3,5)P2 can be hydrolyzed to PI(5)P by the 
myotubularin (MTM/MTMR)-family of PI-3 phosphatase (Dove, Dong et al. 2009; Poccia and 
Larijani 2009; Shen, Yu et al. 2009).  Although the global concentration of PI(3,5)P2 is very low, the 
local concentration in PIKfyve-enriched microdomains is likely to increase in response to stimuli 
(Botelho, Efe et al. 2008; Ikonomov, Sbrissa et al. 2009), and can reach levels similar to those of 
PI(4,5)P2 at the plasma membrane (~10 M) (Whiteford, Brearley et al. 1997; Duex, Nau et al. 2006; 
Duex, Tang et al. 2006). Mutations in PI(3,5)P2-metabolizing enzymes have been shown to be 
responsible for a variety of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) 
and Charcot-Marie-Tooth (CMT) disease in humans (Chow, Zhang et al. 2007; Chow, Landers et al. 
2009; Dove, Dong et al. 2009). 
 
3.1.2. Cellular consequences of PI(3,5)P2 deficiency 
At the cellular level, PI(3,5)P2-deficient cells, such as fibroblasts from Fig4 or Vac14 KO mice, 
exhibit enlarged endolysosomes/vacuoles and trafficking defects in the late endocytic pathways, 
which include retrograde LEL-to-TGN trafficking, MVB formation, autophagosome-lysosome 
fusion, and exocytosis (Berwick, Dell et al. 2004; Chow, Zhang et al. 2007; Zhang, Zolov et al. 
2007; Jin, Chow et al. 2008; Ferguson, Lenk et al. 2009). In studies of Vac14
-/-
 cells, 
immunoreactivity of a cation-independent mannose-6- phosphate receptor (ciM6PR), a membrane 
protein that shuttles between TGN and the LELs, was detected in Lamp1-positive compartments 
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rather than in the TGN (Zhang, Zolov et al. 2007), suggesting that reformation of ciM6PR-positive 
transport vesicles from LELs was compromised. Consistent with this model, suppression of 
PIKfyve by small interfering RNA or by treatment with YM201636, a potent inhibitor of Pikfyve, 
also induces defective endosome to TGN retrograde traffic and the formation of swollen endosomal 
structures (Rutherford, Traer et al. 2006; Jefferies, Cooke et al. 2008). The detailed molecular 
mechanism for the PI(3,5)P2 dependent retrograde trafficking effect is largely unknown, though 
Atg18 is reported to mediate the effect (Dove, Piper et al. 2004). In addition, PI(3,5)P2 is 
implicated to be important for sorting proteins to MVBs. Several proteins required for protein 
sorting to MVBs are reported to bind to PI(3,5)P2, such as Ent3p and VPS24 (Friant, Pecheur et al. 
2003) (Whitley, Reaves et al. 2003). PI(3,5)P2 may function together with PI(3)P as important 
recruitment markers for ESCRT complex formation in endolysosomal compartments. Disrupting 
the balance between PI(3)P and PI(3,5)P2 may affect the proper sorting of macromoleculars to 
MVBs, as shown in the case that MVB protein sorting is impaired in yeast mutants with deficient 
PI(3,5)P2 synthesis (Dove, Dong et al. 2009). PI(3,5)P2 has also been shown to have an essential 
role in the fusion of late endosomes or lysosomes with other organelles, including autophagosomes 
(Ferguson, Lenk et al. 2009). Consistent with a role for PI(3,5)P2 in exocytosis, PIKfyve has been 
implicated in the translocation of several ion channels and transporters to the plasma membrane 
(Hill, Hudson et al. 2010).   
 
3.1.3. The effectors of PI(3,5)P2 
PI(3,5)P2 exerts its effect through the recruitment of effector proteins that bind to PI(3,5)P2. Several 
effector proteins have been identified, but considering the multifaceted functions that PI(3,5)P2 
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associates with, future research promises the discoveries of many more downstream effectors.  
Atg18 is a protein that potentially mediates retrograde trafficking following its binding of PI(3,5)P2 in 
yeast (Dove, Piper et al. 2004). Similarly, WIP1 has been shown to bind both PI(3)P and PI(3,5)P2 to 
affect ciM6PR recycling in mammalian cells, suggesting that it is an effector of PI(3,5)P2 
(Proikas-Cezanne, Ruckerbauer et al. 2007). Chapter 2 will demonstrate that mucolipin subfamily of 
Transient Receptor Potential channels (TRPMLs) are novel PI(3,5)P2 effectors that mediate the 
release of Ca
2+
 from endolysosomes (Dong, Shen et al. 2010).   
 
3.2.  Sphingomyelin in lysosomes 
Sphingomyelin (SM) is the most abundant sphingolipid in mammalian cells and exists virtually in 
all membranes (Gault, Obeid et al. 2010).  It consists of a ceramide backbone linked to a 
polar phosphorylcholine group, which makes it barely able to flip-flop across bilayers and almost 
water insoluble (Hannun and Obeid 2008; Breslow and Weissman 2010; Gault, Obeid et al. 2010). 
The major synthesis site of SM is the Golgi (Gault, Obeid et al. 2010). From there, SMs were 
delivered via vesicle transport to the plasma membrane, where they mainly localize on the outer 
leaflet of PM, although a small proportion may also exist on the inner leaflet. Upon endocytosis, 
SMs proceed through the endocytic pathway and reach the lysosome compartments. Here they 
predominantly localize on the luminal leaflet of endosomal and lysosomal membranes or internal 
vesicles in the lumen (see Fig 1.3a). The breakdown of SM is mediated by the sphingomyelinase 
family, which hydrolyse SM to ceramide and free phosphocholine (Perrotta and Clementi 2010). 
Three groups of sphingomyelinase have been identified in mammals based on their optimal pH: 
acid sphingomyelinasse (aSMase) (Gatt 1963; Gatt 1976), alkaline sphingomyelinases (Duan, 
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Hertervig et al. 1996) and the neutral sphingomyelinases (Yamaguchi and Suzuki 1978). Among 
them, aSMase predominantly localizes at lysosomes, while the others concentrate at membranes of 
other cellular compartment, such as Golgi and plasma membrane (Gault, Obeid et al. 2010).  
      The catabolism of SM in lysosomes is tightly controlled by aSMase (Perrotta and Clementi 
2010). First discovered by the pioneering work of Shimon Gatt in 1963 (Gatt 1963), aSMase is 
identified as a glycoprotein with in vitro pH optimum between 4.5 and 5, and presents in most 
human tissues (Fowler 1969). The protein is first glycosylated in ER and then phosphorylated in 
Golgi (Schissel, Keesler et al. 1998; Gault, Obeid et al. 2010). These modifications not only 
stabilize the enzyme, but also ensure its proper delivery to lysosomes and protect it from 
proteolysis. In lysosomes, aSMase metabolizes SMs, and its importance is highlighted by the 
discovery that mutations on aSMase gene, SMPD1, leads to Niemann-Pick (NP) type A and type B 
diseases, progressive neurodegenerative diseases of high lethality (Brady, Kanfer et al. 1966). For 
type A NP (NPA) disease, the enzyme activity of aSMase is almost gone, leading to severe 
symptoms including psychomotor retardation, hepatosplenomegaly and premature death (Brady, 
Kanfer et al. 1966; Perrotta and Clementi 2010). For type B NP (NPB) disease, patients survive 
into adulthood due to residual aSMase enzyme activity, but many of them suffer from 
hepatosplenomegaly and lung diseases (Schuchman 2007; Gault, Obeid et al. 2010). In both types, 
SMs build up in the lysosomes of cells in multiple tissues, such as the liver, spleen, and bone 
marrow, resulting in multiple cellular defects such as dysfunction of lysosomal degradation and 
impaired lysosomal membrane trafficking (Schuchman 2007; Smith and Schuchman 2008; Gault, 
Obeid et al. 2010). The NP disease phenotype was recapitulated in the aSMase
-/-
 mouse 
(Horinouchi, Erlich et al. 1995; Marathe, Miranda et al. 2000), which has proved to be an 
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invaluable tool to study the function of SM and aSMase. 
      The various cellular defects observed in aSMase
-/-
 cells point to the fact that SMs have 
multiple roles besides serving as structural components of lysosomal membranes. Numerous 
studies have unraveled SMs as an important precursor for the ceramide-based signaling pathway 
(Kitatani, Idkowiak-Baldys et al. 2008). In lysosomes, the breakdown of SMs by aSMase provides 
a significant source for generating ceramide, a bioactive messager involved in many cellular 
processes of physiological and pathophysiological importance (Bikman and Summers 2011). 
Multiple stress stimuli, such as ultraviolet (UV), death receptor activation, chemotherapeutic agents, 
and pathogens (Smith and Schuchman 2008), can activate aSMase and increase the concentration 
of ceramide, which further activates the downstream effectors (Yu, Nikolova-Karakashian et al. 
2000; Paris, Fuks et al. 2001; Grassme, Cremesti et al. 2003; Dimanche-Boitrel, Meurette et al. 
2005). This stress response is largely abolished in aSMase mutant cells (from NP disease patients) 
(Lozano, Menendez et al. 2001), aSMase
-/-
 mice (Garcia-Barros, Paris et al. 2003), or aSMase 
siRNA knockdown cells (Zeidan, Wu et al. 2008). The activity of aSMase also plays a key role in 
maintaining the integrity of the lysosomal membrane, as the cells from NPA or NPB patients show 
a marked decrease in lysosomal stability (Kirkegaard, Roth et al. 2010). In addition to the 
lysosomal signaling functions of aSMase, upon oxidative stress or cytokine (such as TNF-a, IL-1b) 
stimulation, aSMase can be secreted into extracellular environment, where they catabolize SMs to 
ceramides on the outer leaflet of plasma membrane (Zeidan and Hannun 2007; Jenkins, Canals et al. 
2010). This translocation of aSMase is likely to be mediated by the exocytosis of membrane 
proximal lysosomes, as the secretion can occur within seconds of stimulation (Jaiswal, Andrews et 
al. 2002; Jin, Yi et al. 2008). 
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      In addition, aSMase
-/-
 cells exhibit defects in endolysosomal trafficking (Chen, Patterson et 
al. 1999; Puri, Watanabe et al. 1999; Smith and Schuchman 2008). Recent research has revealed an 
intriguing mechanism by which accumulated SM in aSMase
-/-
 cells might affect endolysosomal 
membrane dynamics (fusion/fission process) (Chernomordik and Kozlov 2003; Trajkovic, Hsu et al. 
2008; Graham and Kozlov 2010). Due to its zwitterionic headgroup, SM has zero spontaneous 
curvature (Graham and Kozlov 2010). On the other hand, ceramide, without the phosphocholine 
headgroup, has a negative spontaneous curvature (Graham and Kozlov 2010). This property 
difference suggests that aSMase activity could change the physical property of the membrane, such 
as its curvature, so as to increase its fusogenic potential (or its potential to fission). Trajkovic,K et 
al recently provide striking evidence that the formation of intraluminal vesicles (ILVs), which are 
vesicles that bud into the lumen of the endosome, is driven by the hydrolysis of SMs to Ceramides 
(Trajkovic, Hsu et al. 2008). This is further supported by the facts that ILVs are enriched with 
ceramides, and application of SMase inhibitors abrogates the ILV formation (Trajkovic, Hsu et al. 
2008). Thus the conversion from SMs to ceramides on the cytosolic leaflet of the endosome 
promotes the budding of ILVs into the lumen space (ceramide is engulfed into the lumen of ILVs). 
Interestingly, when aSMase is secreted during lysosomal exocytosis, increased ceramide 
concentration on the outer leaflet of plasma membrane induces inward budding of endocytic 
vesicles (again, ceramide is engulfed into the lumen of vesicles) (Tam, Idone et al. 2010). Therefore, 
it is likely that the activity of aSMase in the lumen of lysosomes, which increase ceramide 
concentration on the luminal leaflet of lysosomes, might drive the budding of vesicles to cytosol 
side and promote the formation of retrograde trafficking vesicles. Consistent with this idea, in 
aSMase
-/-
 fibroblasts, the retrograde trafficking from LELs (budding off vesicles) to Golgi is 
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largely impaired (Puri, Watanabe et al. 1999).  
      Whether the SM-based pathway regulates endolysosomal Ca
2+
 signaling is still an open 
question. Yet several groups have reported that SM is involved in maintenance of cellular Ca
2+ 
homeostasis in other cellular compartments (Church, Hessler et al. 2005; Ginzburg and Futerman 
2005; Hannun and Obeid 2008). For example, aSMase
-/-
 mice have defects in ER Ca
2+  
homeostasis due to reduced expression levels of SERCA and of the inositol 1,4,5-triphosphate 
receptor (IP3R), which may contribute to the onset of neuropathology in NPA disease (Ginzburg 
and Futerman 2005). It is possible that in lysosomes, SM metabolism might also play an important 
role in regulating the Ca
2+
 transport machineries, either by modulating their expression level (like 
the previous example), or by directly regulating their activity. Indeed, a recent study revealed that 
the phospho-head of SM can stabilize the positively charged voltage sensor of voltage-activated K
+
 
(Kv) channels on the plasma membrane (Xu, Ramu et al. 2008). This stabilization effect provides a 
novel mechanism by which hydrolysis of SM regulates Kv channels (Xu, Ramu et al. 2008). A 
similar mechanism might also exist in the lysosomal environment. In Chapter 4, I will test whether 
SMs negatively regulate TRPML1, and whether lysosomal Ca
2+
 signaling is impaired in aSMase
-/-
 
cells due to the dysfunction of TRPML1. 
 
3.3.  Cholesterol in lysosomes 
Cholesterol is a key component of mammalian membranes, serving not only as a structural lipid but 
also an important regulator for membrane proteins (Maxfield and Wustner 2002; Mesmin and 
Maxfield 2009; Rosenbaum and Maxfield 2011). Cholesterol forms “lipid rafts” with other 
sphingolipids (mainly SM), which largely determines the fluidity of a membrane. The proper 
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cholesterol level on the membrane ensures the function of many receptors and enzymes as well as 
membrane sorting and trafficking processes (Maxfield and Wustner 2002; Mesmin and Maxfield 
2009; Lingwood and Simons 2010). Cells can generate cholesterol through de novo synthesis in the 
ER, or alternatively, through the uptake of low density lipoprotein (LDL) particles via endocytosis 
(Mesmin and Maxfield 2009; Blom, Somerharju et al. 2011). It is interesting that ER, the site of 
cholesterol synthesis, has a very low concentration of cholesterol (0.5-1% of total). Instead, the 
majority of cellular cholesterol (60-80% of total) is delivered to the plasma membrane (Blom, 
Somerharju et al. 2011). Along the endocytic pathway, early endosomes or recycling endosomes are 
cholesterol rich, while LELs contain much less cholesterol. The regulation of cholesterol level in 
different intracellular organelles is of fundamental importance and governed by multiple tightly 
interconnected mechanisms (Maxfield and Wustner 2002; Mesmin and Maxfield 2009). 
      LELs are critical stations for the redistribution of cholesterol to other intracellular 
compartments (Mesmin and Maxfield 2009; Rosenbaum and Maxfield 2011). When lipoprotein or 
endocytosed pieces of membrane are delivered into the lumen of LEL, an acidic hydrolase called 
lysosomal acid lipase liberates cholesterol from cholesteryl ester (Anderson and Sando 1991) (see 
Fig 1.3a). The unesterified cholesterols then efflux from LELs and transport to the plasma 
membrane, the endoplasmic reticulum or other intracellular membranes (Mesmin and Maxfield 
2009). The mechanism of cholesterol efflux from LELs is an area of active investigation. Two 
proteins, Niemann-Pick C1 (NPC1) (Carstea, Morris et al. 1997) and Niemann-Pick C2 (NPC2) 
(Naureckiene, Sleat et al. 2000), are essential for the efflux, although the precise molecular 
mechanism remains elusive. The best supported model is that liberated cholesterols can bind to 
NPC2 and are later transferred from NPC2 to NPC1 (Cheruku, Xu et al. 2006; Infante, Wang et al. 
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2008). NPC1, which is located on the lysosomal membrane, then transports cholesterol out of the 
lysosomal compartments (Higgins, Davies et al. 1999; Neufeld, Wastney et al. 1999; Davies and 
Ioannou 2000) (Fig 1.3a). The concerted action of NPC1 and NPC2 are tightly regulated and can 
be modulated by the lipids in lysosomes. For example, in vitro studies have shown that NPC2 
activity can be stimulated by BMP (Cheruku, Xu et al. 2006) or ceramide (Abdul-Hammed, 
Breiden et al. 2010), but inhibited by SM (Abdul-Hammed, Breiden et al. 2010).  
      The significance of lysosomal cholesterol metabolism is underscored by its association with 
a fatal, autosomal recessive neurodegenerative disorder called Niemann Pick type C (NPC) disease 
(Schiffmann 2010), which is caused by mutations of NPC1 (~95% of patients), or NPC2 (~5% of 
patients). The major symptoms of NPC patients include progressive cognitive impairment, seizures, 
dystonia, liver dysfunction and early mortality (Higgins, Patterson et al. 1992; Vanier 2010). At the 
cellular level, NPC cells accumulate abnormally large amounts of cholesterol, SM and saturated 
fatty acids in LEL compartments (Rosenbaum and Maxfield 2011; Sztolsztener, Dobrzyn et al. 
2012). This primary defect leads to secondary defects such as the disturbance of endolysosomal 
trafficking processes, which further worsen the cellular pathology (Choudhury, Sharma et al. 2004; 
Pipalia, Hao et al. 2007). For example, in NPC cells, although the formation of autophagosome is 
reported to be normal, the degradation of contents of autophagosomes is largely impaired, 
indicative of the defective fusion process of lysosome and autophagosome (Liao, Yao et al. 2007; 
Pacheco, Kunkel et al. 2007; Fraldi, Annunziata et al. 2010). Studies have also shown that lipid 
transport along the endocytic pathway and retrograde trafficking from LELs to TGN are also 
compromised in NPC cells (Chen, Patterson et al. 1999; Puri, Watanabe et al. 1999; Fraldi, 
Annunziata et al. 2010; Knez and Peake 2010). Potential therapies that target primary or secondary 
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defects have proved to be effective on the cellular level, but there is still no cure for patients yet 
(Vanier 2010).  
      The mechanism by which mutations of NPC1 or NPC2 cause endolysosomal trafficking 
defects remains to be clarified. One possibility is that the failure of efflux of cholesterol may lead 
to the excessive formation of cholesterol/SM-rich microdomains on the lysosomal membrane, 
which makes the membrane more “rigid” and thus less likely to undergo fusion/fission processes 
(Graham and Kozlov 2010; Lippincott-Schwartz and Phair 2010). Indeed, increasing 
cholesterol-enriched regions on lysosomal membrane by cholesterol loading significantly impairs 
the fusion of lysosomes with endosomes and with autophagic vacuoles, while lowering cholesterol 
in diseased cells rescued normal lysosomal fusion (Fraldi, Annunziata et al. 2010). Another 
possibility is that the build-up of cholesterol might have a direct effect on integral lysosomal 
membrane proteins including channels or transporters that are important regulators of membrane 
trafficking. Extensive studies have shown that cholesterol alters the function of many ion channels 
on plasma membrane (Hampshire, Burghel et al. 2010; Levinger, Howlett et al. 2010). For example, 





 channels (Chang, Reitstetter et al. 1995), inhibits L-type Ca
2+
 channels (Jennings, Xu 
et al. 1999), and decreases the current density of inwardly rectifying K
+
 channels by changing the 
number of active channels (Romanenko, Rothblat et al. 2002). Due to the intracellular localization 
of the lysosome membrane, which defies conventional patch clamp analysis, the effect of 
cholesterol on lysosomal channels has been barely investigated. However, with the advance of 
lysosomal patch clamp technique first described by Xu lab, it is now possible to examine whether 
the accumulation of cholesterol in diseased conditions changes the activity of channels in 
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lysosomes, and how these changes relate to trafficking defects.  
 
4. Lysosomal storage disease 
The aforementioned Mucolipidosis type IV and Niemann Pick disease(type A,B,C) all belong to 
lysosomal storage diseases (LSDs), which are a group of inherited diseases caused by the 
deficiency of lysosomal hydrolases, membrane proteins, or other proteins important for normal 
functions of lysosomes (Bellettato and Scarpa 2010; Vitner, Platt et al. 2010; Schultz, Tecedor et al. 
2011; Shachar, Lo Bianco et al. 2011).  Over 50 LSDs have been identified, and the common 
hallmark of LSDs is the abnormal accumulation of undigested substrates in lysosomal 
compartments (Vitner, Platt et al. 2010). The storage does not follow a one-enzyme, one-substrate 
relationship; instead, there is often secondary storage of other lipids unrelated to the primary defect 
and such accumulation is progressive (Schultz, Tecedor et al. 2011). Failure to degrade the 
accumulated substrates eventually impairs lysosomal function, causes cell death and leads to 
debilitating symptoms such as mental retardation, loss of motor ability and premature death. 
Neurons are especially vulnerable to such accumulation; thus most of LSDs involve central 
nervous system dysfunction (Bellettato and Scarpa 2010). There are currently no effective cures for 
most LSDs (Schultz, Tecedor et al. 2011). 
  
Although caused by different genetic defects, LSDs share many common trafficking defects (Vitner, 
Platt et al. 2010; Schultz, Tecedor et al. 2011). For instance, the perturbation of LEL-to-Golgi 
trafficking is observed in a number of LSDs (i.e. Niemann-Pick disease, Mucolipidosis IV, GM1 
gangliosidosis, GM2 gangliosidosis, Fabry disease) (Chen, Patterson et al. 1999; Puri, Watanabe et 
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al. 1999)(See Fig 1.3b). The fusion of lysosomes with autophagosomes is also impaired in many 
LSDs, leading to autophagosome accumulation and cell death (Fukuda, Roberts et al. 2006; 
Jennings, Zhu et al. 2006; Pacheco, Kunkel et al. 2007; Settembre, Fraldi et al. 2008; Venugopal, 
Mesires et al. 2009; Curcio-Morelli, Charles et al. 2010). In addition, defective intracellular Ca
2+
 
signaling is also a common factor in LSDs (Korkotian, Schwarz et al. 1999; Lloyd-Evans, Pelled et 
al. 2003; Pelled, Lloyd-Evans et al. 2003; Ginzburg and Futerman 2005; Ginzburg, Li et al. 2008; 
Lloyd-Evans, Morgan et al. 2008). These similar cellular defects suggest that the common 
regulatory machineries for intracellular membrane trafficking pathways are impaired in LSDs, 
despite their distinct primary causes. Understanding which and how the regulatory machineries are 
affected in LSDs will not only bring us new insight into lysosomal physiology, but also lay critical 
foundations for future therapeutic development (Shachar, Lo Bianco et al. 2011). Chapter 4 will 
discuss that TRPML1, an important regulator for endolysosomal trafficking, is compromised in 
several LSDs, and the dysfunction of TRPML1 contributes to the trafficking defects and secondary 
lysosomal storage seen in these LSDs’ cells. This work is the first functional investigation into the 
effect of accumulated luminal lipids on lysosomal channels, and raises an intriguing possibility that 
enhancing TRPML1 activity may speed membrane trafficking and thus up-regulate the waste 










Figure 1.1: Overview of the endocytic pathway and lysosomal fusion/ fission processes. 
Endolysosomes are Ca
2+
 stores, with a luminal Ca
2+
 concentration estimated to be approximately 
0.5 mM. Early endosomes (EEs; pH 6.0) are derived from the primary endocytic vesicles after 
endocytosis. EEs can undergo maturation through membrane trafficking to become late endosomes 
(LEs; pH 5.5). LEs can fuse with lysosomes (LYs; pH 4.5) to form late endosome and lysosome 
hybrids (LELHs). LYs can be reformed from LELHs in a fission-dependent mechanism (referred to 
as lysosome biogenesis). Besides fusion with LEs, LYs also fuse with autophagosomes (APs) to 
form autolysosomes (ALs), fuse with phagosome to form phagolysosome, or fuse with the plasma 
membrane during exocytosis. Retrograde transport vesicles, derived from LEs or LYs upon 













Fig 1.2: Phosphoinositides and Ca
2+
 channels in endolysosomes.   
A: An overview of phosphoinositide (PI) synthesis in endolysosomes. PI(3)P is synthesized from PI 
via a PI 3-kinase (Vps34) present in endosomes, while PI(3,5)P2 is synthesized from PI(3)P via a PI 
5-kinase (PIKfyve/Fab1).  PIKfyve is a PI(3)P effector that is associated with late endosomes and 
lysosomes (LELs), and is positively regulated by Vac14. PI(3,5)P2 can be dephosphorylated by Fig4 
or MTM/MTMRs to generate PI(3)P or PI(5)P, respectively.   
B: The distribution of PI(3)P and PI(3,5)P2 associated with the membranes of early and late 
endosomes, as well as lysosomes, are represented by yellow and red outlines at the membrane of 
these vesicle types. respectively (Dove, Dong et al. 2009). TRPML1-3, TRPM2, and TPC1-2 are 
putative Ca
2+
 release channels associated with endolysosomal membranes that are also labeled in this 
diagram (Cheng, Shen et al. 2010; Dong, Wang et al. 2010; Zhu, Ma et al. 2010).  TRPML1-3 
channels are predominantly localized to LELs, while TRPML2 and TRPML3 are also associated with 
recycling and early endosomes, respectively.  TPC2 is mainly localized in the LELs, and TPC1 is 
mainly associated with early and late endosomes.  TRPM2 is expressed in specific cell types, and is 
associated with LELs as well as the plasma membrane. The concentration of Ca
2+
 stores associated 
with each vesicle type is also indicated, with luminal [Ca
2+
] estimated to be in the micro- to 




Fig 1.3:  Sphingomyelin and cholesterol in late endosomes/lysosomes.  A). The breakdown 
of sphingomyelins (SMs) in lysosome is mediated by acid sphingomyelinase (aSMase), which 
hydrolyse SM to ceramide (Cer) and free phosphocholine. aSMase is a glycoprotein with in vitro 
pH optimum between 4.5 and 5. It metabolizes both the SMs on the luminal leaflet of the 
limiting lysosomal membrane and those on the outer leaflet (luminal side) of internal vesicles.  
Late endosomes/lysosomes are also critical stations for the metabolism of cholesterol. 
Cholesteryl esters are hydrolyzed by lysosomal acid lipase to produce free cholesterol and fatty 
acid. Free cholesterol is transferred to NPC2, and then to NPC1. NPC1 help free cholesterol flip 
to the cytosolic side, where cytoplasmic carrier protein transport free cholesterol to its various 
destinations in the cell. B). In NP fibroblasts, accumulation of SMs or cholesterol in LELs causes 
LEL-to-Golgi trafficking defects. Same defects are also observed in PI(3,5)P2-deficient cells (Zhang, 
Zolov et al. 2007), ML4 fibroblasts (Chen, Bach et al. 1998; Shen, Wang et al. 2011), as well as 
fibroblasts from several other sphingolipid LSDs (Chen, Patterson et al. 1999; Puri, Watanabe et al. 
1999), which suggest that SMs, cholesterol, PI(3,5)P2 and TRPML1 may function in the same 











PI(3,5)P2  DIRECTLY BINDS AND ACTIVATES MUCOLIPIN CA
2+
 RELEASE 




PI(3,5)P2 is a low abundance endolysosome-specific phosphoinositide (PIP), the deficiency of which 
causes enlarged endolysosomes and endocytic trafficking defects in cells. Similar trafficking defects 
are also observed in mammalian cells that lack TRPML1, a Ca
2+
-permeable channel primarily 
localized on membranes of late endosomes and lysosomes. Here we hypothesized that endolysosomal 
Ca
2+
 release through TRPML channels is regulated by PI(3,5)P2. By directly patch-clamping 
endolysosomal membranes, we found that PI(3,5)P2 potently and specifically activates TRPML1 in 
both heterologous and endogenous systems. Lipid-protein binding assays showed that PI(3,5)P2 binds 
directly to the N terminus of TRPML1. The multiple positively charged amino acid residues are 
critical for the binding, and mutations on these residues abolished the PI(3,5)P2 sensitivity of 
TRPML1. Overexpression of TRPML1 rescued the enlarged vacuole phenotype in PI(3,5)P2- deficient 
cells, suggesting that TRPML1 is a downstream effector of PI(3,5)P2. Notably, this PI(3,5)P2-
dependent regulation of TRPML1 is evolutionarily conserved. In budding yeast, hyperosmotic stress 
induces Ca
2+
 release from the vacuole. Here, we showed that this release requires both PI(3,5)P2 
production and a yeast functional TRPML homolog. We propose that TRPMLs regulate membrane 
trafficking by transducing information about PI(3,5)P2 levels into changes in juxtaorganellar Ca
2+
, 







 is a key regulator of synaptic vesicle fusion during neurotransmission.  Similarly, Ca
2+
 is thought 
to regulate other, more general membrane trafficking pathways (Hay 2007).  However, in these cases, 
the source of Ca
2+
 is unknown.  For these general pathways, it has been postulated that Ca
2+
 is 
released through unidentified Ca
2+
 channels from the lumen of vesicles and organelles (Peters and 
Mayer 1998; Hay 2007; Luzio, Pryor et al. 2007).   Transient receptor potential (TRP) proteins are a 
superfamily of Ca
2+
-permeable cation channels that are localized in the plasma membrane and/or 
membranes of intracellular organelles (Dong, Wang et al. 2010).  For example, mucolipin TRPs 
(TRPML1-3) are localized in the membranes of endosomes and lysosomes (collectively 
endolysosomes) (Puertollano and Kiselyov 2009; Cheng, Shen et al. 2010).  Mutations in the human 
TRPML1 gene cause mucolipidosis type IV (ML4) neurodegenerative disease (Sun, Goldin et al. 2000; 
Nilius, Owsianik et al. 2007).  Cells that lack TRPML1 exhibit enlarged endolysosomes and 
trafficking defects in the late endocytic pathway (reviewed in Refs. (Puertollano and Kiselyov 2009; 
Cheng, Shen et al. 2010)).  TRPMLs are, therefore, natural candidate channels for Ca
2+
 release in the 
endolysosome.   
  PI(3,5)P2 is a low-abundance endolysosome-specific phosphoinositide (Bonangelino, Nau et 
al. 2002; Chow, Zhang et al. 2007; Zhang, Zolov et al. 2007; Dove, Dong et al. 2009).  PI(3,5)P2 can 
be generated from PI(3)P through PIKfyve/Fab1,  a PI 5-kinase that is localized in the endolysosome 
of  both yeast and mammalian cells (Duex, Nau et al. 2006; Botelho, Efe et al. 2008; Dove, Dong et al. 
2009; Poccia and Larijani 2009).  The activity of PIKfyve/Fab1 can be positively regulated by several 
associated proteins such as Fig4, Vac14, and Vac7 (Chow, Zhang et al. 2007; Zhang, Zolov et al. 2007; 
Jin, Chow et al. 2008; Dove, Dong et al. 2009).  On the other hand, PI(3,5)P2 can be metabolized into 
PI(5)P through the myotubularin (MTM/MTMR)-family of PI-3 phosphatase (Dove, Dong et al. 2009; 
Poccia and Larijani 2009; Shen, Yu et al. 2009).  Human mutations in PI(3,5)P2-metabolizing enzymes 
and their regulators cause a variety of neurodegenerative diseases including amyotrophic lateral 
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sclerosis (ALS) and Charcot-Marie-Tooth (CMT) disease (Chow, Zhang et al. 2007; Chow, 
Landers et al. 2009; Dove, Dong et al. 2009). At the cellular level, PI(3,5)P2-deficient cells reportedly 
exhibit enlarged endolysosomes/vacuoles and trafficking defects in the endocytic pathways (Chow, 
Zhang et al. 2007; Zhang, Zolov et al. 2007; Jin, Chow et al. 2008; Dove, Dong et al. 2009).   
  Because the cellular phenotypes in PI(3,5)P2-deficient cells are similar to those observed in 
cells lacking TRPML1, we hypothesized that TRPML1 may act as an endolysosomal Ca
2+
-release 
channel that is regulated by PI(3,5)P2.  In this study, by directly patch-clamping of the endolysosomal 
membrane, we found that PI(3,5)P2 activates TRPMLs with striking specificity and potency. Protein-
lipid interaction and mutational analyses revealed that PI(3,5)P2 binds directly to the N-terminus of  
TRPML1.  Overexpression of TRPML1 suppresses the enlarged vacuole phenotype observed in 
PI(3,5)P2-deficient cells.  We conclude that PI(3,5)P2 controls endolysosomal membrane trafficking by 
regulating TRPML channels to change juxtaorganellar Ca
2+





Molecular biology and biochemistry. Full-length mouse TRPML1, 2, and 3  were cloned into the 
EGFP-C2 (Clontech) or mCherry vector (Xu, Delling et al. 2007; Dong, Cheng et al. 2008; Dong, 
Wang et al. 2009).  TRPML1 non-conducting pore mutant (D471K/D472K; abbreviated TRPML1-KK) 
and PIP2-insensitive mutant (R42Q/R43Q/R44Q/K55Q/R57Q/R61Q/K62Q; abbreviated TRPML1-7Q) 
were constructed using a site-directed mutagenesis kit (Qiagen). For glutathione S-transferase (GST) 
fusion constructs, DNA fragments corresponding to the N- (amino acid residues 1-69) terminal 
regions of mouse TRPML1 were generated by PCR amplification and cloned into the EcoRI and XhoI 
site of pGEX4T1, in frame to generate GST-fusion protein plasmids (pGEX-ML1-N). For 
overexpression of TRPML1 in yeast, full-length mouse TRPML1 was cloned into the XhoI and EcoRI 
site of the pCuGFP416 vector, and the XhoI and Hind III site of the pVT102U-GFP vector.  FKBP*2 
fragment was PCR-amplified from EGFP-FKBP12-Rab5 and inserted into the HindIII and XhoI site 
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of EGFP-Rab7 vector.  RFP-FRB-MTM1 and EGFP-FKBP*2-Rab5 were kind gift from Dr.Banasfe 
Larijani.  All constructs were confirmed by sequencing, and protein expression was verified by 
Western blot.  HEK293T, Cos-1, human fibroblasts, or mouse primary fibroblast cells were transiently 
transfected with TRPML1-3 and the TRPML1 mutants for electrophysiology, biochemistry, live-cell 
imaging, and confocal imaging. Confocal images were taken using a Leica (TCS SP5) microscope. 
TRPML1 Western blot analyses were performed with an anti-GFP monoclonal antibody (Covance).  
 
Endolysosomal electrophysiology. Endolysosomal electrophysiology was performed in isolated 
endolysosomes using a modified patch-clamp method (Dong, Cheng et al. 2008; Dong, Wang et al. 
2009).  HEK293 or Cos-1 cells were used for all the heterologous expression experiments and were 
transfected using Lipofectamine 2000 (Invitrogen) with TRPML1 or mutants fused to GFP or mCherry. 
Human skin fibroblast cells from a ML4 patient (TRPML1
−/−
, clone GM02048) and age-matched 
control (TRPML1
+/+
, clone GM00969) were obtained from the Coriell Institute for Medical Research 
(NJ, U.S.A).  LEL size is usually < 0.5 m, which is suboptimal for patch clamping. We therefore 
treated cells with 1 M vacuolin-1, a lipid-soluble polycyclic triazine that can selectively increase the 
size of endosomes and lysosomes, for ~1h (Huynh and Andrews 2005). Large vacuoles (up to 5 m; 
capacitance = 0.68 ± 0.05 pF, N = 44 vacuoles) were observed in most vacuolin-treated cells. 
Occasionally, enlarged LELs were obtained from TRPML1-transfected cells without vacuolin-1 
treatment. No significant difference in TRPML channel properties were seen for enlarged LELs 
obtained with or without vacuolin-1 treatment. Vacuoles positive for both mCherry-TRPML1 and 
EGFP-Lamp1 were considered enlarged LELs. Whole-endolysosome recordings were performed on 
isolated enlarged LELs. In brief, a patch pipette (electrode) was pressed against a cell and quickly 
pulled away to slice the cell membrane. Enlarged LELs were released into a dish and identified by 
monitoring EGFP-TRPML1, the mCherry-TRPML1 or EGFP-Lamp1 fluorescence. Unless otherwise 
stated, bath (internal/cytoplasmic) solution contained 140 mM K-Gluconate, 4 mM NaCl, 1 mM 
EGTA, 2 mM Na2-ATP, 2 mM MgCl2, 0.39 mM CaCl2 , 0.1 mM GTP, 10 mM HEPES (pH adjusted 
with KOH to 7.2; free [Ca
2+
]i approximately 100 nM). Pipette ( luminal) solution was pH 4.6 standard 
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extracellular solution (modified Tyrode’s) with 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
20 mM HEPES, 10 mM glucose (pH adjusted with NaOH). All bath solutions were applied via a fast 
perfusion system to achieve a complete solution exchange within a few seconds. Data were collected 
using an Axopatch 2A patch clamp amplifier, Digidata 1440, and pClamp 10.0 software (Axon 
Instruments). Whole-endolysosome currents were digitized at 10 kHz and filtered at 2 kHz. All 
experiments were conducted at room temperature (21-23ºC), and all recordings were analyzed with 
pCLAMP10 (Axon Instruments, Union City, CA), and Origin 8.0 (OriginLab, Northampton, MA).  
All PIP antibodies are from Echelon Biosciences Inc.  All PIPs are from A.G. Scientific, Inc. 
 
GST fusion proteins. To purify GST-tagged proteins, Escherchia coli BL21DE3 was transformed 
with empty pGEX vectors or pGEX-TRPML1-N (abbreviated as pGEX-ML1-N). After growth to 
approximately OD600 = 0.6 in a SuperBroth medium supplemented with ampicillin, expression was 
induced with IPTG (1 mM) for 7 h at 37°C. Cells were collected and resuspended in 30 ml of ice-cold 
PBS supplemented with protease inhibitor cocktail, 0.5 mM EDTA, and deoxytibonuclease, and lysed 
with a French press. Cell lysates in 1% Triton-X100 were incubated with 2 mL mixed glutathione 
Sepharose (GE Healthcare) for 1 h at 4°C. After three washes with 30 mL PBS, proteins were eluted 
with 7 mL elution buffer (10 mM Glutathione, 50 mM Tris, pH 8).  
 
Lipid Strip Binding Assay.  Lipid binding analysis of GST-ML1-N and GST-ML1-7Q-N fusion 
proteins was conducted using PIP Strips (Echelon Biosciences Inc.), with each spot containing 100 
pmol active lipids. Membranes were blocked with Phosphate Buffered Saline Tween (PBST) solution 
(supplemented with 3% fatty acid-free bovine serum albumin) for 1 h at room temperature, and 
incubated with 0.5-3 g GST-fusion protein in blocking buffer overnight. After six washes, the 
membranes were incubated with a mouse anti-GST antibody (1:5000, Sigma) for 1 h at room 
temperature, and secondary antibody HRP-labeled goat anti-mouse (1:5000) was added before 
detection by enhanced chemiluminescence.  
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PIP bead binding assay. Purified GST fusion proteins (10 g) were diluted in 1 mL binding buffer 
(50 mM Tris, 150 mM NaCl, 0.25% NP-40, pH 7.5) and incubated with 50 μl of 50% lipid-conjugated 
Sepharose beads (Echelon Biosciences Inc.) for 2 h. After three washes, proteins were eluted from the 
PIP beads by heating at 50°C for 10 min in 2X SDS-PAGE sample buffer and visualization by Western 
blot. 
 
Liposome binding assay. Purified GST fusion proteins (3 g) were incubated with 20 l  liposome 
(Echelon Biosciences Inc.) in 1 mL binding buffer (50 mM Tris, 150 mM NaCl, 0.05% Nonidet P-40, 
pH 7.5) for 10 min. Liposomes were pelleted at 16,000 x g for 10 min and washed multiple times with 
binding buffer. Bound fractions were analyzed by Western blot. 
 
Yeast Strains 
Wild-type and mutant yeast strains are listed in Table 2.1 (next page). Strains were grown at 24°C or 
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 imaging. Yeast Ca
2+
 imaging experiments were performed using an aequorin-based 
genetic Ca
2+ 
sensor method (Denis and Cyert 2002). PEVP11/AEQ plasmid was kindly provided by 
Dr. Patrick H. Masson (University of Wisconsin-Madison, Madison, WI).  Transformed yeasts were 
inoculated from a saturated overnight culture to OD600 ~ 0.3 in a synthetic defined (SD) medium with 
3 M coelenterazine, and grown overnight (OD600 = 2–3) at 24°C or 30ºC to convert apo-aequorin to 
aequorin. For each experiment, an aliquot of 250 l was harvested, re-suspended in 100 l SD 
medium, and transferred to 94-well plates for luminescence measurement. Baseline luminescence was 
recorded every 3 s for 30 s using a PHERAstar plate reader (BMG Labs). Hyperosmotic shock was 
performed by adding an equal volume of SD medium (100 l) containing 1.8 M NaCl to a final 
concentration of 0.9 M. All experiments were concluded with 14% ethanol or 0.03 % SDS, which 
resulted in maximal luminescence and served as a positive control for aequorin transformation.  
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Table 2.1 Yeast strains. 
Genotype Strains Genetic background References 
WT LWY7217 MATa leu2,3-112 ura3-52 his3-Δ200 trp1-Δ901 
lys2-Δ801 suc2-Δ9 
Ref. (Duex, Tang et al. 2006) 
vac7Δ LWY2054 LWY 7217; vac7Δ::HIS3 Ref. (Duex, Tang et al. 2006) 
WT LWY 7235 MATa leu2,3-112 ura3-52 his3-Δ200 trp1-Δ901 
lys2-Δ801 suc2-Δ9 
Ref. (Duex, Tang et al. 2006) 
vac14Δ LWY 5177 LWY 7235; vac14Δ::TRP1 Ref. (Duex, Tang et al. 2006) 
fig4Δ LWY 6474 LWY 7235; fig4Δ::TRP1 Ref. (Duex, Tang et al. 2006) 
yvc1Δ LWY 6848 LWY 7235; yvc1Δ::Kan This study 
WT SEY6210 MATa leu2-3,112 ura3-52 his3-Δ200 trp1-Δ901 
lys2-Δ801 suc2-Δ9 
Ref. (Botelho, Efe et al. 
2008) 
fab1Δ fab1Δ2 SEY6210; fab1Δ::HIS3 Ref. (Botelho, Efe et al. 
2008) 




Yeast vacuole labeling. Log-phase yeast cells were labeled with FM4-64 dye (Molecular Probes) 
(Duex, Tang et al. 2006). Phase contrast and fluorescence images were taken using a Zeiss microscope 
with a 100X objective.  
 
Mouse fibroblast vacuole assay. Vac14
−/−
 mouse fibroblast cells were isolated and cultured as 
described previously (Zhang, Zolov et al. 2007). Briefly, fibroblasts were transiently transfected by 
electroporation (260 V, 950 F) with 100 g of the following expression constructs: mCit,  mCit-
Vac14, GFP-ML1, GFP-ML1-KK, or GFP-ML1-7Q. Cells were grown on 100-mm plates to 90% 
confluence and distributed to six 35-mm plates after electroporation. Cells were fixed with 4% 
paraformaldehyde 24 h after electroporation. Fibroblasts were considered to be vacuolated if they had 
43 
at least one enlarged (> 3 m) cytoplasmic vacuole.   
 
Confocal imaging. All images were taken using a Leica (TCS SP5) confocal microscope. Lamp1 
antibody was from the Iowa Hybridoma Bank.   
 
Data analysis.  Data are presented as the mean ± standard error of the mean (SEM).  Statistical 





Activation of endolysosomal TRPML channels by PI(3,5)P2   
TRPML1 is primarily localized on membranes of late endosomes and lysosomes (LELs) (Pryor, 
Reimann et al. 2006; Cheng, Shen et al. 2010), which are inaccessible to conventional 
electrophysiological approaches. Using our recently-established modified patch-clamp method (Dong, 
Wang et al. 2009; Dong, Wang et al. 2010), native LEL membranes were directly patched.  HEK293T 
or Cos-1 cells were transfected with either EGFP-TRPML1 alone, or co-transfected with mCherry-
TRPML1 and EGFP-Lamp1 (a marker for LEL). Whole-endolysosome recordings (see Fig 1.1a; note 
that the inward current indicates cations flowing out of the endolysosome) were performed on 
enlarged vacuoles manually isolated from cells pre-treated with vacuolin-1 (Dong, Cheng et al. 2008), 
which caused an increase in the diameter of the vacuoles from < 0.5 m to up to 5 m (mean 
capacitance = 0.68 ± 0.05 pF, N = 44 vacuoles). The majority (> 85%) of mCherry-TRPML1-positive 
vacuoles were also EGFP-Lamp1-positive, confirming that the TRPML1-positive vacuoles were 
enlarged LELs (Dong, Cheng et al. 2008).  In the TRPML1-positive enlarged LELs, small basal 
inwardly rectifying currents (72 ± 12 pA/pF at -140 mV, N = 65 vacuoles) were seen under the whole-
endolysosome configuration (Fig 2.1b, 2.1c).  Bath application of 100 nM PI(3,5)P2 in a water-soluble 
diC8 form, rapidly and dramatically activated TRPML1-mediated current (ITRPML1; = 15  ± 4 s at -
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140 mV, N = 8 vacuoles; 18.3 ± 2.7-fold increase of basal activity, N = 20 vacuoles) (Fig 2.1b-e ). 
PI(3,5)P2-dependent activation was dose-dependent (EC50= 48 ± 14 nM, Hill slope (n) = 1.9, N = 7 
vacuoles). On average, ITRPML1 in the presence of 100 nM  diC8 PI(3,5)P2 was  982 ± 150 pA/pF at -
140 mV (N = 23 vacuoles).   
 In yeast, PI(3,5)P2 is exclusively produced from PI(3)P by the PIKfyve/Fab1 PI 5-kinase (Cooke, 
Dove et al. 1998; Gary, Wurmser et al. 1998; Bonangelino, Nau et al. 2002).  PI(3,5)P2 can be quickly 
metabolized into PI(3)P by Fig4, or to PI(5)P by MTMR-family phosphatases (Rudge, Anderson et al. 
2004; Duex, Nau et al. 2006; Dove, Dong et al. 2009; Shen, Yu et al. 2009).  Neither PI(3)P (1 M; 
1.05 ± 0.17 fold increase of basal, N = 4; Fig 2.1e) nor PI(5)P (1 M; 0.98 ± 0.05 fold increase of 
basal, N=3; Fig 2.1e) activated ITRPML1. PI(3)P and PI(3,5)P2 are localized in the endolysosome system. 
Other PIPs such as PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3, are localized in the plasma membrane, or in 
other intracellular organelles, and are sequestered from endolysosomes (Poccia and Larijani 2009). 
ITRPML1 was not activated by these other PIPs (Fig 2.1e). Thus, PI(3,5)P2 activated ITRPML1 with a 
striking specificity. TRPML2 and TRPML3 are also localized in the endolysosome (Cheng, Shen et al. 
2010).  PI(3,5)P2, but not PI(3)P activated whole-endolysosome ITRPML2 and  ITRPML3  (data not shown).  
Since PI(3,5)P2 and TRPMLs are both primarily localized in the LEL (Refs. (Cheng, Shen et al. 2010)
,
 
(Dove, Dong et al. 2009); see Fig 2.2),  the insensitivity of ITRPML1 to PI(3)P or  PI(5)P, and its robust 
activation by PI(3,5)P2 suggested that TRPML1 might be acutely regulated by the activities of 
PIKfyve/Fab1, or by Fig4 or MTMR phosphatases in the LEL.     
 
Activation of endogenous TRPML-like currents by PI(3,5)P2   
Next, we investigated whether PI(3,5)P2 activated endogenous TRPMLs.  In enlarged LELs isolated 
from wild-type (TRPML1
+/+
) human fibroblast cells, PI(3,5)P2–activated ITRPML-L was detected in 5 of 
5 tested vacuoles (Fig 2.1f), with an average current amplitude 239 ± 37 pA/pF at -140 mV (N = 5; 
Fig 2.1g).  In contrast, enlarged LELs from human ML4 (TRPML1
−/−
 or abbreviated as ML1
−/−
) 
fibroblasts showed no significant PI(3,5)P2–activated ITRPML-L (15.7 ± 5.2 pA/pF at -140 mV, N = 6;  
Fig 2.1g). These results indicated that PI(3,5)P2 activated endogenous TRPMLs, and that TRPML1 
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was the primary or sole functional TRPML channel in the endolysosome of human fibroblast, 
although a previous study reported the expression of TRPML2 and TRPML3 in human fibroblasts 
(Zeevi, Frumkin et al. 2009).  
 
Binding of PI(3,5)P2 to the N-terminus of TRPML1 in vitro 
Phosphoinoitides are known to bind with high affinity to PI-binding modules such as PH or FYVE 
domain, or to poly-basic region with unstructured clusters of positively-charged amino acid residues, 
such as Arg and Lys, in an electrostatic manner (Suh and Hille 2008).  PI(4,5)P2 can bind directly to 
the cytoplasmic N- and C- termini of several plasma membrane TRPs (Kwon, Hofmann et al. 2007; 
Nilius, Owsianik et al. 2008). Notably, the intracellular N terminus of TRPML1 has a poly-basic 
region (Nilius, Owsianik et al. 2008) (see Fig 2.3a).  To test whether PI(3,5)P2 binds directly to 
TRPML1, we fused GST to the entire N-terminus of mouse TRPML1, up to residue 69 (see Fig 2.3a 
for putative membrane topology). The protein, GST-TRPML1-N (abbreviated as GST-ML1-N), was 
used to probe phosphoinositides immobilized on a nitrocellulose membranes (Kwon, Hofmann et al. 
2007; Nilius, Owsianik et al. 2008; Suh and Hille 2008)(Fig 2.3b). GST-ML1-N, but not GST alone, 
bound to PIP3 and PIP2s, but not to other PIPs or phospholipids (Fig 2.4a). A liposome assay showed 
that GST-ML1-N strongly associated with PI(3,5)P2, but not PI(3)P or control liposomes (Fig 2.4b). In 
a pull-down assay, agarose beads conjugated with PI(3,5)P2, but not control lipids, pulled down GST-
ML1-N (Fig 2.4c). Taken together, these results suggested that PI(3,5)P2 bound directly in vitro to the 
cytoplasmic N-terminus of TRPML1.   
  
Critical amino-acid residues in PI(3,5)P2 binding  
To further map the PI(3,5)P2 binding sites, we systematically replaced positively-charged amino acid 
residues (Arg and Lys) within and adjacent to the poly-basic region with non-charged Gln residues 
and assayed Gln-substituted, purified GST-fusion proteins for PI(3,5)P2 binding. We also tested 
whether PI(3,5)P2 activated Gln-substituted TRPML1 channels using whole-endolysosome recordings. 
A most dramatic decrease in PI(3,5)P2 binding and activation (Fig 2.5, 2.6) was observed in a 7Q 
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mutant, with seven substitutions (R42Q/R43Q/R44Q/K55Q/R57Q/R61Q/K62Q).  In contrast to GST-
ML1-N, GST-ML1-7Q-N failed to bind significantly to PI(3,5)P2 or to other PIPs in the PIP strip and 
pull down assays (Fig 2.5a, 2.5b).  Considering the specificity of PI(3,5)P2 for TRPML1 activation, 
one plausible explanation for the apparent discrepancy between our biochemical assays (see Fig 2.5a) 
and  electrophysiological measurements (see Fig 2.1e) is that the purified GST-ML1-N protein 
fragment did not recapitulate the specificity of PIP-binding of full length TRPML1 in the 
endolysosomal membrane.  Nevertheless, the binding affinity of ML1-N to PI(3,5)P2 was dramatically 
reduced by removing the charges with the 7Q mutations (Fig 2.5a, 2.5b),  suggesting that multiple 
positively charged amino acid residues are critical for PI(3,5)P2 binding.  
  Compared to wild type (WT) TRPML1, TRPML1-7Q was only weakly activated by high 
concentrations of PI(3,5)P2, with a maximal response (efficacy) that was approximately 20% of 





-7Q also exhibited large basal currents (Fig 2.6c), suggesting a relatively specific effect of 
7Q mutations on PI(3,5)P2-dependent activation.  Consistent with the PI(3,5)P2 binding-assay results, 
we found that GST-ML1-N, but not GST-ML1-7Q-N, competitively reduced the activation effect of 
PI(3,5)P2 (Fig 2.7a, 2.7b).  Collectively, our results suggested that PI(3,5)P2 bound directly to the 
cytoplasmic N-terminus of TRPML1, resulting in conformational changes that favor opening of 
TRPML1. 
 
PI(3,5)P2  in vacuolar Ca
2+
 release in yeast  
TRPML1 is a Ca
2+
-permeable channel (Grimm, Cuajungco et al. 2007; Xu, Delling et al. 2007), so 
activation by PI(3,5)P2 may lead to Ca
2+
 release from endolysosomes. Although PIKfyve/Fab1 is a PI 
5-kinase responsible for PI(3,5)P2 generation in both yeast and mammalian cells (Duex, Nau et al. 
2006; Botelho, Efe et al. 2008; Dove, Dong et al. 2009; Poccia and Larijani 2009), the extracellular 
signals that lead to activation of PIKfyve in mammalian cells have not been identified. Furthermore, 
endolysosomal Ca
2+
 release has been difficult to detect in mammalian cells because of the small size 
of the endolysosome (Calcraft, Ruas et al. 2009; Cheng, Shen et al. 2010). In contrast, Fab1-mediated 
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PI(3,5)P2 production has been well documented in yeast  (Duex, Nau et al. 2006; Dove, Dong et al. 
2009). For example, hyperosmotic shock increases PI(3,5)P2 levels more than 20-fold within a few 
minutes (Duex, Nau et al. 2006; Dove, Dong et al. 2009). Interestingly, hyperosmotic shock is also 
known to induce Ca
2+
 release from yeast vacuoles, which share many similar features with 
mammalian lysosomes. Induction of Ca
2+
 release is through Yvc1/TRPY1, a TRP-channel homolog in 
yeast, and occurs with a slightly faster, but otherwise comparable time-course of PI(3,5)P2 elevation 
(Denis and Cyert 2002). Based on our data, we hypothesized that hyperosmolarity-induced vacuolar 
Ca
2+
 release would be dependent on elevated PI(3,5)P2 levels. To test this, we used an a luminescence 
assay based on aequorin, a genetic Ca
2+





]cyt) levels . Consistent with previous reports (Denis and Cyert 2002), 
hyperosmotic shock by addition of 0.9 M NaCl to the culture medium induced a rapid and dramatic 
increase of [Ca
2+
]cyt. The time required for peak [Ca
2+
]cyt increase was 48 ± 4 sec, (N = 10 yeast 
colonies/experiments); the increase of luminescence was 700 ± 94% over basal (N = 4; Fig 2.8a, 2.8b). 
In the yvc1 mutant, however, no significant increase in [Ca
2+
]cyt was seen (29 ± 6 % over basal, N = 
4), consistent with the hypothesis that the [Ca
2+
]cyt increase resulted primarily from vacuolar release 
through Yvc1(Denis and Cyert 2002). Interestingly, in the fab1 mutant, hyperosmotic shock also 
failed to induce any significant increase in [Ca
2+
]cyt (20  ± 8 %, N = 4; Fig 2.8a, 2.8b), in comparison 
with 700 % for the wild-type cells.  Both yvc1 and fab1 cells responded to 14% ethanol or 0.03 % 
SDS (data not shown), which is known to induce Ca
2+
 influx (Denis and Cyert 2002). Consistent with 
previous studies (Duex, Nau et al. 2006; Dove, Dong et al. 2009), fab1 mutant yeasts failed to 
exhibit vacuolar fragmentation in response to hyperosmotic shock (Fig. 2.9).  
  Fab1 kinase activity is regulated by Vac7, Vac14 and Fig4, mutations in which cause a partial 
or nearly complete loss of Fab1-mediated PI(3,5)P2 production (Duex, Nau et al. 2006; Duex, Tang et 
al. 2006; Zhang, Zolov et al. 2007; Dove, Dong et al. 2009; Poccia and Larijani 2009). All these 
mutants exhibited reduced vacuolar Ca
2+
 release: 533 ± 60 % (N = 4) for fig4, 357 ± 77 % (N = 4) 




(fab1 > vac7vac14 fig4correlated well with the severity of the defect of PI(3,5)P2 
production in these strains (Dove, Dong et al. 2009). The loss of Ca
2+
 response in fab1 cells was not 
due to reduced expression of Yvc1 (Fig 2.10d, 2.10e), as transformation of Yvc1-GFP failed to restore 
the response.  In contrast, when wild-type yeast FAB1 was transformed into fab1 mutant yeast, 
hyperosmolarity-induced [Ca
2+
]cyt increase was largely restored (Fig 2.11f, 2.11g).  Mutant fab1 
yeast reportedly hypo-acidify the vacuole (Duex, Nau et al. 2006; Dove, Dong et al. 2009), which 
could result in reduced Ca
2+
 release because of a decrease in H
+
-dependent refilling of vacuolar Ca
2+
 




 exchanger) (Baars, Petri et al. 2007). However, vcx1 
cells exhibit normal Ca
2+
 release in response to hyperosmotic shock (Denis and Cyert 2002), 
indicating that the alternate Pmc1 (vacuolar Ca
2+
 ATPase)-mediated refilling system is sufficient to 
maintain vacuolar Ca
2+
 stores. In support, we found that hypo-acidified cells lacking vma3, an 
essential component of the vacuolar ATPase (Baars, Petri et al. 2007), exhibited normal [Ca
2+
]cyt 
release (Fig 2.12). These results suggested that the Fab1-mediated PI(3,5)P2 generation system was 
required for hyperosmolarity-induced, Yvc1-dependent vacuolar Ca
2+ 
release. Although TRPML1 
shares a degree of sequence homology to Yvc1, they differ significantly in their channel properties 
(Palmer, Zhou et al. 2001; Cheng, Shen et al. 2010) . To test whether TRPML1 functions in yeast, we 
overexpressed TRPML1 in both a wild-type and yvc1 background. Overexpression of TRPML1 in 
wild-type yeast resulted in a significant increase in Ca
2+
 release in response to hyperosmotic shock 
(Fig 2.13a, 2.13b).  In yvc1cells, overexpression of TRPML1, but not a non-functional pore mutant 
of TRPML1 (TRPML1-KK), resulted in a partial rescue of the [Ca
2+
]cyt response, with a 114 ± 14% 
increase over basal luminescence (N = 9) (Fig 2.13d). In contrast, overexpression of TRPML1 in 
fab1 failed to result in significant [Ca
2+
]cyt response (Fig 2.13c), while overexpression of YVC1 in 
yvc1cells completely restored the [Ca
2+
]cyt response (Fig 2.13e).   The rescue might be incomplete 
because Yvc1, but not TRPML1, is activated by cytoplasmic Ca
2+
 and mechanical force (Palmer, Zhou 
et al. 2001), both of which might have synergistic effects with PI(3,5)P2. Nevertheless, these results 
suggested that regulation of lysosomal Ca
2+
 channels by PI(3,5)P2 might be a conserved mechanism in 
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eukaryotic cells.  
 
TRPML1 and PI(3,5)P2 in endolysosomal trafficking  
The data presented here suggest that TRPMLs might be activated downstream of the PI(3,5)P2 
increase, to trigger membrane fusion and fission. If this hypothesis is correct, expression of TRPML1, 
which often exhibits substantial basal activity in heterologous systems (Cheng, Shen et al. 2010), 
might alleviate trafficking defects in PI(3,5)P2-deficient cells. In cultured Vac14
−/−
 fibroblast cells, the 
trafficking defects from PI(3,5)P2 deficiency were reflected by enlarged vacuoles/LELs (> 3 up to 12 
m in diameter) in 79 ± 7% of the cells (N = 3 experiments with >100 cells) (Fig 2.14a; Ref. (Zhang, 
Zolov et al. 2007)). Only approximately 5-10 % of WT cells were vacuolated (< 4 m; data not 
shown). Transfection of a wild-type Vac14 construct was sufficient to restrict vacuoles to 15 ± 2% of 
cells (N = 3 experiments; Fig 2.14a). Interestingly, we were able to rescue the vacuolar phenotype by 
transfection of TRPML1, which showed vacuolation in 18 ± 1 % cells (N = 6), but not pore-mutant 
TRPML1 (ML1-KK) with 69 ± 6% vacuolation (N = 3), or the PI(3,5)P2-insensitive mutant TRPML1 
(ML1-7Q) with 75 ± 7% vacuolation (N = 3) (Fig 2.14a,b). These results suggested that TRPML1 





We used biochemical binding assays to demonstrate that PI(3,5)P2 binds directly to the N-terminus of 
TRPML1. Using whole-endolysosomal patch-clamp recordings, we showed that PI(3,5)P2 robustly 
activates TRPML1 in the endolysosome. The effect of PI(3,5)P2 was strikingly specific; none of the 
other PIPs activated TRPML1. Using a spectrum of yeast mutant strains with variable degrees of 
PI(3,5)P2 deficiency, we established a high-degree of correlation between the amount of vacuolar Ca
2+
 
release and the levels of PI(3,5)P2. Finally, we showed that overexpression of WT, but not the PIP2-
insensitive variant of TRPML1, was sufficient to rescue the trafficking defects in PI(3,5)P2-deficient 
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mammalian cells, as demonstrated by the observation of enlarged vacuoles. Our identification of an 
endolysosome-localizing Ca
2+
 channel that is activated by endolysosome-specific PI(3,5)P2 provides a 
previously unknown link between these two important regulators of intracellular membrane trafficking.   
 Similar trafficking defects are seen in both TRPML1
−/−
 and PI(3,5)P2-deficient cells.  For example, 
LEL-to-Golgi retrograde trafficking, a process that requires membrane fission, is defective in both 
TRPML1
−/−
 cells (Chen, Bach et al. 1998; Treusch, Knuth et al. 2004; Pryor, Reimann et al. 2006; 
Thompson, Schaheen et al. 2007; Cheng, Shen et al. 2010), and in PI(3,5)P2-deficient cells (Duex, 
Nau et al. 2006; Duex, Tang et al. 2006; Zhang, Zolov et al. 2007; Botelho, Efe et al. 2008; Dove, 
Dong et al. 2009; Poccia and Larijani 2009).  Furthermore, both TRPML1 and PI(3,5)P2-metabolizing 
enzymes are implicated in membrane-fusion processes like exocytosis (Dong, Wang et al. 2009; Dove, 
Dong et al. 2009; Poccia and Larijani 2009),  and lysosomal fusion with autophagosomes (Ferguson, 
Lenk et al. 2009; Puertollano and Kiselyov 2009). Thus, both TRPML1 and PI(3,5)P2 play active roles 
in membrane fission and fusion. However, the cellular defects of PI(3,5)P2-deficient cells are 
generally more severe than those of TRPML1
−/−
 cells.  PI(3,5)P2 is proposed to have at least five 
independent functions, including: recruitment of cytosolic proteins to define organelle specificity; 
functional regulation of endolysosomal membrane proteins; determination of physical properties and 
fusogenic potential of endolysosomal membranes; serving as precursor for PI(3)P or PI(5)P; and 
modulation of endolysomal pH (Bonangelino, Nau et al. 2002; Dove, Dong et al. 2009; Poccia and 
Larijani 2009).  Hence, activation of TRPML1 might define a subset of the multiple functions of 
PI(3,5)P2. Such activation, however, may provide an essential spatial and temporal regulation of 
endolysosomal dynamics. Membrane fusion and fission are highly coordinated processes requiring an 
array of cytosolic and membrane-bound proteins and factors. A local increase in PI(3,5)P2 likely 
recruits protein complexes required to generate the membrane curvature necessary for membrane 
fusion and fission (Poccia and Larijani 2009). A local increase in PI(3,5)P2 could also activate 
TRPML1 to elevate juxtaorganellar Ca
2+
, which binds to a putative Ca
2+
 sensor protein such as 
Synaptotagmin/CaM (Luzio, Pryor et al. 2007) or ALG-2 (Vergarajauregui, Martina et al. 2009), to 
exert effects on SNARE proteins or lipid bilayer fusion (Roth 2004; Poccia and Larijani 2009).  A 
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similar mechanism might be employed by NAADP and TPC channels to regulate membrane 
trafficking in the endolysosome (Calcraft, Ruas et al. 2009; Zhu, Ma et al. 2010).  
 The remarkable specificity of PI(3,5)P2 in activating TRPML1 is consistent with the role of Ca
2+
 
in controlling the direction and specificity of membrane traffic (Hay 2007; Luzio, Pryor et al. 2007). 
Although we identified several positively charged amino acid residues as potential PI(3,5)P2 binding 
sites, electrostatic interaction alone is unlikely to provide a high affinity PI(3,5)P2 binding pocket 
(Nilius, Owsianik et al. 2008; Suh and Hille 2008).  Thus, additional structural determinants such as 
hydrophobic amino acid residues must also contribute to specificity by interacting with the lipid 
portion of PI(3,5)P2. Because of the low abundance of PI(3,5)P2 (Dove, Dong et al. 2009), such 
specificity might be a pre-requisite for PI(3,5)P2 and TRPML1 to control the trafficking direction in 
the late-endocytic pathway. In other organelles, however, other PIPs and intracellular Ca
2+
 channels 
are likely to provide machinery necessary for Ca
2+
-dependent membrane fission and fusion. Within 
LELs, membrane fusion and fission are likely to occur in sub-organellar compartments that are 
enriched for both TRPMLs and PIKfyve. While TRPML-mediated juxtaorganellar Ca
2+
 transients 
might be captured using real-time live-imaging methods, these seemingly “spontaneous” events may 
correlate with membrane fusion and fission events that can be simultaneously monitored with 





Figure 2.1. PI(3,5)P2 activates recombinant and endogenous TRPML channels in the 
endolysosomal membranes. (Prepared by Xianping Dong and Xiang Wang)  a)  Illustration of a 
whole-endolysosome recording configuration. Pipette (luminal) solution was a standard external 
(Tyrode’s) solution adjusted to pH 4.6 to mimic the acidic environment of the lysosome lumen. Bath 
(internal/cytoplasmic) solution was a K
+
-based solution (140 mM K
+
-gluconate).  Putative membrane 
topology of TRPML channels is illustrated in the late endosome and lysosome (LEL). Note that the 
inward current indicates cations flowing out of the endolysosome (see red arrow for the direction). b)  
Bath application of PI(3,5)P2 (diC8, 100 nM) activated inwardly rectifying whole-endolysosome 
TRPML1-mediated current (ITRPML1) in an enlarged endolysosome/vacuole from a TRPML1-EGFP-
expressing Cos-1 cell that was pre-treated with vacuolin-1.  ITRPML1was elicited by repeated voltage 
ramps (-140 to +140 mV; 400 ms) with a 4-s interval between ramps.  ITRPML1 exhibited a small basal 
current prior to PI(3,5)P2 application; bath application of PI(3,5)P2 to the cytoplasmic side of the 
endolysosome resulted in maximal activation of 18-fold of baseline within a minute, measured at -140 
mV of  ITRPML1.    c) Representative traces of ITRPML1 before (black) and after (red) PI(3,5)P2 at two 
time points, as shown in a (black and red circles). Only a portion of the voltage protocol is shown; 
holding potential = 0 mV.  d) Dose-dependence of PI(3,5)P2-dependent activation (EC50 = 48 nM, n = 
1.9). e) Specific activation of TRPML1 by PI(3,5)P2 ( in 100 nM), but not other diC8 PIPs (all in 1 
M). f) An endogenous inwardly rectifying TRPML-like current (ITRPML1-L) activated by PI(3,5)P2 (10 
M) in a vacuole isolated from wild type (WT) human skin fibroblast cell. g) Endogenous PI(3,5)P2-
activated ITRPML-L in WT and TRPML1
−/− 
human fibroblasts. Note that PI(3,5)P2 doesn't activate a 
significant ITRPML1-L vacuoles isolated from a human ML4 (TRPML1
−/−
) skin fibroblast cell. For 
histogram graphs of all figures including panels (e,g) of this figure, data are presented as the mean ± 
standard error of the mean (SEM); the n numbers are in parentheses.  Statistical comparisons were 
made using analysis of variance (ANOVA):  P value < 0.05 was considered statistically significant and 





















Figure 2.2. Immuofluorescence of PI(3,5)P2 in Lamp1-positive compartments. Mouse fibroblast 
cells were immunostained with anti-PI(3,5)P2 (green) and anti-Lamp1 (red). The majority of Lamp1-
positive compartments were immunostained by anti-PI(3,5)P2, which also recognized some Lamp1-











Figure 2.3. Purification of TRPML1 N-terminus peptides. a) The cytoplasmic N-terminus of 
TRPML1 contains a poly-basic region and clusters of positively charged amino acid residues as 
potential PI(3,5)P2 binding sites. The positively charged amino acid residues (Arg and Lys) that were 
mutated into neutral amino acids Gln (Q) in this study are shown with enlarged circles and their amino 
acid residue numbers. b) commassie blue staining of the purified GST peptide and GST-tagged 





Figure 2.4. TRPML1 N-terminus peptide binds to PI(3,5)P2. a) Protein-lipid strip assay. The strip 
contained 15 different types of lipids: PA, phosphatidic acid; S1P, sphingosine-1-phosphate. Three 
purified proteins were used to probe the strip: GST alone (left panel), GST-fused to the N-terminal 
fragment of TRPML1 (ML1-N-GST; right panel). Proteins were detected with anti-GST antibodies. b) 
Liposome pull-down assay. Liposomes were incubated with purified GST-fusion proteins, centrifuged, 
and associated proteins visualized by Western blot with GST antibodies. c) Binding of GST-ML1-N to 











Figure 2.5. 7Q mutations on TRPML1 N-terminus renders the peptide unable to bind to 
PI(3,5)P2. a) Protein-lipid strip assay. Gln-substituted mutant of ML1-N-GST (ML1-7Q-N-GST; 
middle) fails to bind to PI(3,5)P2.  Proteins were detected with anti-GST antibodies. ) Compared to 






Figure 2.6. 7Q mutations on TRPML1 N-terminus renders the channel insensitive to PI(3,5)P2. a) 
Whole-endolysosome ITRPML1- 7Q was weakly activated by high concentrations of PI(3,5)P2.  b) 
PI(3,5)P2 dose dependence of  ITRPML1- 7Q .  Dotted line indicates the dose dependence of ITRPML1 
(repotted from Fig. 1d).   c) Large basal whole-endolysosome ITRPML1-Va-7Q.  Charge-removing Gln 














Figure 2.7.  TRPML1 N-terminus peptides, but not the 7Q mutants, competitively reduce the 
activation effect of PI(3,5)P2. a)  GST-ML1-N peptide (5 g/ml) reduced PI(3,5)P2-dependent 
activation of whole-endolysosome ITRPML1.  b) Charge-removing Gln-substituted substitutions (7Q) 











 release from yeast vacuoles after hyperosmostic shock is dependent on PI(3,5)P2 
production. a) Representative Ca
2+
 response measured with aequorin-mediated luminescence in wild-
type (wt), yvc1Δ, and PI(3, 5P)2-deficient strains (vac7Δ, vac14Δ, fig4Δ, fab1Δ) upon hyperosmotic 
shock induced by addition of 0.9 M NaCl. b) Quantitative data to show luminescence responses upon 
hyperosmotic shock in different yeast strains. Fold-response was normalized to basal luminescence 
prior to shock. For b, data are presented as the mean ± standard error of the mean (SEM); the n 
numbers are in parentheses.  Statistical comparisons were made using analysis of variance (ANOVA):  
P value < 0.05 was considered statistically significant and indicated with asterisks (*, 0.01< P < 0.05; 








Figure 2.9.  fab1Δ yeast cells fail to undergo vacuolar fragmentation in response to hyperosmotic 
shock. Hyperosmotic shock increases the number of vacuoles and decreases the vacuolar volume in 
wild type, but not fab1 mutant yeast strains.  Both WT and fab1Δ cells were labeled with FM4-64 dye 
to visualize vacuole volume and the number of vacuole lobes. Cells were treated with 0.45M NaCl 





Figure 2.10. Overexpression of YVC1 in fab1Δ cells fails to restore hyperosmolarity-induced 
Ca
2+
 response. a) Representative Ca
2+
 response measured with aequorin-mediated luminescence in 
wild-type or fab1Δ cells with overexpression of YVC1 channel. b)Quantitative data to show 
luminescence responses upon hyperosmotic shock in wild-type or fab1Δ cells with overexpression of 
YVC1 channel. Fold-response was normalized to basal luminescence prior to shock. Data are 










Figure 2.11. Overexpression of FAB1 in fab1Δ cells restores hyperosmolarity-induced Ca
2+
 
response. a) Representative Ca
2+
 response measured with aequorin-mediated luminescence in wild-
type,  fab1Δ , and fab1Δ cells rescued with FAB1. b) Quantitative data to show luminescence 
responses upon hyperosmotic shock in wild-type,  fab1Δ , and fab1Δ cells rescued with FAB1. Fold-
response was normalized to basal luminescence prior to shock. Data are presented as the mean ± 






Figure 2.12. Hyperosmotic shock induces vacuolar Ca
2+
 release in vma3 mutant yeast strains. 
Showing here is a representative Ca
2+







Figure 2.13. Hyperosmotic shock induces vacuolar Ca
2+
 release though TRPML1 in WT or 
yvc1Δ cells, but not fab1Δ cells. a,b) Overexpression of TRPML1 in WT yeast cells increased 
hyperosmolarity-induced Ca
2+
 response. Hyperosmolarity-induced Ca
2+
 responses were measured 
using the aequorin-mediated luminescence assay. Hyperosmotic shock was induced by addition of 0.9 





 responses (normalized with baseline luminescence before 
hyperosmotic shock) from fab1Δ cells, and pCu-ML1-transformed yvc1Δ cells were re-plotted from 
Fig. 8b and 13d for comparison. d) Overexpression of TRPML1, but not pore mutant TRPML1-KK 
(in pCu and pVT expression vectors), in yvc1Δ yeast cells resulted in small but significant 
hyperosmolarity-induced Ca
2+
 response.  E) Overexpression of YVC1 in yvc1Δ cells restored 
hyperosmolarity-induced Ca
2+
 response. Hyperosmolarity-induced Ca
2+
 responses from pCu-ML1-
transformed yvc1Δ cells were re-plotted from Fig. 13d for comparison. Data are presented as the mean 
± standard error of the mean (SEM); the n numbers are in parentheses. (*, 0.01< P < 0.05; **, P < 




Figure 2.14 Overexpression of TRPML1 rescues the enlarged endolysosome phenotype of 
PI(3,5)P2-deficient mouse fibroblasts. (Prepared by Xiang Wang) 
a) The effects of overexpression of WT TRPML1 and pore (ML1-KK) or PI(3,5)P2-insensitive (ML1-
7Q) mutant TRPML1 on the number and size of the vacuoles in Vac14
−/−
 fibroblasts. Cultured 
Vac14
−/−
 mouse fibroblast cells exhibited variable numbers (1-20) of large (> 3 m) 
vacuoles/endolysosomes. Non-vacuolated cells are indicated with asterisk. Scale Bar = 20 m. b) 
Large vacuoles in 75% of vector (mCit) -transfected Vac14
−/−
 fibroblast cells. Overexpression of 
Vac14-mCit or EGFP-ML1 reduced the percentage (of enlarged vacuoles) to approximately 15%, 
while the 75% of EGFP-ML1-KK or EGFP-ML1-7Q-transfected cells contained enlarged vacuoles. 
Data are presented as the mean ± standard error of the mean (SEM); the n numbers are in parentheses. 














  CHAPTER 3 
 
 
A SMALL-MOLECULE SYNTHETIC AGONIST EVOKES TRPML1-
DEPENDENT CA
2+





TRPML1 is an inwardly-rectifying Ca
2+
-permeable channel in late endosomes and lysosomes. 
Loss-of-function mutations on human TRPML1 gene cause a devastating pediatric 
neurodegenerative disease called type IV Mucolipidosis (ML4). In the preceding chapter, I 
described PI(3,5)P2, a phosphoinositide localized predominantly in the late endosomes and 
lysosomes, as an endogenous activator of TRPML1. Here I will report a membrane-permeable 
small-molecule synthetic agonist for TRPML1, Mucolipin-Synthetic Agonist 1 (ML-SA1). ML-
SA1 potently activates recombinant TRPML1, as well as endogenous TRPML-like currents in 
several cell types, including human fibroblasts, macrophages and Chinese Hamster Ovary cells.  
The activation effect of ML-SA1 can be further potentiated by PI(3,5)P2, suggestive of a 
synergism between the two agonists. By using lysosome-targeting GCaMP3-based Ca
2+
 sensors, I 
found that ML-SA1 evokes TRPML1-dependent Ca
2+
 release from endolysosomes in intact cells. 
Therefore this TRPMLs-specific chemical agonist can be used as a valuable tool for studying 
intracellular functions of TRPMLs. Future studies on the agonist may lead to a novel therapeutic 





Identification of specific ligands and activators is important for ion channel study, since 
characterization of the properties or physiological roles of ion channels often heavily relies on the 
availability of such tools as channel activators. Recent studies on TRP channels have identified a 
number of agonist or antagonists for many TRP channels (Ramsey, Delling et al. 2006; 
Patapoutian, Tate et al. 2009); however, there are still no chemical activators or selective inhibitors 
found for TRPML1. This is mainly due to the intracellular localization of TRPML1, which make 
the channel inaccessible to conventional patch clamp method. By using a modified patch-clamp 
method (Dong, Cheng et al. 2008; Dong, Shen et al. 2010), Xu lab recently identified 
Phosphatidylinositol 3,5-bisphosphate(PI(3,5)P2) as the first endogenous TRPML1 activator. Yet 
due to the membrane impermeability of PI(3,5)P2, its effectiveness as a TRPML1 agonist for 
cellular assays is greatly comprised. Although intracellular delivery of PIP is feasible (Ozaki, 
DeWald et al. 2000), this method is time-consuming and requires extra carrier molecules that may 
introduce unexpected complications. Identification of a plasma membrane permeable chemical 
agonist for TRPML1 is necessary, and such an agonist will provide a useful tool to study the 
biophysical and physiological features of TRPML1. 
            Recently Stefan Heller’s group identified several small molecular activators of TRPML3 
through compound library screening(Grimm, Jors et al. 2010). Given the high similarity of amino 
acid sequences shared by TRPML1 and TRPML3, we tested whether any of these chemicals can 
activate TRPML1 on the endolysosomal membrane. We found several chemicals that can weakly 
activate TRPML1. Interestingly,  they can also activate the di-leucine mutant of TRPML 
(TRPML-4A) on plasma membranes, which contains four amino acid mutations on both di-
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leucine motifs that trap a portion of TRPML1 channels on the plasma membrane (Vergarajauregui 
and Puertollano 2006; Grimm, Jors et al. 2010)). By modifying the structure of one of the 
chemicals - SF51, we found another chemical (ML-SA1) that potently activates both recombinant 
and endogenous TRPML1 channel using lysosomal patch clamp technique. Notably, ML-SA1 
evokes Ca
2+
 release from endolysosomes by activating intracellular TRPMLs in intact cells, 
suggesting that the agonist is membrane permeable. Therefore this TRPMLs-specific chemical 
agonist can be used as a valuable tool for studying intracellular functions of TRPMLs. Future 





Molecular biology and biochemistry. The GCaMP3-ML1 construct was made by inserting the 
full length GCaMP3 sequence (Tian, Hires et al. 2009) between the HindIII and BamHI sites of a 
pcDNA6 plasmid that contains the mouse TRPML1 cDNA at the XhoI site. TRPML1-L
15
L/AA-
L577L/AA (abbreviated as ML1-4A) and the TRPML1 non-conducting pore mutant 
(D471K/D472K; abbreviated ML1-KK) were constructed using a site-directed mutagenesis kit 
(Qiagen). All constructs were confirmed by sequencing, and protein expression was verified by 
western blot. CHO, HEK293T, Cos-1, and human fibroblast cells were transiently transfected with 
GCaMP3-ML1 for electrophysiology, Ca
2+
 imaging, and confocal imaging.  
 
Preparation and culture of mouse macrophages. Bone marrow cells from femurs and tibias 
were harvested and cultured in macrophage differentiation medium (RPMI-1640 medium with 10% 
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fetal bovine serum (FBS) and 100 unit/ml recombinant colony stimulating factor from PeproTech, 
Rocky Hill, NJ).  After 7 d in culture at 37 °C with 5% CO2, the adherent cells (> 95% are 
expected to be macrophages) were harvested for assays (Link, Park et al. 2010). 
 
Mammalian whole-cell electrophysiology. HEK293T, Cos-1, and CHO cells were used for the 
heterologous expression experiments and were transfected using Lipofectamine 2000 (Invitrogen). 
The pipette solution contained 147 mM Cs, 120 mM methane-sulfonate, 4 mM NaCl, 10 mM 
EGTA, 2 mM Na2-ATP, 2 mM MgCl2, and 20 mM HEPES (pH 7.2; free [Ca
2+
]i < 10 nM).  The 
standard extracellular bath solution (modified Tyrode’s solution) contained 153 mM NaCl, 5 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, and 10 mM glucose (pH 7.4). The "Low pH 
Tyrode" solution contained 150 mM Na- Gluconate, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 
mM glucose, 10 mM HEPES, and 10 mM MES (pH 4.6). All bath solutions were applied via a 
perfusion system to achieve a complete solution exchange within a few seconds. Data were 
collected using an Axopatch 2A patch clamp amplifier, Digidata 1440, and pClamp 10.0 software 
(Axon Instruments). Whole-cell currents were digitized at 10 kHz and filtered at 2 kHz. All 
experiments were conducted at room temperature (21-23 ºC), and all recordings were analyzed 
with pClamp 10.0, and Origin 8.0 (OriginLab, Northampton, MA).   
 
Endolysosomal electrophysiology. Endolysosomal electrophysiology was performed in isolated 
endolysosomes using a modified patch-clamp method (Dong, Cheng et al. 2008; Dong, Shen et al. 
2010). Briefly, cells were treated with 1 µM vacuolin-1 for 2-5 h to increase the size of endosomes 
and lysosomes. Whole-endolysosome recordings were performed on isolated enlarged LELs. The 
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bath (internal/cytoplasmic) solution contained 140 mM K-Gluconate, 4 mM NaCl, 1 mM EGTA, 2 
mM Na2-ATP, 2 mM MgCl2, 0.39 mM CaCl2, 0.2 mM GTP, and 10 mM HEPES (pH adjusted 
with KOH to 7.2; free [Ca
2+
]i approximately 100 nM based on the Maxchelator software 
(http://maxchelator.stanford.edu/)). The pipette (luminal) solution consisted of a “Low pH 
Tyrode’s solution”  with 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 




 imaging. Cells were loaded with 5 µM Fura-2 AM in the culture medium at 37 °C 
for 60 min. Fluorescence was recorded at different excitation wavelengths using an EasyRatioPro 
system (PTI). Fura-2 ratios (F340/F380) were used to monitor changes in intracellular [Ca
2+
] upon 
stimulation.  GPN (Glycyl-L-phenylalanine 2-naphthylamide; 200-400 µM, a lysosome-disrupting 
agent) and Bafilomycin A1 (500 nM, a V-ATPase inhibitor) were used as positive controls to 
induce Ca
2+
 release from lysosome and acidic stores, respectively (Calcraft, Ruas et al. 2009). 
Ionomycin (1 µM) was added at the conclusion of all experiments to induce a maximal response 
for comparison.  For endogenous lysosomal Ca
2+
 release measurement, Ca
2+
 imaging was carried 




 imaging. 18-24 h after transfection with GCaMP3-ML1, CHO or human 
fibroblast cells were trypsinized and plated onto glass coverslips. Most experiments were carried 
out within 0.5-3 h after plating when cells still exhibited a round morphology. The fluorescence 




was measured under a "low" external Ca
2+
 solution, which contained 145mM NaCl, 5 mM KCl, 3 
mM MgCl2, 10 mM Glucose, 1mM EGTA, and 20 mM HEPES (pH7.4).  Ca
2+
 concentration in 
the nominally-free Ca
2+
 solution is estimated to be 1-10 µM.  With 1 mM EGTA, the free Ca
2+
 
concentration is estimated to be < 10 nM based on the Maxchelator software 
(http://maxchelator.stanford.edu/). 
 
Data analysis. Data are presented as the mean ± standard error of the mean (SEM). Statistical 






Identification of several weak TRPML1 activators 
15 small-molecule chemical compounds (SF compounds) that can activate recombinant surface-
expressed TRPML3 were identified by a recent high-throughput screen (Grimm, Jors et al. 2010). 
Since TRPML1 is primarily localized on the membranes of LELs (Cheng, Shen et al. 2010), this 
screen, which is based on whole-cell patch clamp and calcium imaging assay, is unable to test the 
effect of these compounds on wild-type TRPML1 channel. Using whole-endolysosome patch-
clamp recordings (Dong, Cheng et al. 2008; Dong, Shen et al. 2010), we found that several SF 
compounds also weakly activated whole-endolysosome TRPML1-mediated currents (ITRPML1 or 
IML1), such as SF22 and SF51 (Fig 3.1).  In HEK293T cells transfected with surface-expressed 




L/AA, abbreviated as ML1-4A 
(Vergarajauregui and Puertollano 2006; Grimm, Jors et al. 2010)), one of the SF compounds, SF-




]cyt) increases (measured with 
Fura-2 ratios; Fig 3.2a, b), and activated small but significant inwardly-rectifying whole-cell 
currents (IML1-4A; Fig 3.2d).   
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Identification of a potent synthetic agonist for TRPML1 
By conducting a Fura-2-based low-throughput-screen for more potent TRPML1 agonists (see 
Table 3.1), we identified a SF-51-related compound (see Fig 3.2c for the chemical structures; 
Mucolipin Synthetic Agonist 1 or ML-SA1) that could induce significant [Ca
2+
]cyt increases in 
HEK293 cells stably- or transiently-expressing ML1-4A (Fig 3.2a). In electrophysiological assays, 
ML-SA1 robustly activated whole-cell IML1-4A (Fig 3.2d) and whole-endolysosome IML1 (Fig 3.2e). 
ML-SA1 also activated whole-cell ITRPML2 and ITRPML3, but not six other related channels (Fig 3.4). 
ML-SA1 (10 M) activation of whole-endolysosome IML1 was comparable to the effect of the 
endogenous TRPML agonist PI(3,5)P2 (1 M; Fig 3.2e), and these agonists were synergistic with 
each other (Fig 3.2f). ML-SA1 activated an endogenous whole-endolysosome TRPML-like 
current (IML-L) in all mammalian cell types that we investigated, including Chinese Hamster Ovary 
(CHO) (Fig 3.3a), Cos-1, HEK293, skeletal muscle, pancreatic , and macrophage cells (Fig 
3.3b). ML-SA1 activated whole-endolysosome IML-L in wild-type (WT; ML1
+/+
), but not ML4 
(ML1

) human fibroblasts (Fig 3.3c), suggesting that although ML-SA1 targets all three 
TRPMLs, the expression levels of TRPML2 and TRPML3 are very low, and TRPML1 is the 
predominant lysosomal TRPML channel in this cell type.  Thus, we have identified a reasonably 
specific and potent agonist that can be a useful chemical tool for studying the functions of 
TRPMLs, especially TRPML1.   
 
A lysosome-targeted genetically-encoded Ca
2+
 indicator  
To measure lysosomal Ca
2+
 release in intact cells, GCaMP3, a single-wavelength genetically-
encoded Ca
2+
 indicator (Tian, Hires et al. 2009), was engineered to the cytoplasmic N-terminus of 
TRPML1 (Fig 3.5a). When transfected into HEK293T, CHO, or Cos-1 cell lines, GCaMP3-
TRPML1 (GCaMP3-ML1) was mainly localized in the Lamp-1 and LysoTracker-positive 
compartments, i.e., LEL (Fig 3.5b,c). To determine the specificity of the GCaMP3-ML1 
fluorescence signal, I tested a variety of Ca
2+
 release reagents and found that GCaMP3 
fluorescence (F470) responded preferentially and reliably to lysosome-acting Ca
2+
-mobilization 
reagents (F/F0 =0.2-1) , including Glycyl-L-phenylalanine 2-naphthylamide (GPN, a Cathepsin C 
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substrate that induces osmotic lysis of lysosomes; Fig 3.5d) and bafilomycin A1 (Baf-A1, a V-
ATPase inhibitor) (Lloyd-Evans, Morgan et al. 2008). In a subset of cells, GCaMP3 also 
responded to large (F/F0> 2) Ca
2+
 increases triggered by thapsigargin (TG, targeting the ER Ca
2+
 
store; Fig 3.5d), which may presumably spread to close proximity of lysosomes.  In the majority 
of the cells, however, TG failed to significantly increase GCaMP3 fluorescence (Fig 3.5d), 
suggesting that small ER Ca
2+
 release was not detected by GCaMP3-ML1. Taken together, 




ML-SA1 induces TRPML1-mediated Ca
2+
 release from lysosomes 
In GCaMP3-ML1-transfected CHO (Fig 3.6a, 3.6b), HEK293T, and Cos-1 cell lines, application 
of ML-A1 (20 M) induced rapid increases in GCaMP3 fluorescence (F/F0 = 0.45 ± 0.05, n = 77 




 + 1 mM EGTA; 
free Ca
2+
 estimated to be < 10 nM). In contrast, no significant increase in GCaMP3 fluorescence 
(F/F0 = 0.03 ± 0.01, n = 32 cells; Fig 3.6c, 3.6d, 3.7f) was observed in cells transfected with a 
plasmid carrying GCaMP3 fused to a non-conducting pore mutant of TRPML1 (Pryor, Reimann et 
al. 2006; Dong, Shen et al. 2010) (GCaMP3-ML1-KK). Both GPN and Baf-A1 largely abolished 
ML-SA1-induced Ca
2+
 responses (Fig 3.7a-f).  In contrast, ML-SA1-induced Ca
2+
 response was 
mostly intact in TG-treated cells (Fig 3.7f).  Collectively, these results suggest that ML-SA1 
activated endolysosomal TRPML1 to induce Ca
2+
 release from lysosomes.  Thus I have 
established a robust Ca
2+




ML-SA1 activates endogenous TRPMLs in intact cells. 
 
To investigate whether ML-SA1 can activate endogenous TRPMLs in intact cells, fura-2 based 
calcium imaging assay were carried out in WT CHO and macrophages cells.  In WT CHO cells, 
small but significant Ca
2+
 increases were seen upon application of 100 µM ML-SA1 in low 
external Ca
2+
 (Fig 3.8a). Similarly, 100 µM ML-SA1 also evoked small Ca
2+
 increases in wild 
type macrophage cells (Fig 3.8b). The ML-SA1-induced lysosomal Ca
2+
 responses are most likely 
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mediated by TRPML1, since NPC1
-/-
 mouse macrophages exhibited a significant reduction in ML-
SA1-induced lysosomal Ca
2+
 release compared to WT cells (Fig 3.8c ).  These results suggest that 




In this study, I reported the discovery of a potent small molecular agonist for TRPML1. Under 
lysosomal patch clamp configuration, the agonist (ML-SA1) can potently activate recombinant 
TRPML channels, but not other related channels on the endolysosomal membranes. The agonist 
also activates endogenous TRPML1 channel in various cell types. By using Gcamp3-based Ca
2+
 
sensors localized on late endosome and lysosomes, I found the agonist could evoke Ca
2+
 release 
from endolysosomes in intact cells by activating intracellular TRPML1 channels. These results 
revealed that ML-SA1 is a potent and specific synthetic chemical activator for TRPMLs. 
            The activation site of ML-SA1 on TRPML1 is yet unknown. Given that ML-SA1 is 
membrane permeable, it is difficult to test which side of the channel ML-SA1 binds to by using 
the electrophysiology method.  Our results showed that ML-SA1 was able to activate TRPML1 
from both the luminal side (whole cell configuration) and cytosolic side (whole lysosomal 
configuration) of the channel.  Under both configurations, the activation is very rapid, and the time 
course is similar, which suggests that either ML-SA1 can activate the channel on both sides, or the 
translocation of ML-SA1 across the membrane is very fast. Further mutagenesis assays on the 
TRPML1 channel are required to map out the activation site of ML-SA1. 
             Although ML-SA1 is able to evoke Ca
2+
 release in intact cells through endogenous 
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TRPML1 (Fig 3.8), such Ca
2+
 release was only observed when using high concentration of ML-
SA1 (>50µM). It is possible that with low concentration of ML-SA1 (<50 µM), the fura-2 based 
assay may not be sensitive enough to catch the Ca
2+
 release events through TRPMLs. Alternatively, 
ML-SA1 might just sensitize the endogenous TRPML1s, but is not potent enough to activate them 
at the low concentration. One interesting observation is that upon agonist application, the 
endogenous Ca
2+
 response is usually bigger for newly-plated cells with round morphology, 
compared to long-time cultured cells with extensive morphology. The major difference between 
these two conditions is that the former cells just went through the trypsinization and pipetting 
processes, which may introduce physical damages to cell membranes, while the latter cells did not. 
It would be interesting to test whether such a difference will cause the change of lysosomal 
calcium store, or even the sensitization of TRPMLs, since certain stress conditions are indeed 
associated with lysosomal biogenesis and increased expression levels of lysosomal genes 
(Karageorgos, Isaac et al. 1997; Helip-Wooley and Thoene 2004).  
            Another interesting observation is that high concentrations of ML-SA1 leads to robust 
calcium oscillations in fura-2 loaded CHO cells. The oscillation was not caused by the Ca
2+
 
channels on plasma membrane, since the experiments were carried out under 0 Ca
2+
 external 
solution conditions. But thapsigagin pretreatment abolished the oscillation (data not shown). A 
possible explanation is that ML-SA1 induces the Ca
2+
 release from lysosomes that are in close 
proximity to ER. This Ca
2+
 release activates the ryanodine receptor on ER (Hamilton and 
Serysheva 2009) and causes massive ER Ca
2+
 efflux , giving rise to the large Ca
2+
 spike.  However, 
increased Ca
2+
 level subsequently inactivates the ryanodine receptor, and cytosolic Ca
2+
 
concentration is quickly reduced due to PM Ca
2+ 




 release from lysosomes will trigger the repetition of the aforementioned process. 
            This study introduced a genetically encoded calcium indicator – GCaMP3-TRPML1 for 
calcium imaging assay. The calcium detection range for GCaMP3 is from 100nM to 2µM, which 
is suitable for monitoring most of the cytosolic [Ca
2+
] change events (Tian, Hires et al. 2009). 
Compared to conventional synthetic calcium indicator (e.g. Fura-2), our GCaMP3-TRPML1 
indicator has at least two advantages. Firstly, it specifically targets to late endosome/lysosome 
compartments, and is more sensitive to local [Ca
2+
] change. Secondly, this indicator can be 
engineered into model organisms, and therefore allows long-term, repeated in vivo measurements, 
while most synthetic calcium indicators cannot. One caveat, however, is that TRPML1 is 
overexpressed when using this indicator, which may affect the intracellular trafficking, and makes 
it impossible to study the endogenous TRPML1 function.  This problem, however, can be 
circumvented by tagging GCaMP3 to different lysosomal protein (e.g.Lamp1 or Vamp7). Special 
care will still need to be taken of the overexpression of that specific lysosomal protein. 
            Overall, the identification of ML-SA1 and GCaMP3 based indicator provides valuable 
tools to study the multiple cellular processes that TRPMLs are involved in, such as exocytosis and 
endolysosomal fusion/fission. For example, the activation of TRPML1 and its coincidence with 
fusion/fission processes may be captured by using high-resolution, live imaging techniques with 
the help of the ML-SA1 agonist and our GCaMP3 based Ca
2+
 sensor. As TRPMLs do not exhibit 
significant voltage-dependent inactivation, even a small TRPML current may lead to substantial 
Ca
2+
 release(Cheng, Shen et al. 2010). Therefore, pretests need to be carried out to determine the 
proper concentration of ML-SA1 for such in vivo assays. Another important direction is further 
characterization of ML-SA1. As many ML4 patients still have residual TRPML1 channel activity 
72 
even though the channel is mutated (Altarescu, Sun et al. 2002; Bargal, Goebel et al. 2002; Goldin, 
Stahl et al. 2004), it is important to study the effect of ML-SA1 on these mutated channels. These 
studies, together with mice model work and clinical trials, may eventually lead to a novel 





























Fig 3.1. Identification of SF-22 and SF51 as weak activators for TRPML1. 
Bath application of different concentrations of SF-22 (a) and SF51(b) activated inwardly 
rectifying whole-endolysosome TRPML1-mediated current (ITRPML1) in enlarged 
endolysosome/vacuoles from a TRPML1-EGFP-expressing Cos-1 cell that was pre-treated with 
vacuolin-1. ITRPML1was elicited by repeated voltage ramps (-140 to +140 mV; 400 ms) with a 4-s 
interval between ramps.  ITRPML1 is small even with very high concentration of agonist (measured 






















Fig 3.2. Identification of ML-SA1 as a potent small molecular agonist for TRPML1. (a) ML-
SA1 induced increases in cytosolic [Ca
2+
], as measured by the Fura-2 ratio (F340/F380) in 




L/AA (ML1-4A) at low pH (pH 4.6) external 
solution. SF-51 (10 M) induced much smaller responses in the same cells.  (b) SF-51 (30 M) 
induced increases in cytosolic [Ca
2+
] in ML1-4A-expressing HEK293T cells at low pH external 
solution. (c) Chemical structures of SF-51 and ML-SA1. The difference between SF-51 and ML-
SA1 is highlighted in red. (d) Activation of whole-cell currents by SF-51 and ML-SA1 in ML1-
4A-expressing HEK293T cells. ML1-4A-mediated current (IML1-4A) was elicited by repeated 
voltage ramps (-140 to +140 mV; 400 ms) with a 4-s interval between ramps. Only a portion of 
the voltage protocol is shown; holding potential = 0 mV. (e) Activation of whole-endolysosome 
IML1 by ML-SA1 and PI(3,5)P2. Enlarged vacuoles/endolysosomes were isolated from vacuolin-
treated HEK293 cells stably-expressing ML1-4A. ML-SA1 and PI(3,5)P2 were applied to the 
cytosolic sides of the isolated vacuoles. The pipette (luminal) solution was a standard external 
(Tyrode’s) solution adjusted to pH 4.6; the bath (internal/cytoplasmic) solution was a K
+
-based 
solution (140 mM K
+
-gluconate). Note that the inward current indicates cations flowing out of the 
endolysosome. (f) Synergistic activation of whole-endolysosome IML1 by ML-SA1 and PI(3,5)P2 
in human fibroblasts. IML1 was activated by PI(3,5)P2 (1 M) and ML-SA1 (10 M); co-
application of PI(3,5)P2 and ML-SA1 further increased IML1. (Fig 3.2 e,f were prepared by Xiang 














Fig 3.3. ML-SA1 activates endogenous TRPM-like currents in the endolysosomal membranes.  a) 
ML-SA1 activated endogenous whole-endolysosome ML-like currents (IML-L) in CHO cells. (b) ML-SA1 
activated whole-endolysosome IML-L in mouse primary macrophages. (c) ML-SA1 activated whole-
endolysosome IML1 in WT (ML1
+/+
), but not ML4 (ML1

human fibroblasts.  (Prepared by Xiang Wang 















Figure 3.4. ML-SA1 activates TRPMLs, but not other related channels. 
(a) Activation of small inwardly rectifying whole-cell currents by ML-SA1 (10 uM) in TRPML2-
expressing CHO cells. (b) Activation of whole-cell ITRPML3 by ML-SA1 (10 uM) in TRPML3- 
expressing CHO cells. (c) ML-SA1 (25 uM) failed to activate whole-cell currents in CHO cells 
transfected with surface-expressing human TPC2 mutant (hTPC2-L11L12/AA-EGFP) channels. 
(d) ML-SA1 (25 uM) failed to activate whole-cell currents in TRPM2-expressing cells. In 
contrast, pipette dialysis of ADPR (100 uM) elicited whole-cell ITRPM2. (e) ITRPV2 was not 
activated by ML-SA1. 2APB(1 mM) activated ITRPV2 in the same cell. (f) ITRPA1 was not activated 
by ML-SA1. Carvacrol (250 uM) activated ITRPA1 in the same cell. (g) ITRPV3 was not activated by 
ML-SA1. Co-application of 2APB(100 uM) and Carvacrol (250 uM) activated I in the same cell. 
(h) ITRPC6 was not activated by ML-SA1 in TRPC6-expressing HEK cells stably-expressing 



































Figure 3.5.  A lysosome-targeted genetically-encoded Ca
2+
 indicator.  
(a) GCaMP3-TRPML1 (GCaMP3-ML1) fusion strategy. GCaMP3 is fused to the N- terminus of 
TRPML1.  (b) Co-localization of GCaMP3-ML1 fluorescence with Lamp-1 in HEK293T cells 
expressing both GCaMP3-ML1 and Lamp-1-mCherry. Scale bar = 5 m. (c) Co-localization of 
GCaMP3-ML1 fluorescence with LysoTracker in GCaMP3-ML1-expressing HEK293T cells. 
Scale bar = 2 m. (d) Preferential detection of Ca
2+
 release from lysosome stores by GCaMP3-
ML1 in GCaMP3-ML1-transfected Cos-1 cells.  ER and lysosome Ca
2+
 releases were triggered by 
thapsigargin (TG, 2 M) and Glycyl-L-phenylalanine 2-naphthylamide (GPN, 200 M), 
respectively, in low (nominally-free Ca
2+
 + 1 mM EGTA; free [Ca
2+
] estimated to be < 10 nM) 
external [Ca
2+
]. All cells responded to GPN; only 1 out 4 cells responded to TG. (Fig 3.5b was 
























(a) ML-SA1 (20 M) induced rapid increases in GCaMP3 fluorescence (measured as change of 
GCaMP3 fluorescence F over basal fluorescence F0; F/F0) under low (< 10 nM) external Ca
2+ 
in CHO cells transfected with GCaMP3-ML1. Subsequent application of GPN (200 M) induced 
smaller responses. Maximal responses were induced by ionomycin (1 M) application.(b) 
Representative micrographs from panel (a) to show the changes of GCaMP3 fluorescence upon 
bath application of ML-SA1 and ionomycin to GCaMP3-ML1-transfected CHO cells.  Scale bar = 
5 m.  (c) ML-SA1 failed to induce significant Ca
2+
 increases in CHO cells transfected with 
GCaMP3-ML1-KK (non-conducting pore mutation). (d) Basal GCaMP3 fluorescence (normalized 
to the maximal ionomycin-induced fluorescence) of GCaMP3-ML1-KK and GCaMP3-ML1. For 
panels d, the responses were averaged for 40-100 transfected cells from at least 3 independent 
experiments; data are presented as the mean ± SEM.  Statistical comparisons were made using 




























Figure 3.7. ML-SA1 induced Ca
2+
 release is from lysosomes.  
(a) GPN (200 M) pretreatment abolished ML-SA1-induced responses in GCaMP3-ML1-
expressing CHO cells.  (b) Bafilomycin A1 (Baf-A1, 500 nM) pretreatment abolished ML-SA1-
induced Ca
2+
 response in GCaMP3-ML1-expressing CHO cells. (c) Repetitive applications of 
ML-SA1 (20 M) induced little or no responses in GCaMP3-ML1-expressing CHO cells.  (d) 
Repetitive applications of GPN (200 M) induced smaller GCaMP3 responses in GCaMP3-ML1-
expressing CHO cells.  (e)  ML-SA1 failed to further increase GCaMP3 fluorescence in GCaMP3-
ML1-expressing CHO cells in the presence of GPN (200 M).  (f)  ML-SA1-induced responses in 
CHO cells transfected with GCaMP3-ML1-KK (non-conducting pore mutation), and GCaMP3-
ML1-transfected cells pretreated with Baf-A1, GPN, or TG.  For panels f, the responses were 
averaged for 40-100 transfected cells from at least 3 independent experiments; data are presented 




























Figure 3.8. High concentration of ML-SA1 activates endogenous TRPMLs in intact cells. (a) 
Endogenous TRPML1-mediated lysosomal Ca
2+
 release (measured with Fura-2 ratios) in WT 
CHO cells. (b,c) Endogenous TRPML1-mediated lysosomal Ca
2+
 release (measured with Fura-2 
































Table 3.1. List of small molecules tested for TRPML1 agonist. 
 
 
CAS # Structure 
Effect of 10uM chemical 
on TRPML1
4A




























































































































































































































LIPID STORAGE DISORDERS BLOCK LYSOSOMAL TRAFFICKING BY 




Lysosomal lipid accumulation, defects in membrane trafficking, and altered Ca
2+
 homeostasis are 
common features in many lysosomal storage diseases. Mucolipin TRP channel 1 (TRPML1) is 
the principle Ca
2+
 channel in the lysosome. Here we show that TRPML1-mediated lysosomal 
Ca
2+
 release, measured using a genetically encoded Ca
2+
 indicator (GCaMP3) attached directly to 
TRPML1 and elicited by a potent membrane-permeable synthetic agonist, is dramatically reduced 
in Niemann-Pick (NP) disease cells.  Sphingomyelins (SMs) are plasma membrane lipids that 
undergo Sphingomyelinase (SMase)-mediated hydrolysis in the lysosomes of normal cells, but 
accumulate distinctively in NP cell lysosomes.   Patch-clamp analyses revealed that TRPML1 
channel activity is inhibited by SMs, but potentiated by SMases.  In NP type C (NPC) cells, 
increasing TRPML1’s expression/activity was sufficient to correct the trafficking defects and 
reduce lysosome storage and cholesterol accumulation. We propose that abnormal accumulation 
of luminal lipids causes secondary lysosome storage by blocking TRPML1- and Ca
2+
-dependent 








The lysosome, which serves as the cell’s recycling center, can mediate the hydrolase-based 
degradation of a variety of biomaterials, including proteins, lipids, and membranes (de Duve 2005). 
Most Lysosomal Storage Diseases (LSDs), of which more than 50 are known, are due to the defective 
activities of specific lysosomal enzymes, which result in lysosomal accumulation of specific substrates 
(Parkinson-Lawrence, Shandala et al. 2010). For instance, in Niemann-Pick (NP) type A and B 
diseases (NPA and NPB), sphingomyelins (SMs) accumulate in lysosomes due to insufficient activity 
of acid SMase (aSMase) (Schuchman 2010); similarly, insufficient aSMase activity and SM 
accumulation occur in Niemann-Pick type C (NPC), where the genetic defect occurs in components of 
an intracellular cholesterol/lipid trafficking pathway (Schuchman 2010; Rosenbaum and Maxfield 
2011). Interestingly, regardless of the nature of the primary undigested metabolites, common cellular 
defects are seen in a spectrum of LSDs (Vitner, Platt et al. 2010). For example, defects in lipid 
trafficking (the exit of lipids from the late endosome and lysosome) and autophagome-lysosome 
fusion are commonly observed in almost all sphingolipidoses, including NPA, NPB, and NPC (Puri, 





homeostasis are also common factors in these LSDs (Kiselyov, Yamaguchi et al. 2010; Parkinson-
Lawrence, Shandala et al. 2010; Vitner, Platt et al. 2010). Thus, it is likely that the common 
trafficking machinery is impaired in LSDs with unrelated origins or primary defects. One intriguing 
hypothesis is that the primary accumulated materials cause a sort of “lysosome stress,” which impairs 
common biochemical and/or signaling pathways in the lysosome, similar to the way unfolded proteins 
cause “ER stress” to trigger an “unfolded protein response” (Parkinson-Lawrence, Shandala et al. 
2010; Vitner, Platt et al. 2010). 
            Cells that lack mucolipin transient receptor potential (TRP) channel 1 (TRPML1) exhibit 
lysosomal defects similar to those seen in NP cells: defective autophagosome-lysosome fusion or 




 homeostasis (Pryor, 
Reimann et al. 2006; Vergarajauregui and Puertollano 2006; Thompson, Schaheen et al. 2007; Dong, 
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Cheng et al. 2008; Venkatachalam, Long et al. 2008; Cheng, Shen et al. 2010; Dong, Shen et al. 2010; 
Shen, Wang et al. 2011).  Furthermore, mutations in the human Trpml1 gene cause mucolipidosis type 
IV (ML4) LSD, which exhibits membrane trafficking defects and excessive lysosomal storage 





-dually permeable channel predominantly localized in late 
endosomes and lysosomes (LELs) (Grimm, Cuajungco et al. 2007; Xu, Delling et al. 2007; Dong, 
Cheng et al. 2008; Cheng, Shen et al. 2010; Grimm, Jors et al. 2010). TRPML1 is specifically 
activated by phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2), an LEL-localized low-abundance 
phosphoinositide (Dong, Shen et al. 2010). In addition, both TRPML1-lacking and PI(3,5)P2-deficient 
cells exhibit defects in LEL-to-Golgi retrograde trafficking and autophagosome-lysosome fusion 
(Pryor, Reimann et al. 2006; Zhang, Zolov et al. 2007; Abe and Puertollano 2011; Shen, Wang et al. 
2011), suggesting that the TRPML1-PI(3,5)P2 system represents a common signaling pathway 
essential for late endocytic trafficking.  
            Because of the high degree of similarity in lysosomal defects, we hypothesize that TRPML1-
PI(3,5)P2 signaling is compromised in NPs and many other LSDs.  In this study, by measuring 
lysosomal Ca
2+
 release using lysosome-targeted, genetically-encoded Ca
2+
 indicators, we found that 
TRPML1-mediated lysosomal Ca
2+
 release was compromised in NPC and NPA cells.  Patch-clamp 
analyses demonstrated that TRPML1’s channel activity was inhibited by micromolar concentrations of 
SMs, but potentiated by SM-hydrolyzing enzyme SMases.  In type C NP (NPC) cells, increasing 
TRPML1’s expression/activity was found to be capable of correcting the trafficking defects and 
decrease cholesterol accumulation. We conclude that SMs are negative regulators of TRPML1 
channels under physiological conditions, and that abnormal accumulations of SMs in the lysosome 
lumen block Ca
2+







Molecular biology and biochemistry. The GCaMP3-ML1 construct was made by inserting the full 
length GCaMP3 sequence (Tian, Hires et al. 2009) between the HindIII and BamHI sites of a 
pcDNA6 plasmid that contains the mouse TRPML1 cDNA at the XhoI site. TRPML1-L
15
L/AA-
L577L/AA (abbreviated as ML1-4A) and the TRPML1 non-conducting pore mutant (D471K/D472K; 
abbreviated ML1-KK) were constructed using a site-directed mutagenesis kit (Qiagen). All constructs 
were confirmed by sequencing, and protein expression was verified by western blot. CHO, HEK293T, 
Cos-1, and human fibroblast cells were transiently transfected with GCaMP3-ML1 for 
electrophysiology, Ca
2+
 imaging, and confocal imaging.  
PCR primers used for real-time qPCR analysis of TRPML expression in human fibroblasts and mouse 
macrophages are as follows:  
Human TRPML1: F, CGGATGACACCTTCGCAGCCTAC;  R, ACGCATACCGGCCCAGTGACAC 
Human TRPML2: F, GGTCACCACACAGCTTGTTCGT;  R, TGATGATACTGATTAATAGCA 
Human TRPML3: F, CCAGAAATTGAAACTGAGTGTT;  R, ATGTTATAGTCAGAGTAAAGTC 
Mouse TRPML1: F, AAACACCCCAGTGTCTCCAG;  R, GAATGACACCGACCCAGACT 
 
ML4 and NPC cell lines. NPC (CT43; NPC1
−/−
) and WT control (RA25) CHO cells were a gift from 
Dr. Chang TY (Dartmouth Medical School). Human skin fibroblast cells from an ML4 patient 
(ML1
−/−
, clone GM02048), an NPC patient (NPC1
−/−
, clone GM03123), an NPA patient (clone 




, clone GM00969) were obtained from the 
Coriell Institute for Medical Research (NJ, U.S.A). Human fibroblasts were transiently transfected by 
electroporation (260 V, 950 µF) with 100 µg of GCaMP3-ML1 plasmid, and then used for Ca
2+
 
imaging experiments 24 h after electroporation.   
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Mouse lines. NPC1 KO mice (BALB/cNctr-Npc1m1N/J) and WT littermates were ordered from the 
Jackson Laboratories.  TRPML1 KO mice were kindly provided by Dr. Susan Slaugenhaupt (Harvard 
Medical School) and Dr. Jim Pickel (NIH) (Venugopal, Browning et al. 2007).  Animals were used 
under approved animal protocols and University of Michigan Institutional Animal Care Guidelines.   
 
Preparation and culture of mouse macrophages. Bone marrow cells from femurs and tibias were 
harvested and cultured in macrophage differentiation medium (RPMI-1640 medium with 10% fetal 
bovine serum (FBS) and 100 unit/ml recombinant colony stimulating factor from PeproTech, Rocky 
Hill, NJ).  After 7 d in culture at 37 °C with 5% CO2, the adherent cells (> 95% are expected to be 
macrophages) were harvested for assays (Link, Park et al. 2010). 
 
Mammalian whole-cell electrophysiology. HEK293T, Cos-1, and CHO cells were used for the 
heterologous expression experiments and were transfected using Lipofectamine 2000 (Invitrogen). 
The pipette solution contained 147 mM Cs, 120 mM methane-sulfonate, 4 mM NaCl, 10 mM EGTA, 
2 mM Na2-ATP, 2 mM MgCl2, and 20 mM HEPES (pH 7.2; free [Ca
2+
]i < 10 nM).  The standard 
extracellular bath solution (modified Tyrode’s solution) contained 153 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 20 mM HEPES, and 10 mM glucose (pH 7.4). The "Low pH Tyrode" solution 
contained 150 mM Na- Gluconate, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM 
HEPES, and 10 mM MES (pH 4.6). All bath solutions were applied via a perfusion system to achieve 
a complete solution exchange within a few seconds. Data were collected using an Axopatch 2A patch 
clamp amplifier, Digidata 1440, and pClamp 10.0 software (Axon Instruments). Whole-cell currents 
were digitized at 10 kHz and filtered at 2 kHz. All experiments were conducted at room temperature 
(21-23 ºC), and all recordings were analyzed with pClamp 10.0, and Origin 8.0 (OriginLab, 
Northampton, MA).   
 
Endolysosomal electrophysiology. Endolysosomal electrophysiology was performed in isolated 
endolysosomes using a modified patch-clamp method (Dong, Cheng et al. 2008; Dong, Shen et al. 
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2010). Briefly, cells were treated with 1 µM vacuolin-1 for 2-5 h to increase the size of endosomes 
and lysosomes. Whole-endolysosome recordings were performed on isolated enlarged LELs. The bath 
(internal/cytoplasmic) solution contained 140 mM K-Gluconate, 4 mM NaCl, 1 mM EGTA, 2 mM 
Na2-ATP, 2 mM MgCl2, 0.39 mM CaCl2, 0.2 mM GTP, and 10 mM HEPES (pH adjusted with KOH 
to 7.2; free [Ca
2+
]i approximately 100 nM based on the Maxchelator software 
(http://maxchelator.stanford.edu/)). The pipette (luminal) solution consisted of a “Low pH Tyrode’s 
solution”  with 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM MES, 




 imaging. Cells were loaded with 5 µM Fura-2 AM in the culture medium at 37 °C for 60 
min. Fluorescence was recorded at different excitation wavelengths using an EasyRatioPro system 
(PTI). Fura-2 ratios (F340/F380) were used to monitor changes in intracellular [Ca
2+
] upon stimulation.  
GPN (Glycyl-L-phenylalanine 2-naphthylamide; 200-400 µM, a lysosome-disrupting agent) and 
Bafilomycin A1 (500 nM, a V-ATPase inhibitor) were used as positive controls to induce Ca
2+
 release 
from lysosome and acidic stores, respectively (Calcraft, Ruas et al. 2009). Ionomycin (1 µM) was 
added at the conclusion of all experiments to induce a maximal response for comparison.  For 
endogenous lysosomal Ca
2+
 release measurement, Ca
2+
 imaging was carried out within 0.5-3 h after 




 imaging. 18-24 h after transfection with GCaMP3-ML1, CHO or human fibroblast 
cells were trypsinized and plated onto glass coverslips. Most experiments were carried out within 0.5-
3 h after plating when cells still exhibited a round morphology. The fluorescence intensity at 470 nm 
(F470) was monitored using the EasyRatioPro system.  Lysosomal Ca
2+
 release was measured under a 
"low" external Ca
2+
 solution, which contained 145mM NaCl, 5 mM KCl, 3 mM MgCl2, 10 mM 
Glucose, 1mM EGTA, and 20 mM HEPES (pH7.4).  Ca
2+
 concentration in the nominally-free Ca
2+
 
solution is estimated to be 1-10 µM.  With 1 mM EGTA, the free Ca
2+
 concentration is estimated to be 
< 10 nM based on the Maxchelator software (http://maxchelator.stanford.edu/). 
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LacCer-BODIPY trafficking. Cells for the Lactosylceramide (LacCer)-BODIPY uptake experiment 
were grown on glass coverslips and incubated with 5 µM BSA-complexed LacCer in “Tyrode” 
solution for 45 min at room temperature. Cells were then washed twice with PBS and incubated with 
normal DMEM/F12 medium containing 10% FBS at 37 °C  for 1h. For the correction experiments, 
NPC1
−/− 
macrophages were pre-treated with ML-SA1 (10 µM) for 12 hrs, and chased in the presence 
of ML-SA1 (10 µM).  Images were taken using a Leica (TCS SP5) confocal microscope.  
 
Filipin Staining. Cells were fixed in 3% paraformaldehyde for 1 h, washed twice with PBS, and then 
incubated with 1.5 mg/ml glycine in PBS for 10 min. Cells were then stained for 2 h with 0.05 mg/ml 
filipin (Lloyd-Evans, Morgan et al. 2008) in PBS supplemented with 10% FBS. All procedures were 
conducted at room temperature.  Images were taken using a fluorescence microscope with a UV filter.  
The lysosome-like storage organelle filipin intensity was calculated based on low- and high-threshold 
intensities in the image (Devlin, Pipalia et al. 2010).  
 
Lysenin Staining.  Cells were fixed with 4% PFA for 20 min, blocked with 1% BSA in PBST for 2h, 
and then incubated with lysenin (0.1 μg/ml, Peptides International) for 20 h at 4 ˚C. The cells were 
then incubated with anti-lysenin antibody (Peptides International) for 1h, followed by Alexa Fluor 488 
anti-rabbit (Invitrogen) for 45 min.  Images were taken using a Leica confocal microscope.  
 
Reagents. Sphingomyelins (Sigma) were dissolved in “Tyrode” or “Low pH Tyrode” solutions by 
sonication. Beta-cyclodextrin, filipin, and fluoxetine were obtained from Sigma; desipramine was 
purchased from Santa Cruz; C6-ceramide was obtained from Matreya, LLC; sphingomyelinase was 
obtained from MP Biomedicals; SF-51 and ML-SA1 were purchased from Princeton BioMolecular 
Research Inc; PI(3,5)P2 was purchased from Echelon; U18666A was purchased from Enzo; LacCer-
BODIPY was purchased from Invitrogen, and lysenin and anti-lysenin antibody were purchased from 
Peptides International.  
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Data analysis. Data are presented as the mean ± standard error of the mean (SEM). Statistical 





Reduced TRPML1-mediated lysosomal Ca
2+
 release in NPC cells 
Whether TRPML1-mediated lysosomal Ca
2+
 release is altered in NP cells was first investigated.  I 
chose an easy-to-transfect NPC cellular model, i.e, NPC (NPC1
-/-
) CHO cells, which exhibit all the 
hallmark features of NPC disease (Cadigan, Spillane et al. 1990; Cruz, Sugii et al. 2000). WT CHO 
cells transfected with GCaMP3-ML1 exhibited large TRPML1-mediated lysosomal Ca
2+
 release (Fig. 
4.1a, c).  In contrast, NPC CHO cells exhibited much smaller TRPML1-mediated Ca
2+
 release with a 
~ 75% reduction compared to WT controls (Fig 4.1b, c).  GCaMP3-ML1 was still mainly co-localized 
with Lamp-1 in NPC cells (Fig 4.2a).  In addition, the expression levels of GCaMP3-ML1, as 
estimated from the maximal fluorescence intensity induced by ionomycin, were comparable for WT 
and NPC cells (Fig 4.2b).  A previous study reported that lysosomal Ca
2+
 stores are compromised in 
NPC cells (Lloyd-Evans, Morgan et al. 2008).  However, we found that GPN- (a cell-permeable 
cathepsin C peptide substrate that, when cleaved, causes osmotic lysis of lysosomes) induced 
GCaMP3-ML1 increases were comparable for WT and NPC cells (Fig 4.3a). Likewise, GPN-induced 
and NH4Cl-induced Fura-2 responses were also comparable in non-transfected WT and NPC cells 
(Fig 4.3b, 4.4a).  Furthermore, TRPML1-mediated, but not GPN-induced lysosomal Ca
2+
 release, was 
also reduced in GCaMP3-transfected NPC human fibroblasts compared to WT cells (Fig 4.4b). 
Collectively, these results suggest that TRPML1-mediated lysosomal Ca
2+
 release is selectively 
reduced in NPC cells.  
   NPC-like cellular phenotypes can be pharmacologically induced with a small-molecule drug 
U18666A (Liscum and Faust 1989).  After incubating GCaMP3-ML1-transfected WT CHO cells with 
94 
U18666A (2 µg/ml) for 16-20 h, cells exhibited significant increases in cholesterol level as detected 
by filipin staining (Rosenbaum and Maxfield 2011) (Fig 4.5a), and sphingomyelin (SM) level as 
detected by lysenin staining (Fig 4.5b). U18666A-treated cells exhibited a ~ 70% reduction in 
TRPML1-mediated lysosomal Ca
2+
 release (Fig 4.6a, b). Conversely, drug treatment failed to result in 
noticeable changes in GPN-induced GCaMP3 responses (Fig 4.3a) or Fura-2 Ca
2+
 responses (Fig 
4.3b). Taken together, these results suggest a specific reduction of TRPML1-mediated lysosomal Ca
2+
 
release in pharmacologically-induced NPC cells.   
   We next investigated the effect of NPC on endogenous Ca
2+
 release using Fura-2 Ca
2+ 
imaging.  In WT CHO cells, small but significant Ca
2+
 increases were seen upon application of 100 
µM ML-SA1 in low external Ca
2+
 (ΔFura-2 = 0.08 ± 0.01, n = 89; Fig 4.7d, f). In contrast, in NPC 
CHO cells, ML-SA1 failed to induce significant Ca
2+
 responses (ΔFura-2 = 0.01 ± 0.002, n = 61; Fig 
4.7e,f). Cyclodextrin, a polysaccharide that reportedly alleviates NPC cellular phenotypes 
(Rosenbaum and Maxfield 2011),  was found to partially restore ML-SA1-induced lysosomal Ca
2+
 
release (Fig 4.8). Finally, NPC1
-/-
 mouse macrophages, one of the major cell types affected in NPC 
(Schuchman 2010), also exhibited a significant reduction in ML-SA1-induced lysosomal Ca
2+
 release 
compared to WT cells (Fig 4.7a,b, f ).  The ML-SA1-induced lysosomal Ca
2+
 responses are most 
likely mediated by TRPML1, as demonstrated by the lack of response in ML1
-/-
 macrophages (Fig 
4.7c, f). Collectively, the reduction in TRPML1-mediated lysosomal Ca
2+
 release may be a general 
feature of most NPC cell types. 
 
Reduced TRPML1-mediated currents in NPC cell lysosomes 
We next investigated the effect of NPC on whole-endolysosome IML1 in human fibroblasts. Compared 
to WT fibroblasts (Fig 4.9a, c), much smaller ML-SA1-activated IML1 was seen in NPC fibroblasts at 
three different concentrations of ML-SA1 (Fig 4.9b, c). On average, whole-endolysosome IML1 
activated by 25 µM ML-SA1 was 75 ± 25 (n = 8) pA/pF for NPC cells, a ~ 70% reduction from the 
values observed for WT cells (442 ± 150 pA/pF; n = 6).  Notably, the mRNA expression levels of 
TRPML1-3 were not decreased in NPC cells (Fig 4.10).  These results suggest that a reduction of 
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whole-endolysosome IML1 accounts for the reduced TRPML1-mediated Ca
2+
 release observed in NPC 
cells.  
 
Inhibition of TRPML1 by SMs  
The reduced TRPML1-mediated lysosomal Ca
2+
 release and IML1 in the presence of normal TRPML1 
expression in NPC cells suggest tonic inhibition of TRPML1 by cytoplasmic and/or luminal factors. 
One possibility is that lipids accumulated in NPC lysosomes, such as cholesterol, SM, sphingosine 
(Sph), and glycosphingolipids (GSLs) (Lloyd-Evans and Platt 2010; Rosenbaum and Maxfield 2011), 
might directly inhibit TRPML1. To test this possibility, we performed whole-cell recordings in ML1-
4A-expressing HEK293T cells. Under this configuration, the extracellular side is analogous to the 
luminal side (see Fig 4.11), making it possible to study the effects of luminal lipids on IML1-4A.  SMs, 
but not cholesterol or GSLs (data not shown), acutely inhibited SF-51- (Fig 4.12a, d) or ML-SA1-
activated IML1-4A. In contrast, SMs failed to inhibit IML1- Va , a gain-of-function mutation that locks 
TRPML1 in the open state (Cheng, Shen et al. 2010) (Fig 4.12b, d). SMs can be hydrolyzed into 
ceramide and phosphocholine via SMase. No significant inhibition was seen with ceramide (Fig. 12c, 
d) or phosphocholine (Fig 4.12d). Sphingosine, a hydrolyzed product of ceramide, potentiated IML1-4A 
(Fig 4.12e).  
   The robust inhibition of IML1-4A by SMs, but not ceramide or phosphocholine, suggests that 
the activity of SMase may regulate IML1-4A. Indeed, bath application of SMases, but not heat-
inactivated enzymes, significantly potentiated SF-51-activated IML1-4A (Fig 4.13a-f), with the 
potentiation being more dramatic at acidic extracellular (luminal) pH than at neutral pH (Fig 4.13f).   
 
SM accumulation reduces TRPML1-mediated Ca
2+
 release 
The results presented above suggest that SM-mediated inhibition underlies NPC-mediated reduction in 
TRPML1-mediated lysosomal Ca
2+
 release. Consistent with this, in fibroblasts derived from NPA 
patients, which completely lack the activity of acid SMase (Schuchman 2010), TRPML1-mediated , 
but not GPN-induced lysosomal Ca
2+
 release (Fig 4.14a-c), was significantly reduced. To further test 
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this hypothesis, we induced lysosomal SM accumulation by incubating cells with desipramine and 
fluoxetine for 2-4 hrs, which cause proteolytic degradation of acid SMase (Hurwitz, Ferlinz et al. 
1994; Kornhuber, Tripal et al. 2008).  Compared to non-treated cells, TRPML1-mediated lysosomal 
Ca
2+
 release was dramatically reduced in desipramine/fluoxetine -treated CHO cells, and the reduction 
was abolished in the presence of a protease inhibitor leupeptin (Hurwitz, Ferlinz et al. 1994; 
Kornhuber, Tripal et al. 2008) (Fig 4.15a-d). Taken together, these results suggest that SM inhibition 
of TRPML1 underlies NPA or NPC-mediated attenuation of TRPML1-mediated lysosomal Ca
2+
 
release.   
 
TRPML1 regulates lysosomal lipid and cholesterol trafficking   
Human NPC, NPA, and NPB fibroblasts exhibit defects in LEL-to-Golgi trafficking of lipids and 
proteins (Puri, Watanabe et al. 1999; Cruz, Sugii et al. 2000). Consistent with this, BODIPY-LacCer, 
a fluorescent analogue of lactosylceramide that is localized in the Golgi apparatus of WT cells after a 
pulse-chase period (Pagano and Chen 1998), was predominantly localized in the LEL-like 
compartments of NPC1
-/- 
mouse macrophages (Fig 4.16a). Because of the established roles of 
PI(3,5)P2/TRPML1/Ca
2+
 in LEL-to-Golgi lipid trafficking (Shen, Wang et al. 2011), it is possible that 
the trafficking defects seen in NP cells are due to the aforementioned attenuated TRPML1-mediated 
lysosomal Ca
2+
 release. If so, one would expect that boosting TRPML1 activity may correct the 
trafficking defects. Indeed, more than 60% of ML-SA1-treated NPC macrophages exhibited a Golgi-
like pattern of LacCer staining, suggestive of a significant restoration in LEL-to-Golgi transport (Fig 
4.16a). In NPC1
-/- 
mouse macrophages  and TRPML1-transfected NPC CHO cells, the puncta number 
of LacCer staining that reflects the function of LEL-to-Golgi transport, was significantly reduced in 
the presence of ML-SA1 (Fig 4.16b-d).  Collectively, these results suggest that increasing TRPML1’s 
channel activity may restore the trafficking defects in NPC cells, and that TRPML1 deregulation is a 
pathogenic mechanism underlying lipid trafficking defects in NP cells.  
   NPC cells accumulate cholesterol, as demonstrated by elevated filipin staining (Lloyd-Evans, 
Morgan et al. 2008). However, in U18666A-treated CHO cells, ML-SA1 induced a significant 
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reduction in filipin staining in TRPML1, but not TRPML1-KK-transfected cells (Fig 4.17a, b).  
Reduction of filipin staining was also seen in aSMase- (Fig 4.17c, d) and TRPML1
Va
- transfected 
NPC CHO cells (Fig 4.17e, f).  These results suggest that increased TRPML1 activity may reduce 




We used a lysosome-targeted GCaMP3-based Ca
2+
 imaging method to demonstrate that TRPML1-
mediated lysosomal Ca
2+
 release, but not the lysosomal Ca
2+
 store as has been previously reported 
(Lloyd-Evans, Morgan et al. 2008), is selectively compromised in NPC and NPA cells.  SM, a 
sphingolipid that is known to accumulate in all three types of NP cells (Rosenbaum and Maxfield 
2011), inhibits TRPML1. Pharmacologically-induced SM accumulation significantly reduces 
TRPML1-mediated lysosomal Ca
2+
 release. Conversely, increasing TRPML1’s expression/activity is 
sufficient to correct the trafficking defects and reduce cholesterol accumulation in NPC cells. 
Collectively, our work has provided a feedback mechanism for luminal lipids to control lipid efflux 
from the lysosome, as well as a pathogenic cause for the secondary lysosome storage present in many 
LSDs. 
            Sphingomyelin is the first negative regulator for TRPML1 that has been identified so far. In 
normal cells, SMs in the late endosome/lysosome would be rapidly degraded by acid SMase activity 
(Kolter and Sandhoff 2010). However, in NP type A and B cells, due to the defective aSMase enzyme 
activity, SMs accumulate in the lumen and limited lysosomal membranes (Fig 4.11). In NP type C 
cells, although the primary storage is likely to be cholesterol, they are found to have a much lower 
level of aSMase activity, which also leads to SMs accumulation. A restoration of aSMase activity has 
been reported to be able to revert cholesterol accumulation (Devlin, Pipalia et al. 2010). It is not 
known whether the level of SM is perturbed in other sphingodoses. However, rather than absolute SM 




 release. Although TRPML1 is the dominant lysosomal TRPML channel in most cell types, in 
other cell types where TRPML2 and TRPML3 are more abundantly expressed (Cheng, Shen et al. 
2010), our proposed SM-mediated inhibitory mechanism may also be applied to TRPML2/3, causing 
lysosomal trafficking defects.  Finally, SM and cholesterol accumulation might also contribute to NP 
phenotypes via mechanisms unrelated to lysosomal trafficking and TRPMLs (Schuchman 2010).  
            LEL-to-Golgi trafficking defects are seen in PI(3,5)P2-deficient cells (Zhang, Zolov et al. 
2007), ML4 fibroblasts (Chen, Bach et al. 1998; Shen, Wang et al. 2011), and NP fibroblasts, as well 
as fibroblasts from several other sphingolipid LSDs (Chen, Patterson et al. 1999; Puri, Watanabe et al. 
1999). Our results suggest that reduced TRPML1-mediated lysosomal Ca
2+
 release directly causes 
trafficking defects, and boosting TRPML1 activity by a small molecular activator can largely rescue 
the trafficking defects. The compromised TRPML1 activity is likely to slow down the trafficking 
process, but not totally block the trafficking. Indeed, while most NPC-/- macrophage cells exhibit a 
puncta pattern of LacCer staining after 1 hour chasing (when most WT macrophage cells have a 
Golgi-like pattern), 4 hours later, 30%-40% of NPC-/- macrophage cells start to exhibit a Golgi-like 
pattern of LacCer (data not shown). Future studies will need to include more chasing timelines for 
lacCer staining in order to fully explore the effect of TRPML1 activity on LEL-to-Golgi trafficking. 
            For most LSDs, impaired lysosomal degradation due to a lack of hydrolytic enzymes leads to 
trafficking defects and lysosome storage. On the other hand, lysosome storage can further affect 
lysosomal degradation and membrane trafficking, which results in a positive feedback loop and a 
vicious cycle (Parkinson-Lawrence, Shandala et al. 2010). We previously reported that impaired Fe
2+
 
homeostasis facilitates the formation of autofluorescent lipofuscin in ML4 cells (Dong, Cheng et al. 
2008). Interestingly, lipofuscin formation is also increased in NPC cells (Fig 4.18).  Although there is 
no study of TRPML1 activity in other LSDs, the impaired Ca
2+
 release we observed in NP cells might 
be a common pathogenic mechanism for many LSDs. Our work suggests a novel concept that 
lysosome enhancement by the manipulation of TRPML1 to speed membrane trafficking may break the 








Figure 4.1. TRPML1-mediated lysosomal Ca
2+
 release is reduced in NPC cells. (a, b) ML-SA1-
induced lysosomal Ca
2+
 release in GCaMP3-ML1-transfected WT (a) and NPC (b) CHO cells. (c) 
ML-SA1-induced peak GCaMP3 responses were reduced in GCaMP3-ML1-transfected NPC cells. 
The results were averaged for 40-100 cells from at least 3 independent experiments; data are presented 


















Figure 4.2. Reduced Ca
2+ 
response in NPC-/- CHO cells is not due to the localization or 
expression level changes of GCaMP3-ML1. a) Co-localization of GCaMP3-ML1 fluorescence with 
Lamp-1 in NPC CHO cells doubly-transfected with GCaMP3-ML1 and Lamp-1-mCherry. Scale bar = 
5 µm. (b) Comparable expression levels of GCaMP3-ML1 in WT and NPC CHO cells.  Expression 
level of GCaMP3-ML1 was estimated by the maximal GCaMP3 fluorescence signal induced by 








Figure 4.3. Reduced Ca
2+ 
response in NPC-/- CHO cells is not due to reduced lysosome Ca
2+ 
store. (a) Comparable GPN-induced GCaMP3 responses in WT, NPC, or U18666A-treated GCaMP3-
ML1-transfected CHO cells. (b) NH4Cl (10 mM) and GPN (200 µM) induced comparable levels of 
Ca
2+
 increases (measured with Fura-2 ratios) in WT, NPC, and U18666A-treated CHO cells.  The 
results were averaged for 40-100 cells from at least 3 independent experiments; data are presented as 








Figure 4.4. TRPML1-mediated lysosomal Ca
2+
 release, not lysosomal Ca
2+
 store, is reduced in 
NPC cells. (a) NH4Cl (10 mM) and GPN (200 µM) induced comparable levels of Fura-2 Ca
2+
 
responses in WT and NPC human fibroblasts. (b) TRPML1-mediated, but not GPN-induced 
lysosomal Ca
2+
 release, was reduced in GCaMP3-ML1-transfected NPC human fibroblasts compared 
to WT cells.  The results were averaged for 40-100 cells from at least 3 independent experiments; data 
are presented as the mean ± SEM. Statistical comparisons were made using analysis of variance: * P 




Figure 4.5. U18666A treatment induces cholesterol and sphingomyelin accumulations in WT 
cells. (a) WT CHO cells were treated with U18666A (2 µg/ml) for 16 h, and then subjected to filipin 
staining. Scale bar = 10 µm.  (b) Sphingomyelins were stained with Lysenin (0.1 µg/ml) in WT CHO 
cells, WT CHO cells treated with U18666A (2 µg /ml) for 16 h, and NPC CHO cells. Scale bar = 10 







Figure 4.6. TRPML1-mediated lysosomal Ca
2+
 release is reduced in pharmacologically indued 
NPC-/- cells. (a) Ca
2+
 responses in GCaMP3-ML1-transfected WT CHO cells treated with U18666A 
(2 µg /ml) for 16-20 h. (b) ML-SA1-induced peak GCaMP3 responses were reduced in GCaMP3-
ML1-transfected NPC or U18666A-treated WT CHO cells. The results were averaged for 40-100 cells 
from at least 3 independent experiments; data are presented as the mean ± SEM. Statistical 

























Figure 4.7. Endogenous TRPML1-mediated lysosomal Ca
2+
 release is compromised in NPC 
cells. (a-c). Endogenous TRPML1-mediated lysosomal Ca
2+
 release (measured with Fura-2 ratios) in 
WT (a), NPC1-/- (b), and ML1-/- (c) mouse macrophages. (d, e) Endogenous TRPML1-mediated 
lysosomal Ca
2+
 release (measured with Fura-2 ratios) in WT (d) and NPC (e) CHO cells. (f) Average 
endogenous ML-SA1-induced lysosomal Ca
2+




 mouse macrophages. The results were averaged for 40-100 cells from at least 3 
independent experiments; data are presented as the mean ± SEM. Statistical comparisons were made 






Figure 4.8.  Cyclodextrin significantly reduces filipin staining and corrects trafficking defects in 
NPC CHO cells. 
(a) Filipin staining in NPC CHO cells that were treated with cyclodextrin (300 µM) for 24 h. Scale bar 
= 10 µm. (b) LacCer staining in cyclodextrin-treated NPC CHO cells. Scale bar = 5 µm. (c) 
Endogenous TRPML1-mediated lysosomal Ca
2+
 release (measured with Fura-2 ratios) in NPC CHO 
cells that were treated with cyclodextrin (300 µM) for 24 h. (d) Endogenous TRPML1-mediated 
lysosomal Ca
2+
 release is partially restored by cyclodextrin treatment. The results were averaged for 
40- 100 cells from at least 3 independent experiments; data are presented as the mean ± SEM. 
Statistical comparisons were made using analysis of variance: * P <0.05. Results for WT and NPC 




Figure 4.9. TRPML-mediated currents are reduced in the lysosomes of NPC cells.  
(a, b) Concentration-dependent activation of whole-endolysosome IML-L in WT (a) and NPC (b) 
human fibroblasts. ML-SA1 (3, 10, 25 µM) was applied to the cytosolic sides of the vacuoles isolated 
from human fibroblasts. (c) Average current densities (pA/pF) of IML-L were reduced in NPC 
fibroblasts compared to WT cells.  The current density was calculated from the current size (pA) 
normalized with the capacitance of the vacuole (pF).  For panels c, data are presented as the mean ± 
SEM; the n numbers are in parentheses. Statistical comparisons were made using analysis of variance: 






Figure 4.10. The mRNA level of TRPMLs is not reduced in NPC cells.  RT-PCR analysis of 
TRPML1-3 mRNA expression in WT and NPC human fibroblasts, and NPC1 
-/-
 mouse macrophages.  
Expression levels were normalized to that of GAPDH (human fibroblast) and L32 (mouse 
macrophage).  Data are presented as the mean ± SEM; the n numbers are in parentheses. Statistical 





Figure 4.11.  Sphingomyelin localization and turnover at the plasma membrane and in the 
lysosome. 
At the plasma membrane, SMs are mainly localized at the outer leaflet. Upon endocytosis, SMs are 
localized in the luminal leaflet of limited membranes and internal vesicles. Acid SMases (aSMase) 
hydrolyze SMs into ceramide (Cer) and phosphocholine (PC). Ceramide can be further converted into 






Figure 4.12. Regulation of TRPML1 by SMs.  
(a) SF-51-activated whole-cell IML1-4A was inhibited by sphingomyelins (SMs; 20 µM) at low 
extracellular pH in ML1-4A-expressing HEK293T cells. (b) Insensitivity of whole-cell IML1-Va to SMs 
(60 µM). (c) Lack of effect of ceramide (Cer, 20 µM) on whole-cell IML1-4A. (d) Summary of the 
effects of various sphingolipids on whole-cell IML1-4A in ML1-4A-expressing HEK293T cells.  PC: 
phosphocholine. (e) SF-51-activated whole-cell IML1-4A was potentiated by sphingosine (Sph; 5 µM) at 
low external pH in ML1-4A-expressing HEK293T cells.  For panels d, data are presented as the mean 
± SEM; the n numbers are in parentheses. Statistical comparisons were made using analysis of 









Figure 4.13.  Regulation of TRPML1 by sphingomyelinase. 
(a) The effects of SMase (50 ng/ml) treatment on IML1-4A  at low external pH. IML1-4A was elicited by 
repeated voltage ramps (− 140 to + 140 mV; 400 ms) with a 4-s interval between ramps.  Current 
amplitudes at -140 mV were used to plot the time dependence.  (b) Representative traces of IML1-4A 
before (black) and after (dark yellow) SMase treatment at two different time points, as shown in f. (c, 
d) SMase (50 ng/ml) treatment alone had no (6 out of 7 cells; see c for an example) or small (1 out of 
7 cells; d) activation effect on basal whole-cell IML1-4A  in ML1-4A-expressing HEK293T cells. (e) 
The effects of SMase (50 ng/ml) treatment on SF-51-activated IML1-4A at neutral external pH (pH 7.4).  
(f) The potentiation effect of SMase was more dramatic at pH 4.6, but abolished by heat inactivation 
of the enzyme activity. HI-SMase: heat-inactivated SMase. For panels f, data are presented as the 
mean ± SEM; the n numbers are in parentheses. Statistical comparisons were made using analysis of 















Figure 4.14.  NPA fibroblasts have reduced TRPML1-mediated Ca
2+
 release. 
(a,b) ML-SA1-induced lysosomal Ca
2+
 release was reduced in GCaMP3-ML1-transfected NPA 
fibroblasts (b) compared to WT fibroblasts (a).  (c) Average ML-SA1 (20 µM) and GPN (200 µM)-
induced responses in GCaMP3-ML1-transfected WT and NPA fibroblasts. For panels c, the results 
were averaged for 40-100 cells from at least 3 independent experiments; data are presented as the 















Figure 4.15.  Phamacutically inducing SM accumulation in lysosomes reduces TRPML1-
mediated Ca
2+
 release. a) Desipramine (25 µM) treatment for 2-4 hrs reduced TRPML1-mediated 
lysosomal Ca
2+
 release responses (20 µM ML-SA1) in GCaMP3-ML1-transfected CHO cells. (b) 
Pretreatment of a protease inhibitor Leupeptin (25 µM) abolished the effects of Desipramine in ML-
SA1-induced GCaMP3 responses.  (c) Summary of the effects of Desipramine (25 µM) and 
Fluoxetine (25 µM) treatment for 2-4 hrs on TRPML1-mediated lysosomal Ca
2+
 release responses (20 
µM ML-SA1) in GCaMP3-ML1-transfected CHO cells. (d) Desipramine and fluoxetine treatment for 
2-4 hrs reduced endogenous lysosomal Ca
2+
 release responses (measured with Fura-2 ratios; 100 µM 
ML-SA1) in CHO cells.  For panels c, d, the results were averaged for 40-100 cells from at least 3 
independent experiments; data are presented as the mean ± SEM. Statistical comparisons were made 





Figure 4.16. ML-SA1 together with TRPML1 overexpression rescues the trafficking defects in 
NPC cells. 
(a) A fluorescent analogue of lactosylceramide, BODIPY-LacCer, was mainly localized in the Golgi-
like structures of WT macrophages after a pulse-chase for 1 h, but accumulated in the LEL-like 
vesicles of NPC macrophages.  ML-SA1 (10 µM) treatment of NPC1
-/-
 macrophages for 12 h resulted 
in a primary Golgi-like localization for LacCer. Scale bar = 10 µm. (b) ML-SA1 reduced the number 
of LacCer puncta in NPC1
-/-
 macrophages.  (c) NPC CHO cells were transfected with TRPML1-
mCherry, treated with ML-SA1 (10 µM) for 24 h and stained with LacCer. Scale bar = 5 µm. (d) 
Number of LacCer puncta in WT and NPC cells that were treated with ML-SA1. For panels b, d, the 
results were averaged for multiple randomly-taken micrographs from at least 3 independent 
experiments. Data are presented as the mean ± SEM. Statistical comparisons were made using 
analysis of variance: * P <0.05.    
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Figure 4.17. ML-SA1 together with TRPML1 overexpression reduces cholesterol accumulation 
in NPC cells. 
(a, b) ML-SA1 reduced unesterified cholesterol (filipin) staining in ML1, but not ML1-KK-expressing 
U18666A-treated WT CHO cells. Differential interference contrast (DIC) images are shown for 
comparison.  Scale bar = 10 µm. (c) Unesterified cholesterol (filipin) staining in NPC CHO cells was 
partially reduced in cells expressing DsRed-aSMase. Scale bar = 10 µm.  (d) Average filipin staining 
(intensity normalized to non-transfected control cells) in DsRed-aSMase-transfected cells.  (g) 
Unesterified cholesterol (filipin) staining in NPC CHO cells was partially reduced in cells expressing 
ML1-Va-EGFP (ML1
Va
). Scale bar = 10 µm.  (h) Average filipin staining (intensity normalized to 
non-transfected control cells) in ML1
Va
-transfected cells.  For panels b, d, f, the results were averaged 
for multiple randomly-taken micrographs from at least 3 independent experiments. Data are presented 
as the mean ± SEM. Statistical comparisons were made using analysis of variance: * P <0.05.    
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Figure 4.18. Lipofuscin-like autofluorescent materials accumulate in the lysosomes of NPC 
fibroblasts. 
An NPC fibroblast showed autofluorescence (green) in LysoTracker-positive compartments. 
Autofluorescence was detected within a range of excitation wavelengths (shown with excitation at 480 
nm). No significant autofluorescence was observed for WT cells. Differential interference contrast 




















Summary of results  
TRPML1 is an inwardly-rectifying Ca
2+
-permeable channel in late endosomes and lysosomes. Loss-
of-function mutations in the human TRPML1 gene cause a devastating pediatric neurodegenerative 
disease called type IV Mucolipidosis (ML4). The aim of this thesis was to explore the intracellular 
regulatory mechanisms of TRPML1, and how the channel activity affects endolysosomal dynamics. 
            In chapter 2 an endogenous TRPML1 agonist - PI(3,5)P2 was identified.  PI(3,5)P2 potently 
and specifically activates TRPML1 in both heterologous and endogenous systems. Biochemical 
binding assays show that PI(3,5)P2 directly binds to the multiple positively-charged amino acid 
residues on the N terminus of TRPML1. Using a spectrum of yeast mutant strains with variable 
degrees of PI(3,5)P2  deficiency, a high-degree of correlation between the levels of PI(3,5)2 and the 
activity of a yeast functional TRPML homologue has been established. Notably, overexpression of 
TRPML1 was sufficient to rescue the trafficking defects in PI(3,5)P2-deficient mammalian cells. 
These results demonstrate that TRPML1, an endolysosome-localized Ca
2+
 channel, is activated by the 
endolysosome-specific PI(3,5)P2, providing a previously unknown link between these two important 
regulators of intracellular membrane trafficking.  
        In Chapter 3, a membrane-permeable small-molecule synthetic agonist for TRPMLs, Mucolipin-
Synthetic Agonist 1 (ML-SA1), was identified. Electrophysiological results showed that ML-SA1 
potently and specifically activates recombinant TRPMLs, as well as endogenous TRPML-like currents 




from endolysosomes in intact cells. ML-SA1 has therefore served as a valuable tool for studying 
intracellular functions of TRPMLs.  
        By taking advantage of ML-SA1, the activity of TRPML1 was examined under a pathological 
context (Chapter 4). I found that TRPML1-mediated lysosomal Ca
2+
 release, measured using a 
genetically-encoded Ca
2+
 indicator (GCaMP3) attached directly to TRPML1, was dramatically 
reduced in Niemann-Pick (NP) disease cells. Patch-clamp analyses revealed that TRPML1 channel 
activity was inhibited by sphingomyelin (SM), but potentiated by spingomyelinase. Importantly, 
increasing the expression/activity of TRPML1 was able to alleviate the lipid accumulation and 
trafficking defects in NPC cells. Our findings suggest that compromised channel activity of TRPML1 
is the pathogenic cause for secondary lysosomal storage seen in many lysosomal storage disorders 
(LSDs). Thus manipulating TRPML1 channel activity by chemical agonists may provide therapeutic 
approaches not only for ML4, but also for other LSDs. 
            Taken together, the studies in this thesis investigated the regulatory mechanisms of TRPML1 
under both physiological and pathological conditions. Two endogenous regulators and a synthetic 
agonist for TRPML1 have been identified. These findings add new perspectives to the roles of 
TRPML1 in the endolysosomal dynamics, yet many issues remain unsolved and new questions have 
been raised. In the following part of the thesis, the significance of the findings will be elaborated and 
unresolved questions will be discussed.  
 
How TRPML1 is regulated by PI(3,5)P2 under physiological conditions 
My study revealed that lysosomal PI(3,5)P2 is a physiological regulator of TRPML1. However, the 
exact concentration of local PI(3,5)P2 in the LEL under basal conditions, or upon cellular stimulation, 
is not known. Therefore, the mechanisms by which PI(3,5)P2 modulates TRPMLs under physiological 
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conditions remain unclear.  A key question is whether PI(3,5)P2 is the sole activator of TRPML1, or 
there are additional factors involved.   
            It is likely that constitutive trafficking signals, or acute stimuli, recruit/activate PIKfyve 
present in microdomains, thereby resulting in a rapid and transient increase in PI(3,5)P2 and 
TRPML1-mediated Ca
2+
 release (Activation model, Fig. 5.1A).  However, although the EC50 for 
recombinant TRPML1 is only ~50 nM (Dong, Shen et al. 2010), higher concentrations of PI(3,5)P2 are 
required to activate endogenous TRPML1 (Wang, Dong, and Xu; unpublished data).  Thus, it remains 
unclear whether physiological levels of PI(3,5)P2, which are presumably in the low nanomolar range, 
are sufficient to activate endogenous TRPML1 in endolysosomes.   
            It is also possible that, in vivo, additional regulatory mechanisms for TRPML1 include factors 
other than PI(3,5)P2.  For example, PI(4,5)P2 has been shown to be a “permissive” factor in the 
activation of voltage gated Ca
2+
 channels in response to depolarization (Wu, Bauer et al. 2002).  
Similarly, PI(3,5)P2 may “sensitize”, yet not fully “activate” TRPML1.  Increases in levels of 
PI(3,5)P2 may also promote Ca
2+
 channels to be maintained in a “willing state”, thereby facilitating 
channel activation in the absence of secondary activation factors (Sensitization model, see Fig. 5.1B).  
Conversely, in the absence of PI(3,5)P2, activation of Ca
2+ 
channels may require much higher 
concentrations or stronger binding interactions by activation factors that exceed the physiologically 
permitted range.  One activation factor to consider is that of mechanical force, which may be 
generated by the membrane curvature achieved prior to fusion(Martens and McMahon 2008). Since 
the Ca
2+
 release site is hypothesized to be in close proximity to the fusion/fission sites (Pryor, Mullock 
et al. 2000; Chen, Ahluwalia et al. 2002; Hay 2007), such mechanical force is likely to be sensed by 
Ca
2+
 release channels.  Indeed, YVC1/TRPY1, the TRPML homolog in yeast, has been shown to be 
directly gated by mechanical force (Su, Zhou et al. 2009).  Further studies will be needed to test 
whether TRPML1 is synergistically gated by PI(3,5)P2 and mechanical force.  However, other 
activation factors should be evaluated as well, including proteins that are recruited to interact with 
TRPML1 following transient elevations in levels of PI(3,5)P2.  These studies would test the 
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sensitization model that PI(3,5)P2, in coordination with these ‘cofactors’, can achieve specific 
activation of endolysosomal Ca
2+
 release channels. 
            In either model, since TRPMLs are specifically modulated by PI(3,5)P2 but not by other PIPs, 
it is possible to regulate Ca
2+
 release via TRPMLs by regulating PI-metabolizing enzymes, such as 
PIKfyve or Fig4 and MTM/MTMR phosphatases. To avoid excessive Ca
2+ 
efflux from endolysosomes, 
the activation of TRPML1 needs to be transient, which can be achieved by tight coupling of the 
synthesis and turnover of PI(3,5)P2  (Botelho, Efe et al. 2008).  This has been shown to be the case in 
yeast where Fab1 (the PI 5-kinase) physically associates with Fig4 (PI 5-phosphatase) and Vac14 (a 
regulator of Fab1) (Sbrissa, Ikonomov et al. 2007; Botelho, Efe et al. 2008; Jin, Chow et al. 2008). 
The formation of the Fab1-Vac14-Fig4 complex allows rapid synthesis and turnover of PI(3,5)P2 in 
response to hyperosmotic stress (Duex, Tang et al. 2006). In mammalian cells, although the PI-
metabolizing enzymes are usually localized to the cytosol (Botelho, Efe et al. 2008), they can be 
recruited to endolysosomal membranes based on the binding of phosphoinositides to their PI-binding 
domains (Kutateladze 2010), or by interacting with key components of the trafficking pathways 
(Botelho, Efe et al. 2008).  For example, PI(3)P can recruit Rab5, and activation of Rab5 can further 
stimulate the activity of Vps34 PI-3 kinase (Shin, Hayashi et al. 2005).  Similar mechanisms may also 
be employed by PI(3,5)P2, Rab7, and PI(3,5)P2-metabolising enzymes (Duex, Tang et al. 2006; 
Botelho, Efe et al. 2008). Therefore, rapid switch on-and-off of PI kinase and phosphatase activity 
may occur near the membrane fusion/fission site, so as to tightly control the extent of Ca
2+
 release 
from endolysosomes (see  Fig 5.2). 
 
How TRPML1 is regulated by SM in a compartment-specific manner 
Similar to PI(3,5)P2,  the exact concentrations of SM in late endosomes/lysosomes or other membranes 
that TRPML1 may temporarily reside on (e.g. the plasma membrane) remain unknown. To help the 
reader get a quick idea, we could make an estimate by comparing SM with PI(4,5)P2, a relatively well-
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studied lipid. It is estimated that PI(4,5)P2 could make up 1.5% of plasma membrane lipids (in molar 
terms) and its concentration at PM can reach ~10 µM range (Ferrell and Huestis 1984; Roth 2004; Suh 
and Hille 2008). Since sphingomyelin comprises of ~15% of PM lipids (in molar terms)  (van Meer, 
Voelker et al. 2008), the concentration of SM at PM could be estimated at ~100 µM range. In late 
endosomes/lysosomes, the concentration of SM drops by more than 3-fold (van Meer, Voelker et al. 
2008; Sztolsztener, Dobrzyn et al. 2012), thus the SM concentration there could be at ~30 µM range. 
However, this estimate (~30 µM) is the average SM concentration of both the limiting and luminal 
membranes in lysosomes. Given that SM/cholesterol are more than 5 times as concentrated in the 
luminal membranes (Mobius, van Donselaar et al. 2003), SM concentration at the limiting membrane 
where TRPML1 resides on would be less than ~6 µM,  one order of magnitude less than that on PM. 
However, in pathological conditions, such as Niemann Pick disease, SM concentration at the limiting 
lysosomal membrane could be much higher than ~6 µM (Sztolsztener, Dobrzyn et al. 2012), or even 
reaches the level at PM (~100 µM) due to the defective aSMase activity. It is worth noting that the 
abovementioned estimates are the overall concentration of SM on the specific membranes, its local 
concentration is likely to vary in different microdomains.  
            Based on the above estimates and my work that high concentration of SMs in TRPML1-
residing membranes (>20µM) can negatively regulate TRPML1, the modulation of TRPML1 by SMs 
appears to be both physiologically and pathologically significant. Under normal conditions, late 
endosomes/lysosomes have relatively low level of sphingomylin/cholesterol, rendering TRPML1 
sensitive to cytosolic activating signals. This is consistent with the fact that TRPML1 is actively 
involved in various membrane trafficking processes that late endosomes/lysosomes are associated 
with (Cheng, Shen et al. 2010).  However, when TRPML1 transiently appear on the plasma membrane 
during lysosome exocytosis (Dong, Wang et al. 2009; Medina, Fraldi et al. 2011), mechanisms must 
exist to rapidly turn off TRPML1 activity so as to prevent the excessive Ca
2+
 influx from the 
extracellular space. While the quick synthesis and turnover of activation signals (such as PI(3,5)P2) 
may be an efficient way as mentioned in the previous section, the massive sphingomyelins on plasma 
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membrane (~100 µM) represent another defense mechanism to prevent Ca
2+
 overload. Such 
mechanism is especially important for TRPML1 since TRPML is not inactivated by voltage or 
desensitized by Ca
2+
 (Dong, Shen et al. 2010). On the other hand, under NP disease conditions, the 
SM concentration in the limiting lysosomal membrane could be as high as that in the PM, therefore 
inhibiting TRPML1. In sum, SM may play an important role in balancing TRPML1’s channel activity 
in different cellular compartments, the disturbance of which may underlie the pathological cause of 
many lysosomal storage disorders. 
            The identification of SM as a negative regulator of TRPML1 also suggests that the breakdown 
of SM has two distinct yet interconnected effects on membrane trafficking processes. On one hand, as 
mentioned in the introduction, the conversion from SM to ceramide can induce local membrane 
curvature, thus increasing the fusogenic potential of the membrane. On the other hand, such 
conversion may also sensitize TRPML1 or even induce Ca
2+
 release from TRPML1 on 
endolysosomes. Both membrane curvature and Ca
2+
 signaling are key components for efficient 
membrane fusion/fission process. Therefore, the activity of ASMase in the lumen of late 
endosomes/lysosomes or during its transient appearance on the outer leaflet of PM upon lysosomal 
exocytosis may represent an economical and efficient means to control the membrane fusion/fission 
processes.  
 
The advantage of regulating TRPML1 from both cytosolic and luminal sides 
The fact that both a cytosol-localized lipid (PI(3,5)P2) and a luminal localized lipid (SM) regulate 
TRPML1 may allow TRPML1 to integrate signals from both sides to orchestrate the Ca
2+ 
release 
events. After two endolysosomal membranes are brought into close proximity, increases in levels of 
PI(3,5)P2 may lead to the direct activation of TRPML1 to elevate levels of juxtaorganellar Ca
2+
, and 
thereby triggering fusion events (Fig 5.2).  Alternatively, regarding the hypothesis that PI(3,5)P2 
configures TRPML1 in a “willing” state, the assembly of SNARE complexes and the membrane 




 release (Fig 5.1B), as in the case for yeast where trans-SNARE complex formation has been 
shown to promote Ca
2+
 release from yeast vacuoles (Merz and Wickner 2004).  Moreover, as 
mentioned in the preceding paragraph, the conversion from SM to ceramide at the luminal side can 
further induce the local membrane curvature to promote fusion or fission events. In this sense, the 
PI(3,5)P2-TRPML1-sphingomyelin signaling pathway add a fine layer of regulation to the late 
endocytic trafficking system, and the balance of PI(3,5)P2 or SM level in the endolysosomal 
membrane need to carefully maintained. Indeed, when SMs are abnormally accumulated in late 
endosomes and lysosomes in NP disease, the inhibitory effect of SMs could be potent enough to 
render TRPML1 insensitive to cytosolic activation signals (Fig 5.3). 
 
Other factors regulated by PI(3,5)P2 / SM or regulating lysosomal Ca
2+
 channels 
In this thesis, TRPML1 was discovered as a downstream effector of PI(3,5)P2 and SM, but it is not 
their only effector. PI(3,5)P2 -deficient cells have been observed to have more defects in their 
membrane trafficking processes than TRPML1
-/-
 cells (Dong, Shen et al. 2010), suggesting that 
PI(3,5)P2 regulates a number of other cellular events besides the modulation of Ca
2+
 signaling.  
Indeed, PI(3,5)P2 has been shown to recruit the necessary cytosolic proteins for membrane fusion and 
fission, and may regulate the functions of other endolysosomal membrane proteins to determine the 
physical properties and fusogenic potential of endolysosomal membranes (Dove, Dong et al. 2009; 
Poccia and Larijani 2009; Dong, Shen et al. 2010).  Similarly, SM is likely to have other effectors 
along the endolysosome trafficking pathway. It has been reported that increased cholesterol content in 
endolysosomal membranes can aberrantly sequester the soluble N-ethylmaleimide attachment protein 
(SNAP) receptor (SNARE) proteins, thereby blocking efficient endolysosomal fusion (Fraldi, 
Annunziata et al. 2010). Since SM is usually associated with cholesterol, it would be interesting to test 
whether the assembly and disassembly of endolysosomal SNARE complex is also defective in NP 
disease cells.  
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            Likewise, It is possible that PI(3,5)P2 and SM are not the only endogenous regulators of 
TRPML1. Future studies need to test for other possible modulators of TRPML1 at the cytosol side, 
such as various effectors of PIP or Rab proteins, phosphorylated derivatives of sphingolipids and 
mechanical force. At the lysosomal lumen side, other offending metabolites that inhibit TRPML1, 
and/or PI(3,5)P2-metabolizing enzymes, may be identified when investigating TRPML1 activity in 
other LSDs. As many TRP channels function as polymodal receptors (Clapham 2003; Wu, Sweet et 
al. 2010), it is not surprising to expect more endogenous regulators of TRPML1 to be discovered in 
the near future. 
            The link between lysosomal lipids and TRPMLs also brings us new insights into the gating 
mechanisms of the Ca
2+
 channels along the endolysosomal pathway. Like various channels on the 
plasma membrane whose function is usually phospholipid-dependent, endolysosomal Ca
2+
 channels 
are likely to be modulated by the lipids mainly enriched in endolysosomes. We speculate that 
lysosomal specific phosphoinositides or sphingolipids may also modulate other Ca
2+
 channels such as 
TPCs and TRPM2 in the endolysosomal system. 
 
Downstream events after Ca
2+
 release. 
My thesis work mainly focused on the upstream events of Ca
2+
 release from endolysosmes (how they 
are regulated), the downstream events following Ca
2+ 
release are largely unknown. There are at least 
two outstanding questions remain unanswered. First of all, the Ca
2+
 sensors are yet unidentified. Given 
the specificity of endolysosomal trafficking processes, compartment-specific Ca
2+
 sensors might be 
involved. The best candidate is ALG-2, a penta-EF-hand protein that physically associates with 
TRPML1 in a Ca
2+
-dependent manner (Vergarajauregui, Martina et al. 2009).  Calmodulin has also 
been implicated in endolysosomal trafficking processes (Peters and Mayer 1998; Pryor, Mullock et al. 
2000; Burgoyne and Clague 2003), with vacuolar fusion being found to be defective in loss-of-




 sensor that have been shown to be essential for exocytosis (Suh and Hille 2008).  Since 
lysosomes also undergo Ca
2+
-regulated exocytosis for plasma membrane repair (Reddy, Caler et al. 
2001), synaptotagmins may play a role in the fusion of lysosomes with other membranes.  In addition, 
recent studies have demonstrated that Doc2b, a high-affinity Ca
2+
 sensor, is important for the 
spontaneous release of neurotransmitters and may play a role in endolysosomal trafficking (Groffen, 
Martens et al.).  Future studies promise exciting discoveries of compartment-specific Ca
2+
 sensors. 
            Another unanswered question is how Ca
2+
 sensors transduce the Ca
2+
 increase to fusion/fission 
events. One possibility is that upon binding of Ca
2+
, a putative Ca
2+
 sensor may exhibit high-affinity 
associations with phospholipids such as PI(3,5)P2, thus bringing two membranes into closer proximity.  
This has been observed during the release of neurotransmitters using functional assays of 
synaptotagmins and PI(4,5)P2 (Arac, Chen et al. 2006).  Another possibility is that a putative Ca
2+
 
sensor may interact with SNARE proteins to facilitate the formation of a SNARE complex, and 
thereby promoting membrane fusion.  Correspondingly, calmodulin has been shown to interact with 
SNAREs and promote intracellular membrane fusion (Burgoyne and Clague 2003).  A third 
possibility is that Ca
2+
 signaling may regulate other trafficking factors including phosphoinositide 
effectors.  For example, TRPML2 and Ca
2+
 have been shown to promote the activity of Arf6 GTPase 
and other ArfGAPs, respectively (Karacsonyi, Miguel et al. 2007).  Ca
2+
/calmodulin is shown to be a 
positive regulator of Vps34 in phagosomes (Vergne, Chua et al. 2004).   Thus, functional cross-talk 
between endolysosomal Ca
2+
 channels, phosphoinositides, phosphoinositide effectors and other lipids 
may regulate the release of Ca
2+
 in a spatiotemporal manner, thus ensuring the specificity of 
endolysosomal membrane trafficking.    
 
TRPML1 as a new therapeutic target 
My thesis work highlights the significance of TRPML1 in the pathological causes of lipid storage 
disorders. Studies on Mucolipidosis type IV disease have revealed that total or partial loss of 
TRPML1 channel activity causes trafficking defects and lipid storage, leading to severe 
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neurodegenerative symptoms in MLIV patients. My work demonstrates that in several other LSDs, the 
comprised TRPML1 channel activity due to SM accumulation also impairs endolysosomal trafficking, 
causing secondary lipid storage and cell damage (Fig 5.3). Since I only examined the acute effect of 
lipids on TRPML1, future work should utilize a longer time scale (hours or days of lipid incubation) 
to see if other sphingolipids or cholesterol can also modulate TRPML1 activity. Many LSDs are 
characterized with progressive accumulation of mucopolysaccharides and oligosaccharides with 
defective membrane trafficking (Parkinson-Lawrence, Shandala et al.). Naturally, these accumulated 
lipids are also good candidates to be tested as potential regulators of TRPML1. 
            The importance of TRPML1 is further illustrated by a recent finding that TFEB, a transcription 
factor that regulates lysosomal genes, can reduce the pathologic storage in many LSDs except 
Mucolipidosis IV (Medina, Fraldi et al. 2011), suggesting that TRPML1 may represents a key entry 
point to reduce lysosomal storage. Consistent with this hypothesis, my work shows that increasing 
TRPML1’s expression/activity was able to alleviate the lipid accumulation in NPC cells. Such rescue 
effects could be due to increased retrograde trafficking from the late endosome/lysosome to Golgi, or 
increased lysosomal exocytosis, or even enhanced activities of hydrolase upon ML-SA1 application. 
Further study is needed to distinguish these possibilities. But in either case, a novel concept is brought 
up that clearance of lysosome storage might be achieved by up-regulating membrane trafficking using 
chemical agonists of TRPML1. Thus, TRPML1 may represent a promising therapeutic target for the 
treatment of lysosomal storage disorders. Future investigation of the toxicity of ML-SA1 and its 
effectiveness in animal model is required. Given the fact that constitutively active TRPML1 channel 
may actually worsen cell condition in the long run (Dong, Wang et al. 2009) presumably due to the 
Ca
2+
  overload caused by the channel, great care needs to be taken to avoid over-activating the 
channel. An ideal scenario is to use low dose of the agonist to sensitize the channel while only 
removing the lipid inhibitory effect without over-activating it. Since lysosome storage is also observed 
in common neurodegenerative diseases such as Alzheimer’s and Parkinson’s (Bellettato and Scarpa 
2010; Schneider and Zhang 2010), manipulating TRPML1’s channel activity may provide therapeutic 





Fig 5.1. Two working models for PI(3,5)P2-dependent TRPML1 activation in endolysosomes.  
A:  “Activation” model.  Physiological levels of PI(3,5)P2 activate TRPML1 by binding to the poly-
basic domain in the N- terminus of TRPML1, leading to the release of Ca
2+
.  
B:  “Sensitization” model.  In this model, physiological levels of PI(3,5)P2 are not sufficient to 
activate TRPML1.  Instead, PI(3,5)P2 is hypothesized to sensitize TRPML1 by converting the channel 
from a “reluctant” state to a “willing state” (see ref. (Wu, Bauer et al. 2002)).  Channel 
opening/activation and Ca
2+
 release are then induced by unidentified trafficking cues, one of which 
may be the mechanical force generated during pre-fusion membrane curvature/bending.  This model 
confers multiple layers of regulation upon TRPML1 activity.  Under stress conditions that are 
analogous to hyper-osmotic shock in yeast, acute stimuli may induce high levels of PI(3,5)P2 to 





Fig  5.2.  A proposed model for PI(3,5)P2- and Ca
2+
-dependent endolysosomal membrane fusion. 
Microdomain specific recruitment of an array of tethering and priming factors has the potential to 
bring into close proximity two endolysosomal membranes (the upper membrane and lower membrane 
illustrated) . 
A: Recruited proteins that may be involved include Rab GTPases (Rab7 for LEL), lipid kinases 
(PIKfyve for LEL), and several phosphatases (Fig4 and MTM/MTMRs).  Activation of the assembled 
PI(3,5)P2-metabolizing complex would ensure a transient and local increase in the level of PI(3,5)P2.  
PI(3,5)P2 effectors would also be subsequently recruited and/or activated.   
B: The release of Ca
2+
 from the lumen of endolysosomes would transiently elevate the levels of 
juxtaorganellar Ca
2+
 to activate a putative Ca
2+
 sensor protein, such as ALG-2/Synaptotagmin/CaM, to 
promote the fusion of the lipid bilayers.  Both SNARE complex formation and PI(3,5)P2 may facilitate 
Ca
2+
 release.  An increase in PI(3,5)P2 levels could also alter the physical properties of the membranes 
involved, and regulate the interactions between SNARE complexes and Ca
2+





Fig 5.3. Sphingomyelin accumulation affects membrane trafficking by inhibiting TRPML1. 
Under normal conditions, late endosome/lysosome has relatively low level of sphingomylin or 
cholesterol, rendering TRPML1 sensitive to cytosolic activating signals. The activation of TRPML1 
leads to elevated levels of juxtaorganellar Ca
2+
, thereby triggering fusion or fission events. Under 
Niemann Pick diseases condition, however, SM (and cholesterol) may accumulate at the limiting 
lysosomal membrane, subsequently inhibiting TRPML1 and making the channel insensitive to 
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